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Abstract+
Addiction treatment guidelines recommend routinely screening for cooccurring mental disorders. Improvement in the identification of clients with psychiatric comorbidity has been prioritized because of the negative consequences of failing
to detect it. There is a lack of research on the prevalence of co-occurring mental disorders in residential alcohol and other drug treatment services. There is need for research that validates and compares the short screening measures used to identify cooccurring mental disorders in alcohol and other drug treatment participants. In Study
1, the mental disorder status of 278 participants resident in alcohol and other drug
treatment settings in Australia was estimated using the Addiction Severity Index—
Self Report (Cacciola, Pecoraro, & Alterman, 2008) and the Mental Health Screening
Form III (Carroll & McGinley, 2001). The estimated rate of diagnosable Axis I mental disorder comorbidity varied from 64% to 71% depending upon the cutoff score
used. Due to the high estimated rates of comorbid mental disorder the prevalence and
taxonomy of mental disorder comorbidity in residential alcohol and other drug treatment services was then assessed in Study 2 using a semi-structured interview. Study 2
involved administration of five commonly used mental disorder screening instruments
validated against the Structured Clinical Interview for DSM-IV-TR Axis I Disorders
(First, Spitzer, Gobbon, & Williams, 2002). Participants were 124 randomly selected
clients with alcohol and other drug problems attending residential recovery services of
The Salvation Army. Presence of comorbid Axis I mental disorder(s), total scores on
the Psychiatric Status domain of the Addiction Severity Index, the Mental Health
Screening Form III, the Self-Reporting Questionnaire 20, the Self-Reporting Questionnaire 25 and the Modified Mini Screen were recorded. Lifetime prevalence of any
comorbid Axis I disorder was 87.5% and 30-day prevalence was 73.3%. More than
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19% of participants met full criteria for a psychotic disorder over the previous 30days. Among the short screening measures validated the Modified Mini Screen and
the Mental Health Screening Form III displayed high sensitivity, high negative predictive values and high area under the curve scores. Psychiatric comorbidity exists in
almost eight-out-of-ten clients in residential alcohol and other drug treatment services.
Psychotic disorders are particularly prevalent when compared to the general population (19% vs. 0.45%) (Morgan et al., 2011). The findings suggest a need for integrated treatment of comorbid disorders, strong linkages between alcohol and other drug
treatment services and psychological services and training for alcohol and other drug
treatment workers to better address comorbidity.
+
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Chapter+1+Introduction+
Screening for co-occurring mental disorders in alcohol and other drug treatment services is a formal process that assesses clients for symptoms of comorbid mental disorders. Screening does not determine a mental disorder diagnosis but indicates the
need for further assessment (Connecticut Department of Mental Health and Addiction
Services, 2007). Screening for co-occurring mental disorders is needed in alcohol and
other drug treatment services because the prevalence of co-occurring mental disorders
is high. Over a 25-year period, epidemiological and service utilization data have consistently shown that mental disorders and addictions co-occur at least as frequently as
they exist independently of one another (Davidson & White, 2007). The successful
identification of co-occurring mental disorders using validated screening measures is
a first necessary step towards improving treatment for the co-occurring disorders population (Croton, 2005b; Ziedonis et al., 2005).
According to the US Surgeon General, ‘Mental disorders are health conditions
… characterized by alterations in thinking, mood or behaviour … associated with distress and/or impaired functioning’ (US Department of Health and Human Services,
1999, p. 6). The Diagnostic and Statistical Manual of Mental Disorders-IV-TR nosologises 15 major categories of mental disorder including substance-related disorders
(American Psychiatric Association, 2000). Substance-related disorders are divided
into substance use disorders and substance-induced disorders. Substance use disorders
are further taxonomized into substance abuse and substance dependence. Substance
abuse is defined as a ‘maladaptive pattern of substance use manifested by recurrent
and significant adverse consequences related to the repeated use of substances’
(American Psychiatric Association, 2000, p. 198). Substance dependence is seen as
more serious than substance abuse and involves negative sequelae such as physical

!

16!

dependence upon the substance, (tolerance to and/or withdrawal from use), and an
almost obsessive continuation in using the substance despite negative life consequences (American Psychiatric Association, 2000). There are 11 categories of substance use disorder under these two heads corresponding to 11 categories of substance
that can be abused and/or the subject of dependence: alcohol, amphetamines, caffeine,
cannabis, cocaine, hallucinogens, inhalants, nicotine, opioids, phencyclidine (PCP)
and sedatives, hypnotics or anxiolytics (American Psychiatric Association, 2000).
To be diagnosed with a substance-induced, as opposed to a substance use, disorder there must be evidence of substance intoxication or withdrawal temporally related to maladaptive behaviour and any of a wide variety of symptoms characteristic
of other mental disorders. Symptoms such as, ‘delirium, dementia, amnesia, psychosis, mood disturbance, anxiety, sleep disorders, and sexual dysfunction’ (US
Department of Health and Human Services, 2007, p. 2). Examples of substanceinduced disorders include substance-induced depression being experienced by someone in cocaine withdrawal and substance-induced psychosis being experienced by
someone intoxicated on crystal methamphetamine (ice).
Mental disorders that are not substance related include anxiety disorders,
mood disorders, psychotic disorders and somatoform disorders (American Psychiatric
Association, 2000). Anxiety disorders occur when people suffer the normal feelings
experienced in response to danger or stress, but at extreme levels that disrupt daily
functioning (Queensland Health, 2010). Anxiety disorders include panic disorder,
generalised anxiety disorder, social anxiety disorder, posttraumatic stress disorder,
obsessive compulsive disorder and specific phobias. Mood disorders are reported to
be common among adults and occur when a person’s mood is sufficiently extreme in
pole and duration to cause clinical impairment in key areas of function such as social
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or work performance (American Psychiatric Association, 2000; Australian Bureau of
Statistics, 2007). Mood disorders include major depressive disorder, dysthymic disorder and bipolar disorder. Psychotic disorders involve disturbances to perception
and/or thinking along with negative symptoms such as catatonia and flat emotion that
result in a disconnection with reality, significant distress and impaired functioning
(American Psychiatric Association, 2000). Psychotic disorders include schizophrenia,
schizoaffective disorder, schizophreniform disorder and brief psychotic episode. Somatoform disorders are when a person experiences symptoms suggestive of a physical
illness, but these symptoms cannot be fully explained by an identifiable medical condition or the direct effect of a substance, nor are they due to another mental disorder
(American Psychiatric Association, 2000). Somatoform disorders include conversion
disorder, somatization disorder, hypochondriasis, body dysmorphic disorder and pain
disorder.
The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5, American Psychiatric Association, 2013), released during the period of this
study, has approximately the same number of conditions as its predecessor (324 down
from 374) (Grohol, 2013). Whilst there are some nosological changes and changes to
form in DSM-5 (see tables 1-2 below and tables 23-24 in Appendix A), very little of
substance changed that is relevant to this study.
Table 1. Changes from DSM-IV-TR to DSM-5 (Peele, Goldstein, & Crowel, 2013)
DSM-IV-TR
Multiaxial

DSM-5
No axes

Not otherwise specified (NOS)

Replaced with “other disorder” or “unspecified
disorder”

Coded diagnosable conditions, 374

Coded diagnosable conditions, 324

Number of ICD-9-CM’s factors influencing health status, V-codes,
22

Number of ICD-9-CM’s factors influencing
health status, V-codes listed, 88

Number of ICD-9-CM’s codes ex-

Number of ICD-9-CM’s codes explicating abuse
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placating abuse (995.xx), 5 abuse
codes

(995.xx), 44 abuse codes

DSM-IV-TR = Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (American Psychiatric
Association, 2000), DSM-5 = Diagnostic and Statistical Manual of Mental Disorders, fifth edition (American Psychiatric
Association, 2013), ICD-9-CM = The International Classification of Diseases, Ninth Edition, Clinical Modification (National
Center for Health Statistics & Centers for Medicare and Medicaid Services, 2010).

Table 2. DSM-IV-TR disorders combined in DSM-5 (Peele et al., 2013)
DSM-IV-TR
Expressive language disorder and mixed
receptive expressive language disorder

DSM-5
Language disorder

Autistic disorder, Asperger disorder, childhood disintegrative disorder, and Rett disorder

Autism spectrum disorder

Shared psychotic disorder and delusional disorder

Delusional disorder

Catatonic schizophrenia, disorganized schizophrenia, paranoid schizophrenia, residual
schizophrenia, undifferentiated schizophrenia

Schizophrenia

Bipolar disorder, most recent episode mixed

Bipolar disorder I or II (no unique code in DSM5)

Panic disorder without agoraphobia and panic
disorder with agoraphobia

Panic disorder

Dissociative fugue and dissociative amnesia

Dissociative amnesia

Somatization disorder, undifferentiated somatoform, pain disorder

Somatic symptom disorder

Primary insomnia and insomnia related to another mental disorder

Insomnia disorder

Primary hypersomnia and hypersomnia related
to another mental disorder

Hypersomnia disorder

Sleepwalking disorder and sleep terror disorder

Non-rapid eye movement sleep arousal disorders

Vaginismus and dyspareunia

Genito-pelvic pain/penetration disorder

Sexual aversion

Not listed in DSM-5

Abuse disorder, dependent disorder (alcohol,
cannabis, phencyclidine, hallucinogen, inhalant, opioid, stimulant, sedative/hypnotic/
anxiolytic, and other use disorder

Use disorders (mild or moderate/severe)

Polysubstance dependence

Not listed in DSM-5

DSM-IV-TR = Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (American Psychiatric
Association, 2000), DSM-5 = Diagnostic and Statistical Manual of Mental Disorders, fifth edition (American Psychiatric
Association, 2013).
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The circumstance where a person is said to meet diagnostic criteria for both
one or more substance use disorders and one or more mental disorders at the same
time has been described using a variety of phrases including mentally ill chemical
abuser (MICA or MICAA), mentally ill substance user (MISA), mentally ill substance
using (MISU), chemically abusing mentally ill, or chemically addicted mentally ill
(CAMI), substance abusing mentally ill (SAMI), mentally ill chemically dependent
(MICD), dually diagnosed, dually disordered, co-morbidity, comorbidity, comorbid
disorders, complex presentations, concurrent disorders, co-existing disorders and individuals with co-occurring psychiatric and substance misuse disorders (ICOPSD)
(Center for Substance Abuse Treatment, 2005; Queensland Health, 2010). Many of
these terms do not sit well with recovery-oriented approaches that seek to avoid labeling people and thereby reducing their human experience and identity to an often stigmatized mental and/or substance use disorder label. Some of the above terms have
also been used to refer to different situations causing some confusion and necessitating a careful examination of the circumstance being described whenever one encounters any of these terms. For example “co-morbidity” as a neologism in medicine was
first used by Feinstein in 1970 to describe any co-existing clinical entity to an index
disease under study and “dual diagnosis” can refer to the co-occurrence of a mental
disorder and a developmental disorder (Feinstein, 1970). Amongst these variations in
terminology, according to Croton (2005a) the most longstanding and widely recognised term is ‘dual diagnosis.’ This term has been criticized for failing to
acknowledge that there may be more than two diagnoses for an individual and for
portraying individuals in this situation as more homogenous than they are (Drake et
al., 2001; Howard, Stubbs, & Arcuri, 2007). The term ‘comorbidity’ has currency in
Australia but has also been criticized by carer groups for its pathological overtones
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(Croton, 2011). ‘Co-occurring disorders’ is the preferred term in the United States of
America (Croton, 2005a). Most recently a new phrase, ‘mental health-substance use’
has appeared (Croton, 2011). This thesis will use the term ‘co-occurring disorders’
(COD), but other terms such as comorbid mental disorder(s) and comorbidity may be
used synonymously where appropriate.
A concurrent diagnosis with at least one or more mental disorders and one or
more substance use disorders is necessary for a person to be said to have “cooccurring disorders” (Center for Substance Abuse Treatment, 2005). It should be recognised, however, that whatever the descriptive term employed, it is being appended
to a functionally and diagnostically heterogenous group with a range of clinical needs
(Ridgely, Goldman, & Willenbring, 1990).
In short, the term co-occurring disorder includes a multiplicity of diagnostic categories, a broad range of severities of disorder, and a potential for confounding between
severity in one area and diagnosis in another (Flynn & Brown, 2008, p. 38).

The term “co-occurring disorders” therefore refers to the co-occurrence of all types of
substance use and mental disorders at all levels of severity (Flynn & Brown, 2008).

A"Note"on"Aetiology"
An extensive literature has built up attesting to the strong association between substance use disorders and mental disorders and at least five different models have been
proposed to explain possible aetiological mechanisms underlying this apparent association (Merikangas et al., 1998). These aetiological models may be categorised as
secondary psychopathology models, secondary substance abuse models, bidirectional
models, common-factor models, and a final type of model which proposes the two
conditions are unrelated (Hall, 1996; Kay-Lambkin, Baker, & Lewin, 2004). Of the
five, only the final model allows that the rate of co-occurrence could simply be a statistical phenomenon (Lehman, Myers, & Corty, 1989).
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Secondary psychopathology models propose mental disorder problems are
triggered (caused) by substance misuse in individuals who have an existing vulnerability to mental disorder (Dixon, Haas, Weiden, Sweeny, & Frances, 1991; KayLambkin et al., 2004; Soar, 2003). According to Zubin and Spring who first elucidated the model, each human is endowed with a degree of vulnerability that under varying circumstances will express itself as an episode of mental disorder (1977). In the
context of co-occurring substance misuse with psychosis, the vulnerability model posits substance use as causally related to the onset and relapse of mental disorder
(Hides, Lubman, & Dawe, 2004). A large number of studies have demonstrated a
simple association between substance misuse and psychosis (Degenhardt & Hall,
2001; Hall, 1998; Solowij & Michie, 2007; Tien & Anthony, 1990). In some research
correlational, cross-sectional and prospective data has suggested causation when there
is a temporal sequence involved (when substance use, predominantly cannabis, precedes the onset or relapse of psychosis cross-sectionally or prospectively) (Berglund
& Ojehagen, 1998). According to Mueser, Drake and Wallach (1998), however, there
are several reasons why the temporal order of onset does not clearly demonstrate
causative aetiology. Firstly these authors note that onset is gradual for both mental
disorders and substance use disorders with no clear demarcation of the moment of onset (Mueser et al., 1998). Further, attempts to find demographic or clinical differences
based upon the order of onset have failed (Mueser et al., 1998). It may also be added
that epidemiological data support an earlier median age of onset for mental disorders
than substance use disorders and not the other way around. For example, during 20012003 83.5% of 9, 282 respondents with a lifetime history of comorbidity reported that
the mental disorder arose before any abuse or dependence upon substances in the nationally representative National Comorbidity Survey Replication conducted in the
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United States of America (Kessler, Berglund, Demler, Jin, & Walters, 2005; Kessler
et al., 1996). Additionally, no aetiological mechanisms underlying any proposed
causative process or processes have been elaborated by researchers who support this
model. It would seem equally possible it is a common vulnerability underlying both
the substance use and the mental disorder(s) as it is one disorder causing the other.
Given that rates of mental disorder (including psychosis) have been relatively stable
or perhaps even fallen in the general population while rates of substance misuse have
increased significantly during the same time period, a directly causal relationship
seems less likely (Degenhardt, Hall, & Lynskey, 2003; Der, Gupta, & Murray, 1990;
Jablensky, 1995 for a review; Joyce, 1987). A number of reviews of the available evidence have been unable to reach any strong conclusions on causality (Hall, 1998;
Hall, Degenhardt, & Teesson, 2004; Thorncroft, 1990).
Secondary substance misuse models posit that mental disorder increases a person’s susceptibility to substance misuse or given an alternate formulation that mental
disorder symptoms lead to substance misuse (Kay-Lambkin et al., 2004; Soar, 2003).
Based upon psychodynamic work in the 1970s early formulations of this theory established a self-medication hypothesis whereby susceptible (mentally disordered) individuals were drawn to substance misuse by the specific psychotropic effects of substances intentionally chosen to alleviate the symptoms and general malaise of their
mental disorder (Khantzian, 1985). In the context of psychosis and substance misuse,
Hides and others refer to this theory as the self-medication (coping) model (2004).
The basic premise of this model is that people with mental disorder symptoms selfmedicate to provide relief from the accompanying general symptoms of dysphoria and
therefore to help cope with the debilitating effects of chronic mental disorder (Hides
et al., 2004). Relying upon correlational, time sequenced cross-sectional and prospec-
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tive data, some researchers assert there is little evidence for the selfmedicating/coping model (Hides et al., 2004; Mueser, Yarnold, & Bellack, 1992).
Other researchers think there is evidence (Berglund & Ojehagen, 1998; Brady et al.,
1990; Deykin, Levy, & Wells, 1986; Dixon et al., 1991) and argue the self-medication
model is one of the most compelling reasons why people with a mental disorder use
drugs (Khantzian, 1985).
Bidirectional models assert that mental disorders and substance misuse disorders interrelate. Thereby either or both disorders may influence the other(s) (Soar,
2003). According to this model multiple different factors may be involved in causing
mental disorder problems and substance misuse problems (Kay-Lambkin et al., 2004).
In 1998 commentators stated that despite intuitive appeal, bidirectional models remained largely untested and theoretical (Mueser et al., 1998). However, one example
of a bidirectional model did find that personality traits are both influenced by, but also
play a role in, the development of a lifetime history of alcohol dependence and abuse
and also of anxiety and depression (Ostlund, Spak, & Sundh, 2004).
Common factor models involve one or more common factors thought to increase the risk of both mental and substance use disorders. Possible common factors
include personality disorder(s), genetic factors, neurobiological problems and stressful events (Kay-Lambkin et al., 2004). There is moderately strong evidence Antisocial
Personality Disorder is a common factor that contributes to increased rates of COD
(Mueser et al., 1998). Other factors that have been proposed include socioenvironmental stress (e.g., poverty, unemployment), poor social competence (Soar, 2003) socioeconomic status and cognitive functioning (Mueser et al., 1998). A number of
studies may be cited as evidence that shared genetic factors do not account for increased rates of comorbidity (Mueser et al., 1998), however, one example of a com-
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mon factor model based upon genetics is provided by Wilhelm, Wedgwood, Niven
and Kay-Lambkin (2006). In the case of smoking/nicotine dependence these authors
opine that a common genetic vulnerability could increase both the likelihood of experiencing depression and the likelihood of experiencing the positive effects of nicotine
(an elevation in mood, subjective increases in wellbeing and even anti-depressant
properties through excitation of the serotonergic system) (Wilhelm et al., 2006).
Finally the unrelated model suggests mental disorders and substance use disorders may be unrelated (Kay-Lambkin et al., 2004). A personality model provides an
example of one of these “unrelated” models (2004). This personality model proposes
two different enduring personality characteristics as causative of substance misuse in
those with mental disorder (psychosis). Neuroticism (habitually negative mood states,
low stress tolerance and control of one’s mood) and impulsivity (sensation-seeking,
risk taking and behavioural disinhibition) (Hides et al., 2004). Essentially the model
suggests that people with high neuroticism and impulsivity do not deal well with
stress when it is encountered, choosing harmful ways to deal with it (substance misuse). Although initially unrelated, disorders may still interact and exacerbate each
other under the unrelated model (Lehman et al., 1989).
Comorbid psychiatric disturbance can arise prior to, concurrently with, or following the commencement of substance abuse. There is an additive effect, a cumulative interaction between the two disorder types, but there is no persuasive evidence to
suggest one model should be adopted over others to explain any possible association
between the aetiology of the two (Howard et al., 2007; Wilhelm et al., 2006). Instead
researchers assume no single model accounts for all cases of comorbidity and allow
both that different models may explain comorbidity in different COD subgroups and
that more than one model may apply to an individual (Lehman et al., 1989; Mueser et
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al., 1998; Wilhelm et al., 2006). It should be recognised that ‘[a]s in other areas of
medicine, monolithic theories about etiology, coupled with simplistic approaches to
treatment, spells disaster for patients with complicated problems’ (Mirin, 1988, p.
154). !

Costs"and"Consequences"of"Co4occurring"Disorders"
Substance use disorders and mental disorders are significant personal and societal
problems. Monetarily, estimates vary as to the exact annual cost to society of substance-related problems, but all the estimates agree that it is a huge amount of money.
For example, whilst it has been asserted the annual estimated cost to society of substance-related problems worldwide is more than US$200 billion (Fabricius, Langa, &
Wilson, 2008), there are also estimates of US$600 billion and more recently US$700
billion that cover the United States alone (National Institute on Drug Abuse, 2012,
2015). The social cost of alcohol and drug abuse in Australia alone was estimated at
AUD$55.2 billion during the 2004/2005 financial year (July 1, 2004 to June 30, 2005)
(Collins & Lapsley, 2008). Such figures suggest the worldwide US$200 billion figure
is likely to be a gross underestimation. The AUD$55.2 billion total cost of alcohol
and drug abuse in Australia during 2004/2005 consisted of AUD$15.3 billion due to
abuse of alcohol (27.3%), AUD$31.5 billion due to tobacco (56.2%) and AUD$8.2
billion due to the abuse of illicit drugs (14.6%) (Collins & Lapsley, 2008). Irrespective of the exact accuracy of what are very large figures, the monetary costs of alcohol
and drug misuse are significant and they are on the rise, having risen by 23% in Australia from 1998/99 to 2004/05 in adjusted dollars (Collins & Lapsley, 2008).
Like substance use disorders, there is no question mental disorders in and of
themselves are an enormous burden on the individual and society as a whole. Mental
disorders caused more than 18% of disability worldwide according to the Global Bur-
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den of Disease study conducted by the World Health Organization (Lopez & Murray,
1998). Measured by the number of years living with a disabling condition, depression
has been reported as the leading cause of disability worldwide (Edward, Hearity, &
Felstead, 2012; Murray & Lopez, 1996). The burden of mental disorders even exceeds
the burden of disease caused by all cancers (Alonso et al., 2004). In Australia in 2004,
mental disorders were the leading cause of the nonfatal burden of disease and injury
and third only to cancer and cardiovascular disease as the leading overall cause of the
burden of (fatal and nonfatal) disease and injury (Begg et al., 2007).
Comorbidity or suffering both substance use and mental disorders at the same
time also has important consequences for society and the individual. Problems facing
people with CODs include poorer treatment response (Grella & Stein, 2006; Hasin et
al., 2002), increased incidence of relapse (Hasin et al., 2002; Mueser et al., 1998;
Swofford, Kasckow, Scheller-Gilkey, & Inderbitzin, 1996), an inability to maintain
functional stability (Ziedonis & Stern, 2001), family difficulties and limited social
relationships (Ziedonis & Stern, 2001), increased unemployment (Ziedonis & Stern,
2001), victimization (Goodman, Rosenberg, Mueser, & Drake, 1997), incarceration
(Abram & Teplin, 1991), violence (M. S. Swartz et al., 1998), depression, suicidal
behaviour (Bartels, Drake, & McHugo, 1992), homelessness (Drake, Osher, &
Wallach, 1991), hospitalization (Haywood et al., 1995), HIV (Adams, 2008; Brunette,
Mueser, & Drake, 2004), and Hepatitis C (Rosenberg et al., 2001). On a systemicbasis undetected comorbidity leads to higher service utilization and costs (Dickey &
Azeni, 1996). Combined data from 2010-2011 in the United States of America
showed that 44.7% of past year emergency room visits in that country were from
adults with co-occurring mental and substance use disorders (Substance Abuse and
Mental Health Services Administration, 2013). In 2005, in most cases in Australia
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where a mental or behavioral disorder was recorded as the underlying cause of death,
the abuse of psychoactive substances such as alcohol and heroin was also involved
(Australian Institute of Health and Welfare, 2008).!

The"Clinical"Emergence"of"Co4Occurring"Disorders"
Internationally, the problem of co-occurring disorders was first highlighted by clinicians who identified “young mentally disordered vagrants” and “young adult chronic
patients” in the mid 1970s to early 1980s (Bachrach, 1982; Bassuk & Gerson, 1980;
Caton, 1981; Pepper, Kirshner, & Ryglewicz, 1981; Robbins, Stern, Robbins, &
Margolin, 1978; Segal, Baumohl, & Johnson, 1976-1977; S. R. Swartz & Goldfinger,
1981). The young adult chronic patients, as opposed to older deinstitutionalized patients, were the first of the post-deinstitutionalization generation of people with chronic mental disorder who had never been institutionalised in asylums for a significant
period of time (S. R. Swartz & Goldfinger, 1981). These quite quickly came to be described as ‘a problem of considerable dimension, one seriously compromising the operation of the mental health system’ (Galanter, Castaneda, & Ferman, 1988, p. 231).
When the asylums were progressively closed from the 1950s onwards, people with
chronic mental disorders were moved out of institutions into the world to face all the
demands and pitfalls of daily living including access to substances of abuse. At the
same time as these past institutionalised patients were being disinterred from the institutions, a new generation of people with serious mental disorder also arrived who
twenty or thirty years previously would have been long-term asylum patients, but instead were now supposed to be managed in the community (Bachrach, 1982). According to some with the benefit of hindsight this era of deinstitutionalization into a society with high availability of substances set the scene for the co-occurrence of substance
use and mental disorder becoming a serious social concern (Mueser et al., 1998). The
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heavy patterns of ineffective service utilisation characteristic of this new population
were of great concern to early commentators (Ridgely et al., 1990). These patients
were quickly known as regulars at hospital emergency departments and psychiatric
units and according to some authors it was particularly those with histories of drug
abuse who evidenced a service utilisation pattern described as intensively ‘heavy, discontinuous, and episodic’ (Richardson, Craig, & Haugland, 1985, p. 104).
Segal and Baumohl (1980) and Prevost (1982) give two early summaries of
the system-stressing characteristics of the co-occurring disorder population:!
The chronically dysfunctional have long histories of unemployment and minimal occupational skills. They show consistently poor judgment in the management of their
finances and social relationships and have long-standing psychological problems that
have resulted in multiple hospitalizations and frequent minor entanglements with the
law. They are often said to be drug or alcohol abusers and are described as “minimizing,” “denying,” and “projecting” responsibility for their problems. Characteristically
they do not follow through on treatment plans (Segal & Baumohl, 1980, p. 359).
We do know that although these patients do not make up a diagnostically homogeneous population, they have certain characteristics in common. They have difficulty
forming stable relationships and have little or no natural support systems. Socially
and psychologically fragile, and often psychotic, they are acutely vulnerable to stress.
They frustrate our treatment efforts, resist ongoing affiliation, and frequently choose
a sporadic semi-involvement during recurring crisis periods in their lives (Prevost,
1982, p. 173).

In the thirty-five years since this description three research findings have consistently come out of studies into this population: 1) the co-occurrence of substancerelated disorders and mental disorders is common, indeed in clinical settings cooccurring disorders are expected to be the rule, not the exception (Ridgely et al.,
1990); 2) comorbidity is associated with a plethora of negative outcomes (already
noted above), and 3) the parallel but separate mental disorder and substance misuse
treatment systems have delivered fragmented and ineffective care to this population
(Drake et al., 2001).
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The"Emergence"of"Co4Occurring"Disorders"in"Research"
Knowledge of co-occurring disorders originally emerged as an unexpected feature of
research into the epidemiology of mental disorders in the United States of America.
Internationally, epidemiological surveys of the population prevalence of CODs are
dominated by two large studies done in the United States, the National Epidemiological Catchment Area (ECA) Study and the National Comorbidity Survey (NCS). Between them the Ecological Catchment Area Study and the National Comorbidity Survey established the methods of modern psychiatric epidemiology (Insel & Fenton,
2005). It was these population-based surveys, and others that subsequently mirrored
them internationally, (including Australia’s 1997 and 2007 National Surveys of Mental Health and Wellbeing), that brought to light the size and scope of the co-occurring
disorders problem on an international, population-wide basis. It is because of these
studies that we know the prevalence of CODs among the general population is high
(Kessler et al., 1996).
The National Institute for Mental Health’s multisite Ecological Catchment Area study (ECA) aimed to estimate the prevalence rates of mental disorders in the
United States population. It became ‘the largest, most comprehensive survey of mental disorders ever conducted in the United States’ (Bourdon, Rae, Locke, Narrow, &
Regier, 1992, p. 663). A collaborative research project, the ECA was conducted from
1980 to 1984 by five university research teams sponsored by the National Institute for
Mental Health (NIMH): Yale University (New Haven), Johns Hopkins University
(Baltimore), Washington University (St Louis), Duke University (North Carolina) and
the University of California at Los Angeles (UCLA) (Los Angeles) (Bourdon et al.,
1992; Regier et al., 1990). The five geographically-defined catchment areas had populations ranging from 270,000 to 420,000 (Regier et al., 1988). From these, the ECA
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study originally surveyed a total of 18,571 household and 2,290 institutional residents
personally or by proxy means (Bourdon et al., 1992). Whilst the ECA study was considered the largest and most comprehensive survey of mental disorders ever conducted at the time, the methodology the study employed involved surveying people from
five distinct areas only – instead of surveying a nationally representative sample. This
method has subsequently been criticized as being a significant flaw that resulted in the
study not being generalizable (Helzer & Pryzbeck, (1988). The sample reported on
and used for the prevalence rates cited below excludes the proxy interviews, leaving a
total of 20,291 participants. These participants went through two interviews one-year
apart with a telephone interview in between (Bourdon et al., 1992). They were assessed for current disorders according to the third edition of the Diagnostic and Statistical Manual for Mental Disorders (American Psychiatric Association, 1980) over the
past month, past six-months, past year and over their entire lifetime using the NIMH
Diagnostic Interview Schedule (Robins, Helzer, Croughan, & Ratcliff, 1981)
(Bourdon et al., 1992; Regier et al., 1990). The prevalence of mental disorders recorded by the ECA study is reported in Table 3 below.
Table 3. Ecological Catchment Area Survey Disorder Prevalence Rates (Regier et al.,
1990).!!
Drug/Disorder
Type
Any Disorder

1 Month
Prevalence
15.7%

6 Months
Prevalence
19.5%

Lifetime
Prevalence
32.7%

Mental Disorders
Anxiety
Affect
Schizophrenic

13%
7.3%
5.2%
0.7%

15.1%
8.9%
5.8%
0.9%

22.5%
14.6%
8.3%
1.5%

Substance Use Disorders
Alcohol
Other Drug

3.8%
2.8%
1.3%

6.1%
4.8%
2%

16.7%
13.5%
6.1%

Substance use disorders accounted for a high proportion of the disorders detected by the ECA study. Alcohol disorders were the most frequently detected disor-
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der and other drug disorders were the third most frequently detected disorder (Helzer
& Pryzbeck, 1988). The median age of onset for disorders as a whole was 16 years,
the median duration people experienced disorders as a whole 10.4 years and 75% of
all disorders had their onset before 24 years of age (Hall, 1996). The median age of
onset for anxiety disorders was 15 years, for drug disorders 19 years and for alcohol
disorders 21 years (Christie et al., 1988).
The ECA study’s figures on comorbidity concentrate on lifetime comorbidity,
or the experience of a person having one or more disorders over the course of their
lives, (not necessarily concurrently) (Regier et al., 1990). More than 60% of the 33%
of ECA respondents with at least one lifetime disorder had two or more disorders
(Kessler et al., 1994). Of the 22.5% who had a lifetime prevalence for a nonsubstance-related mental disorder, 16.2% had mental disorders only, 3.1% had mental
and alcohol disorders, 1.5% had mental and other drug disorders and 1.7% had disorders from all three categories combined (Regier et al., 1990). Eighty percent of these
respondents with multiple disorders reported onset before the age of 20 (Christie et
al., 1988). Those with a lifetime history of alcohol disorder were almost twice as likely to have a (comorbid) mental disorder (37%) than the general population (Regier et
al., 1990). Perhaps most significantly, 53% of those with a drug other than alcohol
disorder also had a lifetime history of comorbid mental disorder, a rate more than
double that found in the general population (Regier et al., 1990).
A methodological advantage that the ECA study enjoyed over predecessor
community studies was its measurement of base-rates for positive and negative
groups on a disorder-by-disorder basis (Regier et al., 1984; Weissman, Myers, &
Harding, 1980). This allowed proper odds ratios to be calculated reporting on the increased risk of having a comorbid disorder given the presence of an initial disorder
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(Regier et al., 1990). The adjusted odds ratios or increased risks of having a comorbid
mental or alcohol and other drug disorder for those with, as opposed to those without
specific disorders are reported in Table 4 below:
Table 4. Odds Ratios For Comorbidity On a Disorder-by-Disorder Basis (Regier et
al., 1990)
Initial Disorder
Alcohol

Odds Ratio
Comorbid Mental
2.3*

Other Drug
Marijuana
Cocaine
Opiate
Barbiturate
Amphetamine
Hallucinogen

4.5*
3.8
11.3
6.7
10.8
6.2
8.0

Mental
Anxiety
Schizophrenia

Odds Ratio
Comorbid Substance

2.2
1.7
4.6

*Significant at p < .001

!

These figures revealed for the first time those with an alcohol disorder were 2.3 times
more likely to have a comorbid mental disorder than those without an alcohol disorder. Those with a drug other than alcohol disorder were 4.5 times more likely to have
a comorbid mental disorder than those without a drug other than alcohol disorder
(Regier et al., 1990). These figures agreed with other studies conducted around the
same time that reported when drug problem severity increases, likelihoods for comorbid disorders also increase (Flynn, Craddock, Luckey, Hubbard, & Dunteman, 1996;
H. E. Ross, Glaser, & Germanson, 1988). On a disorder-by-disorder basis, some of
the odds ratios of suffering a comorbid mental disorder given a certain substance use
disorder were quite remarkable: for example those with cocaine disorders had 13.2
times as many schizophrenia disorders as those without cocaine disorders (Regier et
al., 1990).
Examined from the reverse standpoint of those with a mental disorder, individuals with a lifetime history of a mental disorder were 2.2 times as likely to have a
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substance use disorder (with a lifetime prevalence of substance use disorders of
28.9% against a general population rate of 16.7% and a rate of 13.2% among those
who did not have a mental disorder) (Regier et al., 1990). Forty-seven percent of
those with a schizophrenia disorder had a comorbid substance use disorder, 4.6 times
as many as those without a schizophrenia disorder (Regier et al., 1990). Those with an
anxiety disorder were 1.7 times more likely to have a substance use disorder as those
without an anxiety disorder (Regier et al., 1990).
Finally, it was also notable that with alcohol use disorders, there was a strong
association between alcohol disorders and gender (Hall, 1996). The lifetime prevalence of alcohol disorders was 24% for men and 5% for women while the 12-month
prevalences were 12% for men and only 2% for women (Hall, 1996). Men also reported a significantly higher lifetime prevalence of mental, alcohol and other drug
disorders overall (35.4% for men vs. 30.0% for women, p < .01) (Bourdon et al.,
1992). The extent of comorbidity revealed by the landmark ECA study provided the
impetus for a follow-up NIMH-supported National Comorbidity Survey (NCS)
(Bourdon et al., 1992). The mental disorder screening measure used in the ECA, the
Diagnostic Interview Schedule, was also developed by an international taskforce auspiced by the World Health Organisation into the Composite International Diagnostic
Interview (CIDI) (Bourdon et al., 1992; Robins et al., 1988).
The National Comorbidity Survey (NCS) was a congressionally-mandated
study into the comorbidity between substance-related mental disorders and nonsubstance-related mental disorders conducted between September 14, 1990 and February 6, 1992 (Kessler et al., 1994). The NCS was the first time a structured psychiatric interview had been administered to a nationally-representative sample (Kessler et
al., 1994). For this collaborative, epidemiologic investigation, 8098 respondents com-
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prised a ‘stratified, multistage area probability sample of persons aged 15 to 54 years
in the noninstitutionalized civilian population in the 48 coterminous states’ (Kessler et
al., 1994, p. 18).
The NCS had several advantages over the Ecological Catchment Area study:
1) countering some criticisms of the ECA study (e.g., made by Helzer and Pryzbeck
(1988)), the NCS sample was a genuinely nationally representative sample; 2) NCS
diagnoses were based upon the revised third edition of the Diagnostic and Statistical
Manual for Mental Disorders (American Psychiatric Association, 1987), an update
from the third edition; and 3) in addition to prevalence and incidence, the NCS focused in upon risk factors as well (Kessler et al., 1994).
The NCS used a modified version of the newly developed Composite International Diagnostic Interview (CIDI) (Robins et al., 1988) to report upon the lifetime
prevalence and 12-month prevalence of 14 DSM-III-R disorders (Kessler et al.,
1994). Major depression, mania, dysthymia, panic disorder, agoraphobia, social phobia, simple phobia, generalized anxiety disorder, alcohol abuse, alcohol dependence,
drug abuse, drug dependence, antisocial personality disorder and nonaffective psychosis (NAP) were assessed. NAP was a summary category for schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder and atypical psychosis (Kessler et al., 1994). “Severe disorders” were defined as ‘(1) 12-month mania
or NAP, (2) lifetime mania or NAP with 12-month treatment or role impairment, or
(3) 12-month depression or panic disorder with severe impairment (hospitalization or
use of antipsychotic medication)’ (Kessler et al., 1994, p. 9). Any respondent who reported psychotic symptoms was re-interviewed by experienced clinicians using an
adapted version of the Structured Clinical Interview for DSM-III-R (Spitzer,
Williams, Gibbon, & First, 1988, 1992) due to this instrument’s reliability in the di-
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agnosis of schizophrenia (Kessler et al., 1994; Williams et al., 1992). NCS diagnoses
of NAP were based upon these clinical re-interviews, not the CIDI (Kessler et al.,
1994). Table 5 below contains the prevalence rates reported by the nationally representative National Comorbidity Survey and also notes the comparable ECA study lifetime prevalence.
Table 5. National Comorbidity Survey Disorder Prevalence Rates (Kessler et al.,
1994; Regier et al., 1990)
Drug/Disorder
Type
Any Disorder
Substance Use Disorder
Anxiety Disorders
Affective Disorders
Psychosis

NCS 12-Month
Prevalence
29.5%
11.3%
17.2%
11.3%
0.5%

NCS Lifetime
Prevalence
48%
26.6%
24.9%
19.3%
0.7%

ECA Study Lifetime
Prevalence
32.7%
16.7%
14.6%
8.3%
1.5%

NCS = National Comorbidity Study, ECA = Ecological Catchment Area Survey.
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The prevalence figures for substance use disorders reported by the NCS suggested slightly more than one-in-four Americans would experience a substance use
disorder in their lifetime and that more than one-in-ten Americans were currently experiencing a substance use disorder at any given time. The retrospectively reported
median age of onset for mental disorders was 11-years-old and for substance use disorders 21-years-old (Kessler et al., 1996). Anthony and colleagues published a report
that included both the incidence and prevalence of any non-medical use of each substance as recorded by the NCS (Anthony, Warner, & Kessler, 1994). The figures are
reported in Table 6.
Table 6. Prevalence of non-medical lifetime use and dependence on substances
(Anthony et al., 1994)
Substance
Alcohol
Cannabis
Cocaine
Stimulant (Amphetamine)
Anxiolytic/Sedative/Hypnotic
Analgesic
Psychedelic
Heroin
Inhalant

!

Lifetime
Use (%)
91.5%
46.3%
16.2%
15.3%
12.7%
9.7%
10.6%
1.5%
6.8%

Dependence
(%)
14.1%
4.2%
2.7%
1.7%
1.2%
0.7%
0.5%
0.4%
0.3%
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Notably for comorbidity; of the 48% of respondents who reported a lifetime
history of disorder, 21% had one disorder, 13% had two disorders and 14% had three
or more disorders (Kessler et al., 1994). These figures revealed for the first time on a
population-wide basis that 56% (or more than half) of Americans who had a lifetime
history of disorder, had more than one disorder in that lifetime (or that comorbidity
was more likely than not) (Kessler et al., 1994). The rates of co-occurring mental disorders in those with a substance-related disorder were also high. Of those with a lifetime substance-related disorder 51.4% also had at least one lifetime mental disorder
(Kessler et al., 1996). Of those with a 12-month substance-related disorder 42.7% also
had at least one 12-month mental disorder (Kessler et al., 1996). Conversely among
those with a lifetime mental disorder, 50.9% also had at least one lifetime substancerelated disorder and among those with a 12-month mental disorder, 14.7% also had at
least one 12-month substance-related disorder (Kessler et al., 1996). These figures
revealed that at any given point in time (12-month prevalence) the rate of cooccurrence of mental disorders in those with a substance-related disorder was much
higher than the co-occurrence of a substance-related disorder in those with a mental
disorder (42.7% vs. 14.7%). That is, a co-occurring disorder of the other type was
much more common among the substance-disordered than the mentally disordered
(Kessler et al., 1996). Another interesting measurement relevant to comorbidity the
NCS offered was a temporal analysis of which type of disorder occurred first in those
with comorbidity. This analysis revealed that among respondents with a lifetime history of comorbidity 83.5% retrospectively reported that the mental disorder arose before any abuse or dependence upon substances (Kessler et al., 1996). Among the 12month co-occurring disordered, 89.3% retrospectively reported the mental disorder
arose before the substance use disorder (Kessler et al., 1996).

!

37!

A major finding of the NCS was that the great majority of current (12-month)
psychiatric burden in society was concentrated in a highly comorbid 14% of respondents who had a lifetime prevalence of three or more disorders (Kessler et al., 1994).
This highly comorbid sixth of the population suffered six-of-every-ten (58%) 12month disorders and nearly nine-of-every-ten (89%) severe 12-month disorders recorded in the survey (Kessler et al., 1994). It is to this highly comorbid sub-population
this thesis will return when it examines co-occurring disorders among those in residential treatment.
The NCS figures on the population prevalence of mental disorders and the
population prevalence of the co-occurrence of mental disorders and substance use
disorders represented significant increases on those reported by the ECA study
(Kessler et al., 1996). The figures on substance use disorders were generally similar,
except for an increase in cocaine disorders (Anthony et al., 1994). The NCS found
that 51% of those with a lifetime history of substance-related disorder also had a lifetime history of mental disorder compared to the Ecological Catchment Area study
figure which was only 38% (Kessler et al., 1996). As a result of the NCS the lifetime
prevalence of any disorder among the United States population was now estimated at
just under one-in-two people and the 12-month prevalence for current disorder was
nearly one-in-three Americans (Kessler et al., 1994). Fifty-one percent or one-in-two
Americans had tried an illicit drug over their lifetime and the rate of drug dependence
was the highest of any country on record (Anthony et al., 1994). Comorbidity of substance-related and non-substance-related disorders was also now known to be more
likely than not on a population-wide basis (Kessler et al., 1994). For some commentators the implications of the NCS results were clear, Hall stated:
We need to improve our ability to treat people who have co-morbid mental and substance use disorders. Specialist mental health services need to be better at recognizing
and treating co-morbid substance use disorders among their clients. … Specialist
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drug and alcohol staff have a similar responsibility to recognize mental health disorders among their clients (Hall, 1996, p. 168).

Kessler agreed, saying:
These results have a number of implications for treatment. Perhaps the most obvious
is that special assessment and treatment procedures are needed for patients who present with co-occurring addictive and mental disorders. … In addition, clinicians
should routinely consider the possibility of a co-occurring disorder [and] [a]mong patients with only one type of disorder … clinicians should be aware that these patients
are at increased risk of the subsequent occurrence of later disorders … making them
prime candidates for preventive interventions (Kessler et al., 1996, p. 29).

The figures and findings reported by the nationally-representative NCS have
subsequently been mirrored throughout the world in epidemiological studies conducted over the past two decades (Australian Bureau of Statistics, 2007; Merikangas et al.,
1998; WHO International Consortium in Psychiatric Epidemiology, 2000). The National Institute of Mental Health Epidemiologic Catchment Area study and the National Comorbidity Survey were formative to the field of psychiatric epidemiology,
but they are not without limitations and nor have they gone without criticism. Both
studies (and subsequent epidemiological studies) have been criticised for not proceeding beyond merely describing a range of demographic correlates associated with mental disorder to clarifying how such factors may operate (Weissman, 1987). In this
sense they were thought by some to present findings with little utility to the mental
health of ill people (Weissman, 1987). The methodology the two studies employed
has also been criticised for using a cross-sectional, single point in time retrieval of
lifetime psychopathology approach that is heavily reliant upon long term recall
(Anthony, Eaton, & Henderson, 1995; Giuffra & Risch, 1994). This methodology that
relies upon memory has been criticised as severely underestimating the effects of forgetting and is therefore thought to underestimate the rates of lifetime prevalence
(Giuffra & Risch, 1994; Simon & VonKorff, 1995). In this regard the ECA and NCS
studies have been criticised for presuming the accuracy of long-term recall even
though autobiographic memory is often affected in numerous psychiatric disorders

!

39!

(Simon & VonKorff, 1995). Follow-up interviews conducted 12-months after the
ECA study found significant discrepancies in the 12-month and lifetime psychiatric
histories self-reported by respondents when both original and follow-up diagnostic
information was considered. Twelve-month disorder rates rose from 20% to 28% and
lifetime rates from 32% to 44% (Regier et al., 1998). A study that simulated an
ECA/NCS type study but instituted a constant rate of forgetting among respondents
produced the exact cohort effects seen in the ECA and NCS studies (where the rates
of mental disorders were higher in younger cohorts than older cohorts who have had
more time to forget earlier incidences of disorder in their lives). In the ECA study, for
example, the 25-44 year old cohort had a higher lifetime prevalence than the 65-andover cohort on 64 of 68 symptoms used to diagnose disorders (Giuffra & Risch,
1994). The authors involved in this study with simulated rates of forgetting stated forgetting could have a confounding role in producing cohort differences (Giuffra &
Risch, 1994). Whether the results reported by the ECA and NCS studies represented
genuine cohort effects or were due to the confounding effect of forgetting is therefore
unknown due to the methodology used. The authors of the simulated study concluded
the ECA/NCS results strongly suggest methodological flaws in data collection
(Giuffra & Risch, 1994).
The two Australian versions of the ECA/NCS-type studies were completed in
1997 and 2007. Figures on population-wide comorbidity from the first Australian version of this study, the National Survey of Mental Health and Wellbeing were consistent with the rest of the world and are reported in Table 7 below with the NCS figures for comparison (Andrews, Slade, & Issakidis, 2002; Burns, Teesson, & Lynskey,
2001; Teesson & Burns, 2001; Teesson & Proudfoot, 2003).
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Table 7. Epidemiology of Australian Mental Disorders with US Comparison
(Henderson, Andrews, & Hall, 2000; Kessler et al., 1994; Teesson, Hall, Lynskey, &
Degenhardt, 2000)
Drug/Disorder
Type
Any Disorder
Anxiety Disorder
Affective Disorder

NSMHWB 12-Month
Prevalence (%)
17.7%
9.7%
5.8%

NCS 12-Month
Prevalence (%)
29.5%
17.2%
11.3%

Substance Use Disorder
Alcohol
Other Drugs

7.7%
6.5%
2.2%

11.3%
9.7%
3.6%

NSMHWB = National Survey of Mental Health and Wellbeing, NCS = National Comorbidity Study.!

The second Australian epidemiological study, the National Survey of Mental
Health and Wellbeing 2 conducted in 2007, also reported results similar to those reported all over the world (Slade et al., 2009). Nearly half (45.5%) of Australians aged
16-85 years had experienced a lifetime anxiety, affect and/or substance use disorder
(Slade et al., 2009). One-in-five (20%) had experienced a disorder in the 12-months
prior to the survey interview (Slade et al., 2009). These results are reported in Table 8
below with the first Australian national survey as a comparison:
Table 8. Epidemiology of Australian Mental Disorders in 1997 and 2007 (Henderson
et al., 2000; Slade et al., 2009; Teesson et al., 2000)
Drug/Disorder
Type
Any Disorder
Anxiety Disorder
Affective Disorder

NSMHWB 1997
12-Month Prev.
17.7%
9.7%
5.8%

NSMHWB 2007
12-Month Prev.
17.0%
14.4%
6.2%

Substance Use Disorder
Alcohol
Other Drugs

7.7%
6.5%
2.2%

5.1%
4.3%
1.5%

NSMHWB 1997 = National Survey of Mental Health and Wellbeing 1 conducted in 1997, NSMHWB 2007 = National Survey of
Mental Health and Wellbeing 2 conducted in 2007, 12-Month Prev. = 12-month prevalence.

The Australian epidemiologic surveys utilised the same basic methodology as the
ECA and NCS studies. They are therefore susceptible to the same criticisms of the
limitations and possible flawed methodologies utilised by these studies. The Australian epidemiological surveys found, for example, cohort effects indicating the prevalence of mental disorder declines with age where this may not actually be the case.
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The"Prevalence"of"Co4Occurring"Disorders"in"Treatment"Popula4
tions"
In the period between the Ecological Catchment Area study and the National Comorbidity Survey, commentators stated that, ‘Given the apparent magnitude of the dual
diagnosis problem, it is notable that there are so few recent studies on the epidemiology of this syndrome’ (Galanter et al., 1988, p. 220). The epidemiology or populationwide prevalence of COD has been well studied and reported since this lament. At the
same time as epidemiological research highlighted the population-wide prevalence of
co-occurring disorders during the 1990s and 2000s, research into comorbidity among
those seeking treatment for mental and alcohol and other drug disorders was also undertaken. This research noted the poorer treatment response and outcomes experienced by those who suffer COD in treatment settings compared to those diagnosed
with one disorder alone in such settings, (as noted above). Researchers also investigated whether sequential, parallel or integrated treatment produced better outcomes
for the COD population – a question still the subject of debate although commentators
favour integrated treatment (Flynn & Brown, 2008). Twenty-five years of COD research in treatment populations later, what has not improved is research into the
screening, prevalence and nature of comorbidity in the treatment/clinical population.
This is despite the realisation that,
While much is still to be learned about what constitutes effective treatment, there is
general agreement that, in order to provide any treatment, it is first necessary for
treating clinicians and agencies to recognize that a co-occurring disorder exists
(Croton, 2007, p. 2).

In 2008 Flynn and Brown stated,
There is [still] a need to clarify the rates of COD and, more specifically, the rates of
mental disorder among substance abuse treatment clinics. While prevalence for the
general population can be seen as having obvious significance for national planning,
prevalence in substance abuse treatment programs is the immediate concern of the
substance abuse treatment field and constitutes the demand we are required to address
(p. 37).
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Among researchers it is recognised that, ‘Planning processes need to be informed by accurate estimates of the prevalence of co-occurring disorders and identification of best practice responses’ (Croton, 2005b, p. 3). It is generally accepted that
the prevalence of COD in alcohol and other drug (AOD) “treatment-seeking” populations is even higher than that found in the population-wide epidemiological studies
(H. E. Ross et al., 1988; Whiteford & Groves, 2009). Internationally, however, estimates of the proportion of AOD clients across all treatment modalities who also suffer
from a comorbid mental disorder vary as widely as the methods used to obtain the information. One overview summarized the literature by suggesting that comorbid lifetime mental disorder prevalence in treatment populations is between 50% and 75%
(Center for Substance Abuse Treatment, 2007). Figures from 35%-90% are common
(Fabricius et al., 2008), with 42-60% estimated in Australia (Cole & Sacks, 2008),
57% in South Africa (Fabricius et al., 2008), just over 50% in the United States
(Watkins et al., 2004) and 35%-53% in the United Kingdom (Weaver et al., 2001).
The experimental variation used to obtain the above figures, however, renders the research base covering the prevalence of COD in treatment populations largely incomparable and inadequate. See Appendix B for detailed information on the database
searches conducted to inform this thesis.
Perhaps the largest dataset that speaks to comorbidity in substance abuse
treatment populations in general is the National Survey of Substance Abuse Treatment Facilities (N-SSATS) conducted by the Substance Abuse and Mental Health
Services Administration (SAMHSA) in the United States of America (Substance
Abuse and Mental Health Services Administration, 2014). In the most recent example
of this survey 14,148 of 14,630 treatment facilities responded. This provided a oneday census of 1,249,629 clients enrolled in substance abuse treatment on March 29,
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2013. This survey estimates that 563,071 or 45.1% of those 1,249,629 consumers
were suffering co-occurring mental disorders on that day (Substance Abuse and
Mental Health Services Administration, 2014). Methodologically, however, this figure is based upon each of 14,148 treatment services across the United States of America “estimating” what proportion of their clientele suffered a co-occurring mental disorder without giving any information about how this “estimate” is reached at any of
the system, service or individual levels. For example, the estimates of comorbidity in
the survey could be made on the basis of existing official diagnoses only. The estimates could be made on the basis of completely different methodologies from one
service to the next. Against this uncertain methodological background, variation between the estimated rates of comorbidity reported by the survey ranged from a low of
35.8% in “Other” US Federal Government treatment services to a high of 66.7% in
“Department of Veterans Affairs” US Federal Government treatment services. Variation between different facility operations that contain different treatment modalities is
to be expected (a topic that will be discussed in significant detail below). But variation across states from a low estimate of 27.6% of all clients in Hawaii to a high estimate of 73.1% of all clients in New Hampshire is unexpected and difficult to explain
except through methodological variability. Given the lack of a consistent method of
estimating comorbidity being prescribed by the study, such variation on an overall
state-to-state basis is likely due to low reliability in the methods used for estimating
comorbidity rates. As a result, the overall 45.1% figure is unreliable.
In the case of the residential alcohol and other drug treatment modality up-todate research on the prevalence of co-occurring disorders in this treatment context
simply does not exist. This is because much of the previous research into the prevalence of COD in “treatment” populations reports on collective samples sourced from
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mixed treatment modalities. Compton and others (2000), for example, report on a
sample aggregated from public outpatient methadone clinics, outpatient and inpatient
drug-free programs, outpatient programs for drug-abusing prostitutes and residential
recovery shelters for women. Ross and others (1988) and Rush and others (2013) also
use a similar mixed-modality aggregated approach. This approach wrongly assumes
comorbidity across different treatment modalities is monolithic and that co-occurring
disorder sufferers are homogenous. The Committee for the Substance Abuse Coverage Study explains that:
The modalities, [however,] were designed for different types and severities of problems, and prospective clients often have very set ideas about what type of treatment
they want. As a result, the profiles of clients admitted to the major modalities are
quite different, and one cannot compare the performance or results of each modality
with the others as if they were all simply interchangeable (Gerstein & Harwood,
1990, p. 12).

Residential treatment services, for example, are designed for clients ‘with major impairments and social deficits, including histories of serious criminal behaviour’
(Gerstein & Harwood, 1990, p. 188). The overall level of treatment intensity in different treatment modalities increases from a starting point in the outpatient treatment
modality to its highest intensity in the residential treatment modality and in theory this
should match the levels of problem severity or disability. Clients in different treatment modalities should not have homogenous comorbidity needs and research over a
long period of time confirms this is the case (Gerstein & Harwood, 1990; J. Ross et
al., 2005). In one large study that countenanced 30-years of research into substance
abuse treatment populations using three large datasets that covered several million
substance abuse treatment episodes, the authors found across-modality population differences that remained stable over decades (Craddock, Rounds-Bryant, Flynn, &
Hubbard, 1997). Craddock and colleagues stated:
Perhaps most importantly, each modality … [serves] distinctly different clients. [For
example, c]ompared with the other clients in other treatment modalities, long-term
residential clients… were most likely to be male, most likely to have illegal sources
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as their major source of income, least likely to be employed full-time, and most likely
to be involved in a criminal lifestyle in the year prior to treatment. … These commonalities across decades indicate that the distinctiveness of client characteristics
held up over time, thus supporting the importance of studying differences among clients in various treatment modalities. Outcomes from treatment must be interpreted
within the context of these modality differences (1997, p. 56).

More recently, Ross and others (2005) examined heroin users not seeking treatment
and heroin users seeking treatment across three different treatment modalities (detoxification

units,

residential

rehabilitation

facilities

and

outpatient

metha-

done/buprenorphine maintenance agencies). These authors found heroin users in residential treatment services had significantly higher levels of psychological distress,
suicide history, Axis I and Axis II disorders (J. Ross et al., 2005). It was concluded
that heroin users in residential treatment represented a hard core compared with those
in other treatment modalities (J. Ross et al., 2005). A comprehensive review approaching the topic of comorbidity from the reverse standpoint of the prevalence of
comorbid alcohol and other drug disorders among those in mental health services also
found that the prevalence of comorbidity differed across service settings and geographical areas (Carra & Johnson, 2009). In the light of such research, assuming all
co-occurring disorder sufferers across all treatment modalities are homogenous is unjustified and likely to produce inaccurate results, especially where screening instrument validation is concerned, as we will read below. Treating clients from different
modalities as an aggregate for the purposes of research does not adequately deal with
across-modality client differences. Prevalence research needs to be service-modalityspecific to accurately record the needs of clients in each service modality. The population should not be treated as a monolith and results from studies that employ this
methodology should be viewed as suggestive only.
The dearth of contemporary data about mental disorder comorbidity in the residential AOD treatment modality is evident in recent reviews (Center for Substance
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Abuse Treatment, 2007; Mills et al., 2010). Sources of prevalence rates for mental
disorder comorbidity specifically in the residential AOD treatment modality cited in
recent reviews are based on research conducted by Nancy Jainchill 30-to-40 years ago
in the United States of America (Jainchill, 1994). This research conducted between
1974 and 1984 within therapeutic communities reported a lifetime COD rate of 82%
and a 30-day prevalence of just 45% (Jainchill, 1994). But both mental disorder and
AOD treatment environments, diagnostic systems and drugs of abuse have changed
since this time. This research was also conducted before the emergence of
pseudoephedrine-based amphetamines and the drug ice, as well as cannabis of far
greater potency, all of which are thought to have a role in psychosis. Additionally,
Jainchill's (1994) review identified a 10-year pattern of worsening psychiatric symptoms among those entering treatment for substance use disorders during 1974 to 1984.
It is currently unknown whether this worsening trend has continued.
The little research that has been conducted in recent years has tended to focus
on samples with specific drug-problem types. For example, research on heroin-taking
populations that only investigated the co-occurrence of anxiety and depression (Darke
& Ross, 1997) and outpatient clients on methadone maintenance (Callalay, Trauer,
Munro, & Whelan, 2001). Or research into the psychological profile of people admitted to a methamphetamine detoxification program (Dyer & Cruickshank, 2005). In
2005 heroin users were again studied, but only depression and posttraumatic stress
disorder were assessed (J. Ross et al., 2005). Such subpopulations specifically linked
to opioid or amphetamine dependence alone are not generalizable to the broader substance use disorder treatment population.
More recently when Axis I mental disorder comorbidity has been assessed, it
has either been among treatment modalities other than residential treatment or across
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a multitude of modalities mistakenly treated as a monolith. For example, Axis I mental disorder comorbidity has been assessed, but only among outpatients and limited to
youth (Hides, Lubman, Elkins, Catania, & Rogers, 2007). In a second study Axis I
mental disorder comorbidity was again assessed, but this time across specialized assessment, withdrawal management (detox), residential and non-residential treatment
modalities sourced from a teaching hospital, a general hospital and a community
agency all treated as homogenous (Rush et al., 2013).
Despite several decades of research into co-occurring disorders significant
gaps in the literature remain. Little is known about the prevalence or taxonomy of cooccurring disorders in the residential alcohol and other drug treatment modality. Experts have long opined that, !
Plans at the national, state, treatment service and clinician levels need to be informed
by accurate data on the prevalence, nature and harms of co-occurring disorders within
each of the treatment systems. Such data will hone the planning of resource allocation, program design, policy needs, clinical practice needs, and competency needs
(Croton, 2005b, p. 3).

In the absence of such data, treatment for those with CODs may be suboptimal resulting in higher service utilisation and costs as well as all the harms known to attend undetected, untreated CODs (Wilhelm et al., 2006). Study 1 of this thesis addresses this
gap in the literature and aims to provide estimates of the prevalence of co-occurring
mental disorders within the residential alcohol and other drug treatment modality in
Australia. The questions investigated by Study 1 include: What is the prevalence of
co-occurring Axis I mental disorders in residential AOD treatment services? Has
mental disorder comorbidity worsened in those presenting to residential AOD treatment services since the last known figures taken from the 1970s and 1980s? Has the
rate of psychotic-based disorders increased in residential AOD treatment services?
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The"Need"for"Validated"Screening"Instruments"
As government, clinical and research awareness of CODs have increased so has the
realisation the accurate identification of comorbidity is an important first step towards
improving treatment and effectively managing this population (Ziedonis et al., 2005).
One Australian expert put it succinctly in 2005 stating that, ‘The first, necessary step
towards responding more effectively to co-occurring disorders is to improve the detection of any co-occurring disorder’ (Croton, 2005b, p. 6). Accordingly, both Australian and international guidelines have come to advocate routine screening for
CODs (Center for Substance Abuse Treatment, 2005; Dawe, Loxton, Hides,
Kavanagh, & Mattick, 2002; Gordon, 2008; Hawkings & Gilburt, 2004; Health
Canada, 2002; Institute of Medicine, 2006; Mills et al., 2010; NSW Health, 2000;
Substance Abuse and Mental Health Services Administration, 2002). Many government initiatives have also been aimed at improving the identification and treatment of
those suffering both a substance use disorder and a mental disorder in treatment settings. In Australia, for example, the National Comorbidity Project 1998-2003 developed as a response to the National Strategic Drug Framework 1998-2003 and the Second National Mental Health Plan 1998-2003 (Croton, 2011). This project had a
threefold aim: 1) to identify what comorbidity is; 2) to identify effective treatments
for comorbidity; and 3) to identify how the overall response to the issue of comorbidity can be improved (Croton, 2011). The National Comorbidity Project was followed
by the National Comorbidity Initiative 2003-2010 which aimed to: 1) raise awareness
of comorbidity amongst health professionals; 2) promote examples of good practice;
3) support general practitioners and other health professionals to improve treatment
outcomes; and 4) facilitate resources and information for individuals needing care
(Croton, 2011). National Comorbidity Guidelines that advocated routine screening for
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CODs released in 2010 were one facet of the National Comorbidity Initiative (Mills et
al., 2010).
Despite the release of guidelines, government initiatives, and increasing
awareness of the poor outcomes associated with COD, the ongoing failure to identify
and thereafter treat co-occurring mental disorders in substance misuse treatment is
well documented (Flynn & Brown, 2008). In one large 3-year study that assessed the
rates of detection of CODs in the New Jersey addiction treatment system, CODs were
only detected in 22% of actual cases (N = 47,379; Hu, Kline, Huang, & Ziedonis,
2006). In another significant study counselors failed to identify 32% of 2,128 clients
who reported psychiatric symptoms as needing mental health services (Mericle,
Martin, Carise, & Love, 2012). Clinicians often miss the co-occurrence of mental disorders and substance use disorders because of an absence of routine screening
(Croton, 2007; Donald, Dower, & Kavanagh, 2005; Hu et al., 2006; Lubman, Hides,
& Elkins, 2008; Watkins et al., 2004). A number of commentators assert that in the
United States half of those with COD receive no treatment (Alexander, Haugland,
Lin, Bertollo, & McCorry, 2008; Kessler et al., 1996). Among those who do receive
treatment, both disorders are addressed for only 6% (Alexander et al., 2008), 19% (J.
A. Swartz & Lurigio, 2006) or 50% (Watkins et al., 2004) of clients according to various commentators.
Over recent years it has been acknowledged that clients with COD have received poor care due to gaps in service provision (Adams, 2008; Harris & Edlund,
2005) and that the failure to detect (and therefore treat) mental disorder comorbidity
‘contributes to some of the most expensive and intractable social problems’ (Davis et
al., 2006, p. 263). Put simply unrecognised and untreated comorbidity leads to high
costs and poor outcomes. (Alexander et al., 2008). Yet serious under-identification of
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COD continues, at least in part due to the use of diagnostic tools being ‘usually the
exception rather than the rule’ (Mericle et al., 2012, p. 225). A number of barriers to
the detection and treatment of COD have been identified by commentators including a
lack of integration with and/or access to psychiatric support staff and services, a lack
of routine mental health assessments and a relative dearth of screening measures
available (Hides et al., 2007; Kavanagh, Baker, & Teesson, 2004; McGovern, Xie,
Segal, Siembab, & Drake, 2006). A significant additional barrier to improving the
identification of COD is the paucity of validation research into the various screening
instruments that are currently available to detect COD in AOD treatment systems.
Study 2 of this thesis addresses this latter barrier to the effective identification of
CODs and validates a number of screening measures for use in this population.

Validation"of"Screening"Instruments"
Resources have been published that review the screening measures currently available
to detect co-occurring mental disorders (Center for Substance Abuse Treatment, 2005;
Croton, 2007; Dawe et al., 2002). Some measures, such as the Alcohol Use Disorders
Identification Test (AUDIT) and the Drug Abuse Screening Test (DAST) are designed to detect alcohol and other drug use disorders (respectively) and may be used
in psychiatric populations to identify co-occurring disorders. These are different to
measures designed to detect psychological comorbidity. When selecting measures for
review and recommendation, experts have been mindful that, ‘time, cost and effort
[are] severe initial barriers to implementing anything new into a treatment service system’ (Center for Substance Abuse Treatment, 2005, p. 497). For that reason screening
measures selected had to be widely used, ideally free and in the public domain, require no qualifications to possess or administer, cost nothing for instructions, reproduction or administration, be short in duration and be easy to use, requiring minimal
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staff training (Center for Substance Abuse Treatment, 2005; Dawe et al., 2002). The
same requirements were considered when selecting screening measures to be validated in the second study of this thesis. Measures had to be widely used, free and in the
public domain, short and easy to administer with minimal staff training required of
treatment services.
There are a number of measures available to the AOD treatment industry to
screen for co-occurring mental disorders (Center for Substance Abuse Treatment,
2005; Dawe et al., 2002). What is not available is adequate validation research to
guide treatment services in their choice of measure. Screening measures used to identify COD in AOD treatment systems have been recommended before psychometric
validation research into the instruments’ sensitivity, specificity and overall accuracy
has been undertaken (e.g., the Mental Health Screening Form-III, Carroll &
McGinley, 2001; recommended in Center for Substance Abuse Treatment, 2005; see
also the Self-Reporting Questionnaire 20 before 2010, Lee & Jenner, 2010;
recommended by Croton, 2007). Screening measures are often only validated once in
a particular subpopulation by the measure’s creators without further validation in other subpopulations despite evidence that rates of disorders and their severity likely
vary between settings (Carra & Johnson, 2009; J. Ross et al., 2005) and that this variation reduces the appropriateness of validation data (Castel, Rush, & Scalco, 2008),
(for e.g., see the Modified Mini Screen until 2008, Brandau, Alexander, & Haugland,
2005; Alexander, Haugland, Lin, Bertollo, & McCorry, 2008). It is preferable for
screening instruments to be validated with data obtained from the population in which
they will be used (Castel et al., 2008). This is necessary to guide treatment services in
an appropriate choice as to the best measure for their service and to know at what cutoff score the measure should be used.
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Currently there is an absence of adequate research evidence upon which
treatment services can base and improve their practices to identify COD. Studies that
compare the performance of multiple measures’ are rare and have not been conducted
within residential treatment services. Additionally, much of the research that has been
done has involved instruments that cost money to possess and administer (for e.g., the
Psychiatric Diagnostic Screening Questionnaire) or require administration by a registered psychologist (for e.g., the Symptom Checklist-90-R). Costs and/or qualification
requirements often reduce the use of these measures amongst substance misuse treatment organisations that may have limited resources and/or staff who do not have the
required level of training. Instead these organisations require freely available, easily
administrable measures so no further cost or training burden is imposed.
Often research that has been conducted into the screening instruments available to detect CODs has involved instruments being ‘tested against different reference
standards, using samples drawn from different populations, and employing different
procedures’ (Rush et al., 2013, p. 375). The following literature review highlights the
changes in method, criterion and population evident in the literature and the differing
results these methodological variations have produced, sometimes with the same
measure in a similar population.
Early research validated measures through correlational studies that evidenced
a measure’s concurrent validity with other measures. McLellan and others original
(1980) validation of the Addiction Severity Index (ASI) “severity ratings” is an example of this early methodology. The initial version of the ASI covered six domains:
chemical abuse, medical, psychological, legal, family/social, and employment support
(McLellan et al., 1980). The severity ratings were an unanchored scale scored from 09 for each domain based upon a combination of objective questions including the
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number, intensity and duration of problem symptoms and each participant’s selfassessment of their need for additional treatment in the given domain (McLellan et al.,
1980). The ratings cover the previous 30-days with the higher the number, the greater
the impairment. The validity of the ASI psychological severity rating was determined
by reporting its correlations with other like measures. Among 524 male veteran substance abuse clients the ASI psychological severity scale correlated .64 with the
Maudsley Neuroticism scale, .61 with the Beck Depression Inventory, and .58 with
the Hamilton Depression scale (n = 111) (McLellan et al., 1980). A cluster analysis
was also performed on a random sample of 150 participants to determine whether the
ASI could differentiate respondents into subgroups. This cluster analysis produced six
clusters that significantly differed from one another, however, these clusters did not
neatly cover the six domains proposed for the instrument, nor was there any one mentally disordered vs. not mentally disordered cluster. To the contrary there were several
statistically different clusters with and without high expressed need for additional
psychiatric treatment so this cluster analysis did not support the use of the ASI as a
valid screen for mental disorder amongst a substance-abuse-treatment-seeking sample
of veterans (McLellan et al., 1980).
Kosten and others’ (1983) also tested the concurrent validity of the Addiction
Severity Index but used a criterion-type measure. The Addiction Severity Index was
administered to a sample of 204 male and female treatment-seeking opiate “addicts”
(Kosten et al., 1983). A correlational and “categorical” analysis was undertaken, with
the latter involving a comparison and then cluster analysis of ASI performance in
three different pre-defined groups (anti-social personality, current depression and no
disorder) based on the Research Diagnostic Criteria (RDC, Spitzer, Endicott, &
Robins, 1978). Information for making RDC diagnoses was gathered using the
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Schedule for Affective Disorders and Schizophrenia – Lifetime version (Endicott &
Spitzer, 1978). Concurrent validity was reported with highly significant correlations
between the Addiction Severity Index Psychiatric Severity scale and the Beck Depression Inventory (.51), the Global Assessment Scale (–.42) and the Maudsley Personality Inventory (.55) (all p<.0001) (Kosten et al., 1983). The ASI Psychiatric Severity scale and Beck Depression Inventory (BDI) scores were then compared for
those with and without a current RDC depressive disorder. T-tests revealed significantly higher (more impaired) mean scores for those with, compared to those without,
a depressive disorder for both the ASI (t = 12.3, df = 101, p<.0001) and the BDI (t =
13.9, df = 101, p<.0001) (Kosten et al., 1983). Kosten and others (1983) stated a sensitivity and specificity analysis was undertaken but no receiver operating characteristic curve analysis was provided. At a cut off score of 3, the ASI Psychiatric Severity
scale was reported to have 89% sensitivity and 67% specificity (Kosten et al., 1983).
A similar analysis was done with the ASI Psychiatric Severity scale and the Global
Assessment Scale, but this time comparing means for those with and those without
any non-substance abuse RDC mental disorder (not just depression) (Kosten et al.,
1983). Respondents without any other psychiatric disorders had significantly lower
mean ASI and GAS scores (less impaired) when compared to those with other psychiatric disorders (ASI: t = 9.7, df = 101, p<.0001, GAS: t = 2.5, df = 101, p<.05)
(Kosten et al., 1983). Sensitivity (63%) and specificity (83%) scores were again reported at the same cut off score (Kosten et al., 1983). Lastly a cluster analysis of all
the ASI domain scores was performed with the authors reporting four clusters; a normal cluster, an anti-social cluster, a depressed cluster and a medically impaired cluster
(Kosten et al., 1983). From the dispersion of RDC diagnoses across these cluster
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groups, the authors concluded the ASI was able to distinguish between these diagnostic groups (Kosten et al., 1983).
In 1989 Weiss and others (1989) compared the Beck Depression Inventory
(BDI, Beck, Ward, Mendelson, Mock, & Erbaugh, 1961), the Hamilton Rating Scale
for Depression and the depression subscale of the Symptom Checklist 90 (SCL-90,
Derogatis, Meyer, & King, 1981) among 149 cocaine abusing private psychiatric hospital clients. These measures’ abilities to identify major depression were tested by
comparing their results with the independent diagnoses of two psychiatrists. One was
a ward psychiatrist making discharge diagnoses on the basis of interviews and observations of ward behaviour (using DSM-III criteria (American Psychiatric Association,
1980)). The other was an independent psychiatrist. A consensus diagnosis was provided where the two were in disagreement. Thirteen of the clients, (9% of the sample), were diagnosed with major depression. Sensitivity and specificity were reported
based upon data gathered at three different times: admission, 2 weeks after admission
and 4 weeks after admission. Results are reported in Table 9 below.
Table 9. Sensitivity and specificity of three depression rating scales at three times in
detecting major depression in 149 hospitalized cocaine abusers (Weis et al., 1989)
Scale
Beck Depression Inventory ≥ 12
Admission
2 weeks
4 weeks
Hamilton Rating Scale for Depression ≥ 17
Admission
2 weeks
4 weeks
Symptom Checklist 90 Depression Subscale ≥ 0.9
Admission
2 weeks
4 weeks
+

Sensitivity

Specificity

100%
40%
20%

35%
77%
91%

85%
69%
38%

49%
79%
89%

100%
70%
70%

26%
58%
83%

The authors favoured the BDI’s performance and noted it was shorter than the SCL90 and did not require a trained person for administration like the HDRS. Two other
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findings were of note. First the unacceptably low specificity scores of all the measures
when used at cut off scores that gave acceptable sensitivity at admission. Second the
rapid decline in sensitivity scores over time. These results led the authors to conclude
these measures may be more useful at identifying clients without major depression
than identifying those with the disorder. This conclusion was reached despite these
authors expressly naming sensitivity the more important characteristic when the utility of a screening measure is being assessed on the grounds that a comprehensive psychiatric assessment following screening can provide the required specificity (Weiss et
al., 1989).
A Dutch-translation version of the Addiction Severity Index (ASI)! (Hendriks,
Kaplan, Limbeek, & Geerlings, 1989) was also tested against the Beck Depression
Inventory (BDI, Beck et al., 1961), the Symptom Checklist-90 (SCL-90, Derogatis,
Lipman, Rickels, Uhlenhuth, & Covi, 1974) and DSM-III diagnoses of major depression made on the basis of the third version of the Diagnostic Interview Schedule (DIS,
Robins et al., 1981). One hundred and forty-two detoxification clients at the Hague
were administered these measures within two days of admission. Correlations of .55
with the BDI, .54 with the SCL-90 total score, (including .35 with the SCL-90 somatization sub-scale, .48 with the SCL-90 depression subscale, and .52 with the SCL-90
anxiety subscale), evidenced the concurrent validity of the ASI Psychiatric Status Severity scale (Hendriks, Kaplan, Limbeek, & Geerlings, 1989). Sensitivity and specificity figures were cited for the ASI Psychiatric Status Severity scale’s ability to correctly identify those with and without DSM-III depression diagnoses according to the
DIS in a subsample of 84 respondents. At a cut off score of 4, sensitivity was 86%
and specificity 42%. At a cut off score of 5, sensitivity was 72% and specificity 56%.
The statistical technique used to arrive at these figures was not specified, although the
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authors did note that even at the more sensitive cut off score the ASI still failed to
identify 14% of depression cases (Hendriks et al., 1989).
Different procedures, reference standards and population samples produced
conflicting, as well as incomparable, results in another validation study on the Dutch
version of the Addiction Severity Index (Eland-Goossensen, Goor, Garretsen, &
Schudel, 1997). Three-hundred and twenty-seven heroin and methadone addicted individuals were researched in three treatment groups: a low threshold methadone program (n = 91), a clinical detoxification program where participants did not continue
their treatment (n=72) and the same clinical detoxification program where participants
continued their treatment in a therapeutic community (n = 77). Additionally 83 respondents were not in treatment and had not received treatment for more than two
weeks over the past two years (Eland-Goossensen et al., 1997). The Addiction Severity Index Psychiatric Status Severity scale and the (still current) Addiction Severity
Index Psychiatric Status Composite Score were validated against the Composite International Diagnostic Interview (CIDI, Robins et al., 1988). The authors did not use
ROC curve analysis but stated, ‘cut-off points can be used to distinguish between respondents with and without … problems. The choice of such a cut-off point is based
more often on intuition than on empirical data’ (Eland-Goossensen et al., 1997, p.
587). Sensitivity scores (but not specificity scores) were reported for the Severity
scales at cut off scores of 6, 5 and 4 among 99 respondents with anxiety, affect or
psychotic disorders (sensitivity was 43%, 59%, and 73% respectively) (ElandGoossensen et al., 1997). Eland-Goosensen and colleagues opined that a cut off score
of 6 was optimal, (where only 43% of cases were identified), and stated ‘[t]hat the
data … are not totally compatible with the DSM-III-R data’ (Eland-Goossensen et al.,
1997, p. 587). The Composite Score performed less well than the Severity scale, with
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the largest number of respondents with disorders from all four categories, (affective
disorder, anxiety disorder, psychotic disorder, anti-social personality disorder), scoring a middle-range Composite Score, not a high-range score as expected, bringing
into question what was being measured and how, along with what cut off score truly
best represented a positive result (Eland-Goossensen et al., 1997). Earlier researchers
had warned against using arbitrary approaches to cut off score selection like “intuition”. Murphy and others (1987) had lamented a decade before that:
At the present time … sensitivity and specificity are often reported as unalterable features of a test. A potential user must accept an a priori and often arbitrary decision
about the criterion threshold that led to these values. … While it has been appreciated
that changing the threshold can affect the performance of a test, a standard method
for assessing the complete information needed for a threshold decision has not yet
become a regular part of the procedures used by psychological researchers for assessing diagnostic and screening tests (p. 551).

Both the Eland-Goossensen and others (1997) study and the Hendriks and others
(1989) study that preceded it, tested Dutch-translation versions of the Addiction Severity Index. The results of the two studies, however, were significantly different and
incomparable due to being set in different populations, using different reference
measures and statistical techniques to generate their results. This experimental variation is representative of the early validation literature.

The study by Eland-

Goossensen and others (1997) was also an example of where more sophisticated statistical analyses were necessary to better analyze test performance across a range of
cut off scores.

Receiver+Operating+Characteristic+Curve+Analysis+
Described as new to psychiatry in 1989 (Hsiao, Bartko, & Potter, 1989), Receiver
Operating Characteristic (ROC) curve analyses provide a number of statistics on a
measure’s performance at a certain cut off score including sensitivity, specificity, accuracy, positive and negative predictive values, and positive and negative odds ratios.
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Additionally, ROC curve analyses provide an Area Under the Curve (AUC) score indicative of a measure’s performance across all cut off scores.
The sensitivity of an instrument is a measure of an instrument’s ability to identify illness among the ill (Murphy et al., 1987). Sensitivity is calculated by dividing
the number of true-positives detected by the instrument by the number of all diseased
participants (Schmitz, Kruse, Heckrath, Alberti, & Tress, 1999). The specificity of an
instrument is a measure of an instrument’s ability to correctly identify the absence of
an illness or condition among those who do not have that illness or condition (Murphy
et al., 1987). Specificity is calculated by dividing the number of true-negatives detected by the test by the number of all non-diseased participants (Schmitz et al., 1999).
Both sensitivity and specificity are measured on the basis of a division of the test’s
score range by a criterion threshold or cut point (Murphy et al., 1987). When an instrument’s sensitivity (in this case its ability to correctly identify those with a mental
disorder) and its specificity (its ability to correctly identify those without a mental
disorder) are combined, the result is described as the instrument’s overall accuracy,
also known as its efficiency (Harrington & Newman, 2007). By way of example, if in
a population of 200 there were 100 participants with a certain condition and 100 participants without that condition and at a certain cut off score a measure correctly identified 80 of the 100 participants with that condition as having that condition and 70 of
the 100 participants without the condition as not having the condition, the measure’s
sensitivity would be 80/100 (80%), its specificity 70/100 (70%) and its overall accuracy 75%.
The positive predictive accuracy or value is the proportion or percentage of
cases screening positive that are truly positive for mental disorder (Sacks, 2008;
Zimmerman, Sheeran, Chelminski, & Young, 2004). The negative predictive accura-
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cy or value is the proportion or percentage of cases screening negative that are truly
negative for mental disorder (Sacks, 2008; Zimmerman et al., 2004). If in the above
example the measure actually screened 120 participants as positive for the condition
(including the 80 who actually were), its positive predictive value would be 80/120
(66%). That same example would see the measure having screened 80 participants as
negative (including 70 who were truly negative), giving it a negative predictive value
of 70/80 (87.5%). Predictive accuracies or values are said to be clinically useful but
like sensitivity, specificity and likelihood ratios they vary with the underlying prevalence rate of the population in which they are ascertained (Brenner & Gefeller, 1997;
Schmitz et al., 1999). As the prevalence of a disorder in a population decreases, the
sensitivity and positive predictive accuracy of the test also decrease while the specificity and negative predictive accuracy increase (Brenner & Gefeller, 1997). With
higher population prevalences, the opposite occurs (Brenner & Gefeller, 1997). Thus
where underlying population prevalence is high, statistically sensitivity and positive
predictive accuracy are most important. Where underlying prevalence is low, statistically negative predictive accuracy and specificity are most important.
Positive and negative likelihood or odds ratios are an indication of the change
in odds for a person having or not having a mental disorder given a positive or negative screen at a certain cut off score. Expressed another way, the positive odds ratio
(sensitivity/1-specificity) and the negative odds ratio (1-sensitivity/specificity) express the odds that a person with and without a disorder respectively will score above
the given cut off score on the measure in question (Neovius, Linne, Barkeling, &
Rossner, 2004).
The receiver operating characteristic area under the curve score (ROC-AUC)
is a measure of an instrument’s overall performance across all possible cut off scores
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(Swets, 1988). A graphical curve is constructed where at each cut off score the measure’s true-positive rate (sensitivity) is plotted on the y-axis and its false-positive rate
(1 – specificity) is plotted on the x-axis. Each point thus plotted for each cut off score
is then joined to form a curve and the area under the curve is the measure’s overall
performance at correctly differentiating between a random participant with and without the given condition being screened for across all cut off scores. The closer to the
upper left-hand corner of the graph the curve approaches, the better the performance
of the measure (or the more true-positive cases it detects whilst producing less falsepositive results). ROC-AUC results usually vary between 0.50 and 1.0. A ROC-AUC
score of 0.50 represents a diagonal line with a slope of 1 and indicates a complete lack
of predictive ability, (it is the equivalent of chance, a 50/50 result) (Bisoffi, Mazzi, &
Dunn, 2000). A score of 1.0 would represent perfect prediction. Results between 0.70
and 0.80 represent good accuracy (Cacciola et al., 2008). Results greater than 0.80
represent reasonable to excellent accuracy and results above 0.90 excellent to outstanding accuracy (Cacciola et al., 2008; J. A. Swartz, 2007).
The ROC curve analysis technique and the analyses it afforded represented a
significant improvement in screening instrument validation. What a ROC curve analysis still did not provide was an indication of how best to use a test in a given context
or which cut off score was best for making a diagnosis (Hsiao et al., 1989). The pitfalls of blindly reporting a ROC curve analysis without considering the context of
screening and the implications of choosing different cut off scores are discussed below.

Validation+Studies+That+Use+A+ROC+Curve+Analysis+
Subsequent to ROC curve analysis adoption as a statistical technique, for some years
validation studies continued to be largely incomparable due to other variations in ex-
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perimental methodology such as the criterion measure used. Comparative performance of German language versions of the Symptom Checklist 90 Revised (SCL-90R,

Derogatis et al., 1981) and the General Health Questionnaire 12 (GHQ-12,

Goldberg et al., 1997) was conducted on 572 adult German primary care outpatients
in 1999 (Schmitz et al.). Participants were administered these two screening measures
which were validated against German language versions of the Structured Clinical
Interview for the Diagnostic Manual of Mental Disorders – Third Edition Revised
(SCID-III-R) (past 30-days) and the Impairment Score measure of psychological impairment (score 5+ = disordered). The SCID-III-R and the Impairment Score measure
represented movement to a different (as well as) joint criteria for caseness (Schmitz et
al., 1999). A ROC curve analysis revealed that at each instrument’s best cut off score
the SCL-90-R was slightly more sensitive to the detection of mental disorder (64% vs.
60% for the GHQ-12), both measures had the same specificity (74%) and therefore
the SCL-90-R was slightly more accurate at the screening task (75% vs. 73% for the
GHQ-12). The positive predictive values were .58 for the SCL-90-R and .57 for the
GHQ-12 meaning both measures were only right about a positive screen about half
the time. Negative predictive values were .77 and .76 respectively (Schmitz et al.,
1999). The Area Under the Curve (AUC) scores were also slightly in favour of the
SCL-90-R (.75 vs. .73), a small difference that was not statistically significant
(Schmitz et al., 1999). This research was conducted in a primary care population
where the SCID-III-R put the prevalence of mental disorder at 37% of those tested
(Schmitz et al., 1999).
In 2001 Franken and Hendriks validated the SCL-90 and the Addiction Severity Index Psychiatric Status Composite Score (ASI-PSYCS) against CIDI (DSM-III-R)
anxiety and affective disorder diagnoses only (Franken & Hendriks, 2001). Partici-
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pants were 116 consecutively admitted substance abuse treatment inpatients in the
Netherlands (Franken & Hendriks, 2001). Three ROC analyses were undertaken:
SCL-90 and ASI-PSYCS administration prior to detoxification and SCL-90 administration post detoxification (an average of 19 days later when the CIDI was also administered) (Franken & Hendriks, 2001). The study did not report whether these instruments were compared to current or lifetime CIDI prevalence. Lifetime CIDI prevalence of anxiety or affective disorders (only) was 69.8%. Current CIDI prevalence of
anxiety or affective disorders (only) was 46.6% (Franken & Hendriks, 2001). Cut off
scores were chosen that reported at least 90% sensitivity, suggesting that the authors
appreciated the importance of detecting COD in this population. The results were as
follows in Table 10.
Table 10. ROC Analyses for SCL-90 and ASI-PSYCS (Franken & Hendriks, 2001).
Measure
ASI-PSYCS (pre-detox)
SCL-90 (pre-detox)
SLC-90 (post-detox)

Sensitivity (%)
91.3
92.7
90.9

Specificity (%)
24.1
19.7
49.2

Accuracy (%)
57.7
56.2
70.1

AUC Score
.52
.64
.75

ASI-PSYCS (pre-detox) = the Addiction Severity Index Psychiatric Status Composite Score administered pre-detoxification,
SCL-90 (pre-detox) = the Symptom Checklist 90 administered pre-detoxification, SCL-90 (post-detox) = the Symptom Checklist
90 administered post detoxification, AUC Score = Area under the curve score.

+

The authors rightly concluded that only the post-detoxification SCL-90 could be recommended as a screen for anxiety and affect disorder psychiatric comorbidity among
inpatient substance abuse treatment participants (Franken & Hendriks, 2001). This
study highlighted the importance of the time between admission of screening instruments and the criterion they are to be judged against. The pre-detoxification SCL-90
and the pre-detoxification ASI-PSYCS, barely performed at a level better than
chance, but this may have been largely due to the measures being administered on average nearly 20-days prior to the CIDI criterion they were measured against. The
amount of time between administrations made the results effectively incomparable.
In 2004 Calsyn and others validated the Addiction Severity Index Psychiatric
Status Domain Composite Score (ASI-PSYCS) against a veterans’ version of the
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Medical Outcomes Study Short Form- 36 (SF-36V). The Medical Outcomes Study
Short Form – 36 (SF-36, Ware & Sherbourne, 1992), of which the veterans version is
a minor modification, is a frequently used assessment of health-related quality of life
in medical conditions. It is a self-report instrument that measures eight constructs over
a 4-week period: physical functioning, physical role limitations, bodily pain, social
functioning, emotional role limitations, general mental health, vitality and general
health perceptions (Calsyn et al., 2004). When assessing mental health the latter four
components are aggregated and labeled the Mental Component Summary (MCS). The
former four components are aggregated to constitute the Physical Component Summary (PCS) – a measure of physical health (Calsyn et al., 2004). The Mental Component Summary was used as the criterion measure to assess the validity of the ASIPSYCS with participants categorised as impaired if they scored below the 25th percentile of US population norms on the SF-36 MCS (Calsyn et al., 2004). This study was
conducted among 674 veterans entering various substance abuse treatment modalities
in Washington (detox unit, outpatient with beds provided for the homeless and intensive outpatient) (Calsyn et al., 2004). Five hundred and twenty-six of these participants (78% of the sample) fell within the impaired category (Calsyn et al., 2004). A
mean of 20-days after admission to treatment participants were administered the ASIPSYSCS and the SF-36V (Calsyn et al., 2004). Correlations and ROC analyses were
undertaken. The ASI-PSYCS correlated highly significantly not only with the SF-36V
Mental Component Summary aggregate and each of its individual components, but
also with all of the components of the Physical Component Summary as well (p <
.001) (Calsyn et al., 2004). These results provided evidence of concurrent but not discriminant validity for the ASI-PSYCS when compared with the SF-36V (Calsyn et
al., 2004). The ROC-AUC score for the ASI-PSYCS was .90 (Calsyn et al., 2004). At
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a cut off score of .22 the ASI-PSYCS demonstrated 90% sensitivity, 71% specificity
and 80.5% accuracy (Calsyn et al., 2004). The construct validity of the criterion
measure itself (the SF-36V) is another question, an issue that came to the fore in a
study by Degenhardt and others (2005) examined below. Certainly there is a strong
relationship and concurrent validity between the ASI-PSYCS and the SF-36V Mental
Component Summary, the latter representing yet another measure used as a criterion
in this line of research.
The potentially confounding effect of using different “gold standard” criterion
measures was emphasized in a validation study on a brief 7-item Psychosis Screener
(PS) (Degenhardt et al., 2005). The study was conducted in two samples, the first
consisted of 87 inpatient participants whose Psychosis Screener responses were compared to International Classification of Diseases version 9 (ICD-9) diagnoses obtained
from hospital discharge records. Sample 2 consisted of 259 persons whose responses
to the seven screener items were compared to International Classification of Diseases
version 10 (ICD-10) and DSM-III-R diagnoses derived using the Diagnostic Interview for Psychosis (DIP). According to the criterion measures used, sample 1 had
51.3% ICD-9 affective psychosis, 16% schizophrenia and 31.3% some other (nonpsychotic) disorder (Degenhardt et al., 2005). Sample 2 consisted of just under half
(47.1% and 46.4%) schizophrenia according to DSM-III-R and ICD-10 criterion
measures respectively, almost 10% schizoaffective disorder (9.3% and 9.8% DSMIII-R and ICD-10 respectively), around one-quarter affective psychosis (DSM-III-R
23.9%, ICD-10 25.5%), and the remaining fifth either a different diagnosis (DSM-IIIR 15.8%, ICD-10 13.7%) or no diagnosis (DSM-III-R 3.9%, ICD-10 5.0%)
(Degenhardt et al., 2005). The authors concentrated upon psychotic disorders because
even though lower in prevalence than other mental disorders, psychotic disorders ‘uti-
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lise a disproportionately high segment of health services … [and] … impose a considerable public health burden because of their impact on sufferers and their families [citation omitted]’ (Degenhardt et al., 2005, p. v). Narrow and broad definitions of psychosis were used for the analysis; the narrow definition was limited to diagnoses of
either schizophrenia or schizoaffective disorder. The broad definition also included
diagnoses of affective psychosis. The very high population prevalences of the disorders in question meant that sensitivity, positive predictive values and likelihood ratios
should be influenced by this underlying population prevalence to be high (Brenner &
Gefeller, 1997). Even so, the ROC analysis of sample 1 (testing the PS against ICD-9
diagnoses of psychosis that included affective psychoses) produced an area under the
curve score barely better than chance (.55) (Degenhardt et al., 2005). See Table 11
below for full results:
Table 11. ROC Analysis for Broad and Narrow Definition of Psychosis (Degenhardt
et al., 2005)+
Sample
Sample 1 Broad (N=87)
Sample 2 Broad (N=259)
Sample 2 Broad (N=259)
Sample 1 Narrow (N=87)
Sample 2 Narrow (N=259)
Sample 2 Narrow (N=259)

Criterion
ICD-9
ICD-10
DSM-III-R
ICD-9
ICD-10
DSM-III-R

Cut
3
1
1
3
3
3

Sens
25.4
98.1
97.6
57.1
82.1
81.5

Spec
85.7
39.6
35.3
84.9
57.0
56.6

PPV
68.4
87.7
86.0
42.1
70.8
70.8

NPV AUC
82.4
.55
82.6
.79
78.3
.77
91.2
.78
71.4
.73
70.3
.74

Sens = Sensitivity, Spec = Specificity, PPV = Positive Predictive Value, NPV = Negative Predictive Value, AUC = Area Under
the Curve Score, ICD-9 = International Classification of Diseases – 9, ICD-10 = International Classification of Diseases – 10,
DSM-III-R = Diagnostic and Statistical Manual for Mental Disorders III – Revised.

+

The authors hypothesized the barely better than chance result with sample 1 was possibly due to a discrepancy in the “gold standard” used to categorize these patients. In
the words of the authors the poor results may have been ‘due to discrepancies between ICD-9 and ICD-9-CM codes, particularly for affective psychoses’ (Degenhardt
et al., 2005, p. 13). Degenhardt and others thought this possibility was supported by
the fact the PS was able to discriminate between cases and non-cases using the two
other diagnostic systems as “gold standards” (ICD-10 and DSM-III-R) (Degenhardt et
al., 2005). Even in the same sample and being interviewed with the same Diagnostic
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Interview for Psychosis (DIP), however, results for sample 2 still differed slightly depending upon whether ICD-10 or DSM-III-R classification systems were used
(Degenhardt et al., 2005). The different operationalisation of disorders used by the
three different “gold standard” criterion measures in the study caused the authors to
note:
This highlights another issue in the use of “gold standards”: they are assumed to be
valid and accurate. Any limitations in the ability of these diagnostic systems to discriminate between actual cases and non-cases necessarily attenuates the distinction
between true cases and non-cases used in ROC analyses, and hence reduces the ability of the analysis to estimate the true discriminant power of the screener [citation
omitted] (Degenhardt et al., 2005, p. 14).

Recent studies have increased the methodological standardization of this area of
research by settling upon the Structured Clinical Interview for DSM disorders and/or
the Composite International Neuropsychiatric Interview as the criterion measures
against which screening instruments should be validated. Other methodological problems have remained, however, such as using aggregated populations drawn from multiple different settings and failing to report all the statistics necessary to understand
instrument performance. In 2007 more than 150 screening measures then available
were comprehensively reviewed with regard to cost (public domain), brevity (less
than 20 minutes), ease of administration (no specific mental health training needed)
and existing psychometric validation work (Sacks, Melnick, Coen, Banks, Friedmann,
Grella, & Knight, 2007; Sacks, Melnick, Coen, Banks, Friedmann, Grella, Knight, et
al., 2007). Three measures were chosen by an expert panel to be validated against the
Structured Clinical Interview for DSM-IV in a prison substance abuse population; the
Global Appraisal of Individual Needs Short Screener version 1.0 (GSS, Dennis, Chan,
& Funk, 2006), the Mental Health Screening Form (MHSF, Carroll & McGinley,
2000) and the Mini-International Neuropsychiatric Interview - Modified (MINI-M,
Sheehan et al., 1998). A pilot study was conducted among 100 participants with an
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actual rate of mental disorders of 60%. The authors reported in this population the latter two measures, the MHSF and the MINI-M, performed the best when these three
measures were run head-to-head against one another. The MHSF had the highest sensitivity (90%) and the highest overall accuracy score (73%) at a cut-off score of three.
The MINI-M produced the highest specificity score (52.5%) or was the best at identifying cases that did not have a co-occurring mental disorder at a cut-off score of five
(Sacks, Melnick, Coen, Banks, Friedmann, Grella, & Knight, 2007). ROC curve area
under the curve scores for correctly determining whether any co-occurring mental
disorder was present or not across all cut off scores also favoured the MHSF and
MINI-M as outperforming the GSS (.805, .741 and .731 for the MHSF, the MINI-M
and the GSS respectively) (Sacks, Melnick, Coen, Banks, Friedmann, Grella, &
Knight, 2007). ROC curve areas for determining the presence of any “severe” mental
disorder, (defined as major depression, schizophrenia and bipolar disorders), were also calculated and ranked the instruments the same way (.659, .642 and .639 for the
MHSF, the MINI-M and the GSS respectively) (Sacks, Melnick, Coen, Banks,
Friedmann, Grella, & Knight, 2007). Finally in the pilot study a correlation then regression analysis was performed to determine which items from each screener correlated with and explained the variance in positive SCID diagnoses of mental disorder
and severe mental disorder respectively. For mental disorders the authors found that
six items were highly correlated with/explained the variance in SCID diagnoses: four
items from the MHSF, one item from the MINI-M and one item from the GSS. For
severe mental disorder, (major depression, schizophrenia and bipolar disorders), three
items were identified, two from the MHSF and one from the MINI-M (Sacks,
Melnick, Coen, Banks, Friedmann, Grella, & Knight, 2007).
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A subsequent validation study was conducted among 180 participants again
drawn from prison substance abuse settings, this time with an actual rate of mental
disorder of 78.3% (Sacks, Melnick, Coen, Banks, Friedmann, Grella, Knight, et al.,
2007). Table 12 notes the results of this study for determining the presence or absence
of any disorder weighted for gender along with the test-retest reliability of each measure.
Table 12. Sensitivity, Specificity, Accuracy and Test-Retest Reliability of Three
Measures Detecting Any Mental Disorder Weighted for Gender (Sacks, Melnick,
Coen, Banks, Friedmann, Grella, Knight, et al., 2007)
Measure
GSS
MHSF
MINI-M

Cutoff
2
3
5

Sensitivity
81.6%
80.9%
71.3%

Specificity
47.1%
47.5%
60.7%

Accuracy
72.6%
72.1%
68.5%

Test/Re-test
Κ = 0.381
Κ = 0.625
Κ = 0.618

Note. MHSF = Mental Health Screening Form, GSS = Global Appraisal of Individual Needs Short Screener, MINI-M = MiniInternational Neuropsychiatric Interview – Modified.

+

It should be noted the GSS performed better than in the pilot study as the most accurate instrument, but also returned a much lower test-retest reliability score on the important task of consistently indicating the same respondents as needing further assessment for any disorder (Sacks, Melnick, Coen, Banks, Friedmann, Grella, Knight,
et al., 2007). Expressed as a percentage of the time each measure agreed with itself
about the need to refer a participant for further assessment, the scores were: MHSF
(85.0%), MINI-M (81.7%) and GSS (76.7%). Otherwise the scores were quite similar
and the importance of sensitivity given the high prevalence of disorder can be noted
by observing the MINI-M result. Regrettably positive and negative predictive values
and odds ratios were not reported so only a partial picture of instrument performance
could be gained. For detecting severe mental disorders the results are reported in Table 13 below.
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Table 13. Sensitivity, Specificity, Accuracy and Test-Retest Reliability of Three
Measures Detecting Severe Mental Disorders Weighted for Gender (Sacks, Melnick,
Coen, Banks, Friedmann, Grella, Knight, et al., 2007)
Measure
GSS-IDS
MHSF
MINI-M

Cutoff
5
11
10

Sensitivity
37.5%
35.4%
41.8%

Specificity
95.9%
93.3%
60.7%

Accuracy
76.7%
74.5%
68.5%

Test/Re-test
Κ = 0.487
Κ = 0.761
Κ = 0.682

Note. MHSF = Mental Health Screening Form, GSS-IDS = Global Appraisal of Individual Needs Short Screener – Internal Disorder Screener, MINI-M = Mini-International Neuropsychiatric Interview – Modified.

+

The GSS again performed the most accurately in detecting severe mental disorder, but
again did so less reliably/consistently than the other measures. Expressed as a percentage of the time each measure agreed with itself about the need to refer a participant with severe mental disorder for further assessment, the scores were: MHSF
(91.7%), MINI-M (88.3%) and GSS (83.3%) (Sacks, Melnick, Coen, Banks,
Friedmann, Grella, Knight, et al., 2007). The other notable aspect of the above results
was the very low sensitivity demonstrated by all the measures at their statistically
most accurate cut off scores. The cut off scores reported may have been the statistically most accurate, but measures failing to detect far more than half of the cases of serious mental disorder present in a population obviates the purpose of screening. The
important context of screening, a desire to practically identify a maximum number of
clients with mental disorder comorbidity, reveals these statistically generated cut off
scores as clinically inappropriate. The importance of considering the context of
screening is highlighted and in this instance would have led to lower cut off scores
being recommended despite a slight reduction in accuracy so that cases of comorbidity did not slip through the net of screening. At the conclusion of this otherwise excellent comparison study, Sacks and others rightly warned that the instruments concerned could be expected to perform differently in different populations and that the
results reported should not be generalised beyond the prison populations in which
they were found (Sacks, Melnick, Coen, Banks, Friedmann, Grella, Knight, et al.,
2007).
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In 2008 Cacciola, Pecoraro and Alterman conducted an archive analysis to
validate the many indices of the Addiction Severity Index Psychiatric Status domain
(Cacciola et al., 2008). The Addiction Severity Index is mandated for use in licensed
substance abuse treatment programs in a majority of states in the United States of
America (Cacciola et al., 2008). Some of the psychiatric summary scores produced by
the ASI had been validated using straight correlations with pen and paper measures,
but a ROC curve analysis validating the measure against a full structured clinical interview had not been previously undertaken (Cacciola et al., 2008). In a mixed inpatient, residential and outpatient sample of 672 respondents all four ASI Psychiatric
summary scores were included in the analysis (Interviewer Severity Rating, ISR;
Composite Score, CS; Clinical Factor, CF; and Evaluation Indices, EI). Results of the
ROC curve analysis against the SCID-III-R are in Table 14 below.
Table 14. ROC curve analysis of four ASI Psychiatric scales (Cacciola et al., 2008)
ASI Scale
ISR
CS
CF
EI

AUC
.73
.76
.78
.75

Cut off
3
.22
53
52

Sensitivity
81.19%
80.07%
84.98%
79.73%

Specificity
52.89%
60.11%
54.93%
59.66%

Accuracy
67.04%
70.09%
69.96%
69.70%

ASI Scale = Addiction Severity Index Psychiatric Status scale, AUC = Area Under the Curve score, ISR = Interviewer Severity
Rating, CS = Composite Score, CF = Clinical Factor, EI = Evaluation Indices.

+

In the same year Alexander and others (2008) validated a version of the Mini
International Neuropsychiatric Interview - Modified, called the Modified Mini Screen
(MMS, Brandau et al., 2005). The study was conducted in a mixed population of 476
individuals in chemical dependency treatment across 23 different settings in jails,
shelters and street community outreach programs (Alexander et al., 2008). Forty-six
percent of this population met criteria for anxiety, mood or psychotic disorders according to the Structured Clinical Interview for DSM-IV (Alexander et al., 2008).
Eighty percent of the interviews were conducted by telephone and SCID interviews
took place within 2 weeks of the screening interview (Alexander et al., 2008). Three
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indices of reliability were reported, internal consistency (Chronbach’s Alpha = 0.92),
inter-rater reliability (92%), and test-retest reliability (based upon 42 screens = 79%)
(Alexander et al., 2008). A full ROC curve analysis was undertaken and importantly,
these authors reported not only the usual sensitivity, specificity and overall accuracy
values, but also positive and negative predictive values, the proportion of participants
that were indicated as needing further assessment at each cut off score and the number
of true cases that were missed at that cut off score. These last two figures, (number of
cases indicated as needing further assessment and number of true cases missed at a
given cut off score), are particularly helpful for understanding the practical implications of using a screen at a given cut off score and should always be reported by validation studies. Table 15 contains these results. The overall area under the curve score
was 0.81, indicating a high probability the MMS would correctly differentiate a random disordered participant from a random not disordered participant across all cut off
scores (Alexander et al., 2008).
Table 15. Modified Mini Screen (MMS) Validation Results (Alexander et al., 2008)
Cut Off
Score

Sensitivity

Specificity

6
7
8
9

81.9
75.0
69.6
62.8

61.4
69.5
78.3
82.7

Positive
Predictive
Value
61.4
64.8
70.7
73.1

Negative
Predictive
Value
81.9
78.8
77.5
74.8

Overall
Accuracy
70.2
71.8
74.6
74.2

% Sent
Further
Assess.t
57.1
49.6
42.2
36.8

% of True
Cases
Missed
18.1
25.0
30.4
37.2

Based on a SCID-interview prevalence of 42.9% for current anxiety, mood or psychotic disorder.

+

These authors attempted to compare the MMS results they obtained with results other
authors had obtained using other screening measures in other populations published in
other studies. Attempting such a cross study comparison is of questionable value because the studies were completed in different populations with different underlying
prevalences of disorder using different methodologies, criterion measures, etc. Different underlying population prevalences, among other things, effect sensitivity, specificity, positive and negative predictive values and positive and negative odds ratios
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(Brenner & Gefeller, 1997). Cut off scores are unlikely to be the same and instrument
performance will not be as reported in one population or setting when used in another
(Brenner & Gefeller, 1997; Castel et al., 2008). Irrespective in the population in question the MMS performed equally well across gender and ethnic groups. It should be
noted, however, that even when the most sensitive cut off score of 6 on the MMS was
used a full 18% of disordered cases in this study were missed. This is an undesirable
result where the aim of screening is not to let anyone with COD slip through the
screening net. This result again highlights the importance of using a cut off score that
affords high sensitivity to the detection of COD.
Two-years after the study conducted by Alexander and others (Alexander et
al., 2008), two measures were validated for possible use in the Psycheck screening
package. Unfortunately 117 individuals were sourced from mixed treatment modalities for this validation study, a recurrent methodological limitation in the recent literature to be dealt with below (Lee & Jenner, 2010). An amended version of the Self Reporting Questionnaire 20, the Self Reporting Questionnaire 20 – Revised (SRQ-20R)
and the General Health Questionnaire 28 (GHQ-28) were validated against the mental
health module of the Composite International Diagnostic Interview – Auto, a computerized 1997 version of the CIDI that applied DSM-III-R and ICD-10 diagnostic criteria (Lee & Jenner, 2010). The General Health Questionnaire 28 data was collected
using the usual Likert scoring system and this data was then converted to dichotomous score data (GHQ-R; symptoms vs. no symptoms) to facilitate comparison with
the dichotomous SRQ-20R. The Self Reporting Questionnaire was first designed by
the World Health Organisation to screen for psychiatric disturbance in primary health
care settings, especially in developing countries (Beusenberg & Orley, 1994). Originally, the Self Reporting Questionnaire contained 25 questions, 20 related to neurotic
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symptoms, four concerning psychotic symptoms and one question asking about epileptic-type fits or convulsions (Beusenberg & Orley, 1994). This measure is known as
the Self Reporting Questionnaire 25. Lee and Jenner’s (2010) adaptation of this
measure used only the 20 questions related to neurotic symptoms. These questions
were adapted to the AOD treatment environment by the addition of an extra column
that asked respondents to indicate whether the problem they had reported had also occurred at a time when they were not using drugs or alcohol. The resultant measure
was called the Self Reporting Questionnaire 20 – Revised (SRQ-20R). Participants
were recruited from four outpatient counselling clinics, an acute assessment clinic,
ambulatory detoxification services and two pharmacotherapy clinics. Some had already been in treatment for up to three-months at the time of recruitment. This is a
long time frame for the validation of a measure presumably intended to be administered shortly after admission. Clients with a serious medical illness, active suicidal
ideation, acute psychosis, and those in acute drug withdrawal were not eligible to participate (Lee & Jenner, 2010). In what the authors describe as the first validation
study of the Self Reporting Questionnaire 20 in a clinical drug treatment setting, the
following results were reported, see Table 16:
Table 16. Self Reporting Questionnaire Amended and Normal Versions Validation
Results (Lee & Jenner, 2010).
Measure
SRQ-20R

Cut Off
3.5
4.5
5.5

Sensitivity
0.897
0.809
0.765

Specificity
0.755
0.837
0.918

SRQ-20

7.5
8.5
9.5

0.838
0.765
0.706

0.653
0.735
0.796

SRQ-20R = the amended version of the Self Reporting Questionnaire 20, SRQ-20 = the Self Reporting Questionnaire 20.

+

Sensitivity and specificity scores for the General Health Questionnaire 28 were not
reported, making comparison of the two measures at specific cut off scores impossible. Area under the curve scores were reported as follows: SQR-20R (0.895), SRQ-20
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(0.839), GHQ-28 (0.797) and GHQ-R (0.780) (Lee & Jenner, 2010). The authors concluded the SRQ-20R was most successful at identifying non-psychotic mental health
disorders and incorporated it into the Psycheck screening toolkit at a recommended
cut off score of 5 (Lee & Jenner, 2010).
Rush and others (2013) published a promising validation study that compared
four screening measures against the Structured Clinical Interview for DSM-IV-TR
Axis I Disorders – Research Version (First, Spitzer, et al., 2002). Unfortunately there
were some methodological issues with this study. Firstly, the study was conducted
across a mixed modality population and only reported results aggregated across all the
modalities. In this regard Rush and others (2013) stated their sites were intentionally
chosen to include a heterogenous mix of services and clients, but by treating these
heterogenous groups as a monolith for the purposes of screening instrument validation
these authors produced results that would not generalize to any specific treatment
modality individually. As far back as 1982 Hanley and McNeil noted that, ‘ROC
curves have been plotted and evaluated qualitatively with relatively little attention
paid to their statistical characteristics’ (p. 29). Castel, Rush and Scalco (2008) explain
that:
Validity has been referred to as a property of the screening test but is better conceptualized as a property of a procedure, i.e., the use of a screening test, in a given context,
for a specific purpose (Streiner and Norman 2006). Thus, on screening for mental
disorders among clients in treatment for substance use disorders, the question is to
find screening tools that have been validated with samples drawn from the target
population, within the treatment context (p. 65).

If a measure is validated across two or more different settings with different populations in each, (for e.g., an outpatient setting and a residential setting), the different settings will likely have different prevalences and types of comorbidity at different levels of severity (Ries, 2008). For example, a very large study (N = 1,814,830) conducted by Lai and Sitharthan (2012), found different hospital settings had different rates
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of comorbidity. If sensitivity, specificity and AUC scores are calculated from both
settings combined, the measure is unlikely to perform as reported in either of those
settings individually (Brenner & Gefeller, 1997). The question asked by studies that
aggregate different treatment populations in this way might not be specific enough
(for e.g., “Is this screening test valid among clients in treatment for substance use
disorder?” or “Is this screening test valid?”). It is preferable to ask, “Is this screening
test valid among clients in this treatment modality?” Ideally, measures should be validated in the population or setting in which they will be used because ‘validity is not a
property of a screening instrument that remains stable across different populations’
(Castel et al., 2008, p. 70). Sensitivity, specificity, ROC-AUC scores, positive and
negative predictive values and odds ratios all vary with the underlying prevalence and
taxonomy of disorders in the population in which they are used (Brenner & Gefeller,
1997). Research suggests the populations and the prevalence of COD varies across
different treatment modalities (Carra & Johnson, 2009; Craddock et al., 1997;
Gerstein & Harwood, 1990; J. Ross et al., 2005). These differences preclude acrossmodality aggregation or comparisons (Craddock et al., 1997). Screening measure performance including appropriate cut off scores will not be the same in different populations. ‘Thus, the validity of a screening instrument has to be reassessed in accordance
with the intended use in studies that will also inform the choice of cutoff scores’
(Castel et al., 2008, p. 70). As advised by Brenner and Gefeller:
The validity of diagnostic tests can typically be quantified only in relation to a defined distribution of the underlying traits. As a consequence, estimates of sensitivity
and specificity of various diagnostic tests cannot be compared, unless they are derived from populations in which this distribution is comparable. … These findings …
require careful consideration by public health professionals in the design of screening
programs … [which] may be considerably improved by taking the variability of performance of diagnostic tests between patient subgroups into account (1997, p. 989).

Another limitation of Rush and other’s (2013) study was its relevance to an
AOD treatment industry in need of screening instruments that have no costs associat-
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ed with their use. Two of the four screening measures validated in the study have
costs associated with either their purchase and/or administration, making them less
viable as screening options for much of the addiction treatment industry. Rush and
others administered the GAIN Short Screener – Internalizing Disorder Screener
(GSS-IDS, Dennis et al., 2006 a user license costs $100 per site) and the Psychiatric
Diagnostic Screening Questionnaire (PDSQ, Zimmerman & Mattia, 2001, the test
manual costs US$55 + on average US$2.10 per administration for summary scoring
sheets and test booklets). These two measures along with the Psychiatric subscale of
the Addiction Severity Index (McLellan et al., 1992) and the K6 (Kessler et al., 2002)
were administered to 544 clients across three treatment centers, (a teaching hospital, a
normal hospital and a community agency), involved in the provision of a number of
treatment modalities (specialized assessment, withdrawal management, residential
and non-residential services) (Rush et al., 2013). The overall prevalence of Axis I disorders across all these modalities taken as a whole was 69.9% (Rush et al., 2013). The
performance of the four screening measures in this mixed population is summarized
below in Table 17. Note: for reporting purposes the highest aggregate of sensitivity
and specificity for each measure was chosen as the cut off score reported and then the
positive and negative predictive values at that cut off score are also reported.
Table 17. AUC, Sensitivity, Specificity, Positive Predictive Value and Negative Predictive Value of Four Screening Measures (Rush et al., 2013)
Measure
GSS-IDS
K6
ASI(5)
PDSQ

AUC
.78
.78
.77
.82

Cut Off
3
9
61-70
35-39

Sensitivity
71
76
51
74

Specificity
72
70
86
74

PPV
81
86
90
87

NPV
62
56
43
55

AUC = Area Under the Curve score, PPV = Positive Predictive Value, NPV = Negative Predictive Value, GAIN-SS-IDScr =
GAIN Short Screener - Internalizing Disorder Screener, ASI (5) = Addiction Severity Index 5th Edition Psychiatric Status Domain, PDSQ = Psychiatric Diagnostic Screening Questionnaire.

+

A thorough literature review of the validation studies completed to date reveals the lack of research to compare popular, freely available, easily administrable
screening measures in a residential AOD treatment population. The available
!
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measures have not been validated and compared in this population. Study 2 of this
thesis addresses this gap in the literature and aims to provide evidence upon which
residential AOD treatment services can base and improve their practices. There is a
need to conduct validation studies that provide comparative data amongst screening
measures to help identify those that might perform best for particular treatment settings. If treatment services are to improve the identification and (thereafter) treatment
of clients with co-occurring disorders, an evidence-base must be provided to inform
these services which screening instrument(s) to use and at what cut-off score(s). Study
2 validates and compares five commonly used screening measures against a Structured Clinical Interview as a criterion for caseness. Research questions answered by
Study 2 will include:
1.! What is the rate and taxonomy of mental disorder comorbidity in residential
AOD treatment services as determined by a standardized semi-structured clinical interview?
2.! How do commonly used screening measures compare in detecting comorbid
mental disorders?
3.! What are the optimal cut-off scores to be used in this population?
!
!
+
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Chapter+2+Study+11+
1."Introduction"
Currently, internationally and in Australia, there are limited data regarding the extent
of mental disorder comorbidity in AOD residential treatment services. Little is known
about contemporary residential AOD treatment populations specifically. This is likely
to hamper the appropriate development of treatments and services to address comorbidity. This study aims to fill this gap by using standardized, widely used screening
measures to estimate the prevalence of co-occurring Axis I mental disorders in Australian AOD residential treatment services.
!

2."Materials"and"methods"
2.1.+Participants+
The study was conducted across eight of The Salvation Army's AOD recovery service
centers located throughout New South Wales, the Australian Capital Territory and
Queensland during 2008-2009. The Salvation Army residential recovery services provide up to 10-months of residential alcohol and other drug treatment. Participants
were 278 AOD residential recovery service clients. The Salvation Army Bridge Program uses the 12-Step recovery model based upon a disease perspective of addiction
and aims for abstinence. University of Wollongong Human Research and Ethics
Committee approval was gained for the study and all participation followed an informed consent process with participants. There were 233 (84%) males and 44 (16%)
females (one participant failed to enter their gender). Ages ranged from 18 to 68years, averaging 37-years old (SD = 10.90). Participants had been in the programs for
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1
This chapter is based on Mortlock, K. S., Deane, F. P., & Crowe, T. P. (2011). Screening for mental
disorder comorbidity in Australian alcohol and other drug residential treatment settings. Journal of
Substance Abuse Treatment, 40(4), 397-404. doi: 10.1016/j.jsat.2011.01.002
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an average of 16-weeks (SD = 17.05) and indicated they had alcohol or other drug
problems for an average of 17-years (SD = 9.59). Alcohol was the primary drug of
concern for 155 participants (55.8%), followed by amphetamines for 41 participants
(14.8%), cannabis for 29 participants (10.4%) and heroin for 16 participants (5.8%).
Most participants (63%) had sought drug or alcohol treatment previously and almost
half (48%) indicated they had sought treatment for a mental disorder previously. Fifty-seven percent of clients reported at least one historical mental disorder diagnosis.
Sixty-eight participants (24%) were resident in a recovery service that included an
identified dual disorder program for some (less than 50%) of its clients. However, the
overall rate of mental disorder at this service was actually lower than the rate of mental disorder in the rest of the sample so this did not positively skew the estimates.
!

2.2.+Materials+
The rate of CODs in The Salvation Army AOD recovery service centers was estimated by administering two widely used mental disorder screening instruments as part of
a larger cross-sectional study:
Addiction Severity Index—Self-Report Psychiatric Status Domain
The Addiction Severity Index (ASI; McLellan et al., 1992; McLellan et al., 1980) is
the most used measure in research of substance abuse outcomes (Doub, 2001). It has
been extensively validated, including within COD populations (Hodgins & ElGuebaly, 1992). The full ASI is a structured clinical interview that usually takes approximately 40 minutes to complete. It covers seven domains: medical condition, employment, drug use, alcohol use, legal status, family/social relations and psychiatric
condition (McLellan et al., 1992). ASI composite scores in each domain are arithmetically derived indices based upon items that examine problem severity over the last 30
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days. Scores range from 0 (no significant problem) to 1 (extreme problem) (Clark &
Young, 2009).
In this study, a self-report version of the ASI Psychiatric Status domain was
used (ASI-SR; Rosen, Henson, Finney, & Moos, 2000). Cacciola, Pecoraro, and Alterman (2008) reported that at a cutoff score of 0.22 the ASI Psychiatric Status Composite Score had a sensitivity of 80.07% and a specificity of 60.11%, giving the instrument an overall accuracy of about 70% in their sample where it predicted 58% of
the sample was positive for mental disorder and the actual overall prevalence as
measured by a SCID-III-R diagnostic interview was 45.3%.
Rosen et al. (2000) compared the full interview version with the selfadministered version of the ASI and concluded the two formats had similar internal
consistency and were strongly correlated in the Psychiatric scale (0.67). The mean
endorsement of psychiatric symptoms was significantly higher on the selfadministered version (0.36) than in the interview (0.27), p < .01, in line with a general tendency to endorse more problems on the pencil-and-paper questionnaire (Rosen
et al., 2000). The authors speculated this difference may reflect social desirability
concerns with respondents more willing to endorse psychiatric symptoms on a penciland-paper measure than when face to face with an interviewer (Rosen et al., 2000).
Given the negative consequences associated with unidentified comorbidity, the tendency of the ASI Self-Report Psychiatric Status Domain (ASI-SR) to act in a more
sensitive manner was viewed as desirable in our population.
The ASI is considered adequate as a screening instrument for CODs, but the
individual ASI domains examined singly have been criticized for not providing
enough descriptive detail and depth of coverage (Doub, 2001). It has been recommended that the Psychiatric Status section of the ASI be supplemented with more de-
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tailed, domain-specific measures and that validity with respect to DSM-IV diagnostic
criteria could be ‘improved through the addition of expanded descriptors of clinical
symptomatology [sic]’ (Doub, 2001, p. 104). We followed this recommendation in
this study by adding an additional measure detailed below:
Mental Health Screening Form III
The Mental Health Screening Form III (MHSF-III; Carroll & McGinley, 2001) is a
screening instrument designed to detect mental disorder comorbidity in drug and alcohol taking populations. The first four questions on the MHSF-III are not unique to
any particular mental disorder diagnosis. Questions 5 through 17 reflect symptoms
associated with specific diagnoses/diagnostic categories (for example, Q5, schizophrenia; see Table 19 for others). Each MHSF-III question is answered with either
“yes” or “no.” All questions reflect the respondent's life history; therefore, all questions begin with the phrase “Have you ever…”. A total score is calculated by adding
the total number of “yes” responses. The maximum possible score on the MHSF-III is
18 (question 6 has two parts).
The MHSF-III was first validated within a long-term, residential, therapeutic,
AOD treatment community in the Bronx, New York (r

= .74 for test– retest;

Cronbach's α = .83 and .89 at Time 1 and Time 2, respectively; 87% of participants
marked items “ yes” that corresponded with their primary mental health diagnosis;
Carroll & McGinley, 2001). The original recommendation made by the creators of the
MHSF-III was that specialist consultation should be arranged if any of Items 5
through 17 were endorsed with a “yes” response (Carroll & McGinley, 2000). In a
subsequent review of more than 150 screening measures, the MHSF-III was identified
as one of the three best-performing measures when the MHSF-III total score was used
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as an indication of overall need for follow-up (Sacks, Melnick, Coen, Banks,
Friedmann, Grella, & Knight, 2007).!
!

2.3.+Procedure+
Questionnaires were handed out to participants in large group meetings at each of The
Salvation Army recovery service centers. Participation was voluntary, and those who
chose not to participate could return incomplete measures in an envelope without being identified. Participants were given as much time as they required to complete the
questionnaires. Literacy problems were overcome by reading questions to participants
where necessary, although this was rarely required. The data were entered into SPSS
v. 21 for analysis.
!

3."Results"
Almost half (47.6%) of the respondents reported seeking psychological treatment previously and 56.8% self-reported being diagnosed with a mental disorder previously.
Table 18 displays the breakdown of these historical self-reported diagnoses. A historical affect disorder diagnosis was self-reported by 48% of participants, followed by
14% reporting some form of anxiety disorder. Nine percent of self-reported historical
mental disorder diagnoses were schizophrenia or psychosis-related disorders.
Table 18. Percentage of Self-Reported Previous Mental Disorder Diagnoses
Historical Mental Disorder Diagnosis
Depression
Bipolar Disorder
Anxiety
Post Traumatic Stress Disorder
Schizophrenia
Psychosis
Borderline Personality Disorder
!

Proportion of Historical Diagnoses
35%
13%
9%
5%
5%
4%
3%

On the MHSF-III (N = 259) using the first cutoff score of 3, 253 of the 259
(97.68%) participants in our residential AOD treatment sample screened positive for
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mental disorder. Using psychometric validation figures from previous research
(Sacks, Melnick, Coen, Banks, Friedmann, Grella, & Knight, 2007), it is suggested
that if semi-structured clinical interviews were conducted upon the sample it would be
found that the MHSF-III accurately identified 73% of these 253 respondents who
screened positive, meaning the best estimate is that 185 of the 259 (71.31%) respondents who completed the full measure actually have a fully diagnosable mental disorder.
On the MHSF-III (N = 259) using the cutoff score of 6, 229 of the 259
(88.4%) participants screened positive for mental disorder. Again, previous psychometric validation research using semi-structured clinical interviews as the criterion
suggests at this cutoff score, it would be found that the MHSF-III accurately identified 72% of these 229 respondents who screened positive. This returns the estimate
that 165 of 259 (63.66%) respondents actually have a diagnosable mental disorder.
Lastly, on the MHSF-III (N = 259) at the cutoff score of 11 previously recommended for detecting severe mental disorder only (major depression, bipolar disorder and schizophrenia), 137 of the 259 (52.90%) participants screened positive, and
using previous research that reports 76% accuracy, 104 of the 259 (40.20%) clients in
our sample are estimated to have a severe mental disorder.
The mean MHSF-III total score (N = 259) in our sample was 10.60 (SD =
4.07), which indicated clients reported an average of 10.60 symptoms of mental disorder. The breakdown of these positive responses to the different symptom questions
contained within the MHSF-III was as follows in Table 19.
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Table 19. MHSF-III Symptom-Question Response Prevalence
Question Number/Disorder Symptom Queried
Q5
Schizophrenia symptom
Q6a
Depressive disorder symptom
Q6b
Depressive suicide attempt symptom
Q7
Post traumatic stress disorder symptom
Q8
Phobias symptom
Q9
Intermittent explosive disorder symptom
Q10
Delusional disorder symptom
Q11
Sexual & gender identity disorder symptom
Q12
Eating disorders symptom
Q13
Manic episode symptom
Q14
Panic disorder symptom
Q15
Obsessive compulsive disorder symptom
Q16
Pathological gambling symptom
Q17
Learning disorder & mental retardation
Q6a & Q13
Bipolar disorder symptoms
!

Frequency
97/272
215/271
120/262
160/272
201/272
174/270
191/271
136/270
93/270
169/269
209/276
143/276
138/275
64/275
143/269

Percentage
35.7%
79.3%
45.8%
58.8%
73.9%
64.4%
70.5%
50.4%
34.4%
62.8%
75.7%
51.8%
50.2%
23.3%
53.1%

On the ASI-SR (n = 164) using a cutoff composite score of .22, 107 of the
164 (65.2%) participants who validly completed the measure in our sample screened
positive for mental disorder. Using previous psychometric validation figures derived
from comparing the ASI Psychiatric Status score to a SCID-III-R interview (Cacciola
et al., 2008), it is suggested the ASI-SR accurately identified 70% of these 107 respondents who screened positive, with the result that the ASI-SR estimate is that 75 of
the 164 (45.67%) respondents who completed the full ASI-SR measure have a diagnosable mental disorder. The mean ASI-SR Psychiatric Composite score (n = 164)
was .41 (SD = .38). For the reasons to be discussed below, these ASI-SR results
should be considered preliminary.
!

3.1+Comparison+of+MHSFJIII+and+ASIJSR+estimates+
Of those who did screen positive for mental disorder on the ASI-SR, 92.52% (99/107)
validly completed the MHSFIII. At a cutoff score of 3 on the MHSF-III, all of those
99 (100%) who screened positive for current mental disorder when asked about the
last 30 days on the ASI-SR also screened positive for current mental disorder when
asked about their entire lifetime on the MHSF-III (as would be expected). At a cutoff
score of 6 on the MHSF-III, 95.96% (95/99) of those who screened positive for men-
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tal disorder when asked about the last 30 days on the ASI-SR also screened positive
on the MHSF-III. This means four participants who screened positive for mental disorder in the last 30 days on the ASI-SR did not also screen positive for mental disorder when asked about their lifetime experience on the MHSF-III at this higher cutoff
score of 6. At a cutoff score of 11 on the MHSF-III, 69.70% (69/99) of those who
screened positive for mental disorder when asked about the last 30 days on the ASISR also screened positive for severe mental disorder on the MHSF-III. Of those who
screened negative for mental disorder on the ASI-SR, 96.49% (55/57) validly responded to the MHSF-III. At a cutoff score of 3 on the MHSF-III, 98.18% (54/55) of
those who screened negative for mental disorder on the ASI-SR screened positive on
the MHSF-III. At a cutoff score of 6 on the MHSF-III, 83.64% (46/55) of those who
screened negative for mental disorder on the ASI-SR screened positive on the MHSFIII. Even at a cutoff score of 11 on the MHSF-III, 38.18% (21/55) of those who
screened negative for mental disorder on the ASI-SR screened positive for severe
mental disorder on the MHSF-III.
Of the significant number of participants who failed to validly complete the
ASI-SR, 91% managed to validly complete the MHSF-III. Using a cutoff score of 3
on the MHSF-III, 95% of participants who failed to validly complete the ASI-SR
screened positive for mental disorder on the MHSF-III. Using a cutoff score of 6, it
was 84%, and with a cutoff score of 11, 44% of those who failed to validly complete
the ASI-SR screened positive for severe mental disorder on the MHSF-III.
!

4."Discussion"
My results suggest there are very high levels of mental disorder comorbidity in Australian AOD residential treatment services. Sixty-five percent to 98% of participants
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screened positive to the presence of mental disorder using two screening instruments.
Before discussing these results in greater detail it should be noted a problem emerged
with using the ASI-SR in this population. The scoring methodology used with the
ASI-SR requires all items on the form to be completed for a composite score to be
generated. One missing item means the score cannot be generated. In our sample, only 164 of 278 (59%) respondents managed to complete every part of the ASI-SR to
enable a score to be generated. This compares to the MHSF-III, where 259 of 278
(93.2%) respondents successfully completed the MHSF-III measure. The relatively
high frequency of missing data on the ASI-SR measure combined with the limitation
of any missing data to generating a score emerged as a major constraint with using a
self-report version of the ASI with COD populations in my study. As a consequence
of this limitation and the smaller sample size using the ASI-SR measure as a result,
the mental disorder estimates from the ASI-SR should be viewed as preliminary only,
and the mental disorder estimates from the MHSF-III are to be preferred. It is recommended that the ASI should be administered in its interview format to this population
in the future.
Estimates based upon previous psychometric validation research conducted
upon the MHSF-III suggest that diagnosable general Axis I mental disorder comorbidity exists in between 64% and 71% of clients in residential AOD services run by
the Salvation Army in Australia. Severe mental disorder is estimated to be present in
40% of residential clients. These estimates represent a significant increase in psychological comorbidity compared with the figure (45%) reported 30-years ago in a United States of America therapeutic community population (Jainchill, 1994).
Previous research on the MHSF-III reported three different cutoff scores at
which general and severe mental disorder may be indicated (Sacks, Melnick, Coen,
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Banks, Friedmann, Grella, & Knight, 2007). AOD treatment services must weigh up
the relative costs and benefits related to correctly identifying the maximum number of
clients with mental disorder comorbidity with the increased costs from initiating further assessment of the false positives that a more sensitive cutoff score also returns.
This issue is discussed in greater detail later in this thesis, but if the overall true prevalence of mental disorder in a sample is high, then a low cutoff score that provides the
highest sensitivity (for example, at a cutoff score of 3, 90%) will provide the most accurate estimate of mental disorder (71% in our study; Gordis, 2004). Accordingly, my
results suggest a cutoff score of 3 on the MHSF-III is most appropriate for AOD services unwilling to allow clients with current COD to fall through the cracks of screening given the serious consequences that correlate with untreated COD. This is because
previous psychometric validation research indicates a cutoff score of 3 affords maximum (90%) sensitivity and is most unlikely to miss mentally disordered cases. If true
prevalence is not that high and/or services wish to limit false positives for cost or other reasons such as limited access to further mental disorder assessment and follow-up,
then a cutoff score of 6 may be preferred with its increased ability to rule out false
positives (with a higher specificity of 67.5%) at the expense of lesser sensitivity
(75%). In our sample, this cutoff score provided an estimate that 64% of participants
had a COD. The higher cutoff score used to generate this estimate is likely to result in
fewer false positives but lower overall accuracy due to a lower sensitivity that could
see disordered cases missed. At the other end of the scale is the cutoff score of 11
recommended as indicating severe mental disorder, such as major depression, bipolar
disorder and schizophrenia. Services that are interested in identifying the most severe
mental disorder may choose this cutoff score. In our sample, this reduced the number
of participants identified to 40%.
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A significant number of participants screened negative for mental disorder on
the ASI-SR but screened positive on the MHSF-III: 95%, 84%, and 44% respectively
at cutoff scores of 3, 6, and 11 on the MHSF-III. These results could be interpreted in
two ways. The difference in estimated prevalence based upon lifetime (MHSF-III)
and 30-day (ASI-SR) information may reflect the fact that some individuals made a
recovery from mental disorder. Alternatively, the discrepancy may suggest that the
ASI-SR with its truncated taxonomy of mental disorder symptoms lacks sensitivity to
detect a broad spectrum of mental disorders in this population, as suggested by previous research (Doub, 2001). A further complication was the low valid response rate
returned on the ASI-SR. It appears that the self-report format of the ASI-SR may be a
limitation that could see significant comorbidity missed in this population. Unlike the
MHSF-III, which is consistent in its simple “Yes/No” format throughout its (effectively) 18 questions, the ASI-SR varies the format of answers it requires. Some questions ask how many days in the past 30-days the respondent has experienced psychological or emotional problems (requiring a numerical 0-30 response). Other questions
are in a “Yes/No” format. And still other questions ask for a check-box rating according to a rating scale with the following options: not at all, slightly, moderately, considerably, extremely. It is possible this variation in the format of required answers is a
problem for the self-report version of this measure. The interview version of the ASI
needs to be tested in conjunction with the MHSF-III to confirm whether it is the selfreport version or something inherent in the items that raises the risk of missing
comorbidity.
Another notable finding was the high frequency of symptom endorsement.
Participants across the entire valid sample of MHSF-III responses (N = 259) reported
experiencing more than 10 symptoms of mental disorder on average. This high fre-
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quency of symptoms represents a significant departure from previous research using
this measure. The original validation study conducted upon the MHSF-III in a longterm residential therapeutic community program for substance abuse in New York
reported a mean MHSF-III total score of just 5.1 (SD = 4.0; Carroll & McGinley,
2001). More recently, in a prison substance abuse setting, the average MHSF-III total
symptom endorsement score was again only 4.2 (SD = 4.3; Ruiz, Peters, Sanchez, &
Bates, 2009). Our mean MHSF-III total symptom endorsement score (10.60) is double these previously reported figures. This result suggests clients in residential AOD
treatment services in Australia may be presenting with much higher rates of psychological comorbidity than clients in other settings. It could also represent a continuation of the trend towards worsening comorbidity reported in therapeutic communities
in the United States of America by Jainchill over the ten-year period from the 1974 to
1984 (Jainchill, 1994). The clients in this study definitely endorsed a higher number
of psychological symptoms when queried with a short survey. Whether this high
symptom endorsement represents high rates of full-blown mental disorder presenting
to Australian residential alcohol and other drug treatment can only be investigated by
administering a full diagnostic interview that enquires into all the criteria of each disorder.
The breakdown of symptoms experienced by clients in Australian residential
AOD treatment services was very different from epidemiological surveys in the general population. Lending weight to Grella and Stein’s (2006) findings that 36% of residential substance abuse treatment clients with identified comorbidity had a psychotic
disorder, in the present study more than 35% of participants indicated that they had
heard voices no one else could hear or had seen objects or things that others could not
see. Seventy percent of participants endorsed the delusional disorder symptom ques-
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tion, indicating they had felt that people may have something against them without
them necessarily saying so or that some person or group may be influencing their
thoughts or behavior. It is unclear whether these are positive symptoms associated
with a psychotic disorder or secondary to drug use. A semi-structured clinical interview would be needed to clarify this issue further, but the potential that psychotic disorders are much more prevalent than previously thought in this population is clearly
indicated. Many screening measures fail to screen for “lower prevalence” disorders
and may fail to identify these clients in need of further assessment (for e.g., the GAIN
Short Screener, Dennis et al., 2006; the General Health Questionnaire, Goldberg et
al., 1997; the K6 or K10, Kessler et al., 2002; or the Self Reporting Questionnaire 20,
Lee et al., 2007).
When high-prevalence affect and anxiety disorders are considered, they too
may be much more prevalent in my Australian residential AOD treatment sample than
in the general population (Slade et al., 2009). Almost 80% of participants indicated
they had major symptoms of depression, and almost half (45.8%) of the participants
indicated they had attempted to commit suicide previously. Symptoms of a manic episode had been experienced by 62.8% of participants, and when combined with positive responses to the depressive disorders symptom question, 53.1% or more than half
of participants screened positive for possible bipolar disorder. Three quarters (75.5%)
of Australian AOD residential treatment clients endorsed experiencing symptoms of
panic disorder. All of these results represent a significant potential increase in psychiatric comorbidity when compared with the United States of America therapeutic
community studies of the 1970s and 1980s reported on by Nancy Jainchill (1994).
It has previously been noted that chemically dependent persons present with a
variety of disorders across a wide spectrum of diagnoses (Carroll & McGinley, 1998).
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Ross and others (2005) found that those with heroin substance use disorder in residential treatment represented a hard core with significantly greater levels of psychiatric
comorbidity even when compared with heroin users in other treatment modalities. My
results accord with this previous research and suggest the same may well be true for a
broader range of substance-disordered clients in residential treatment. Clearly, more
research using semi-structured clinical interviews is needed in this area to definitively
identify the needs of this population.
!

5."Conclusions"
Axis I mental disorder comorbidity is estimated to exist at high rates (64%-71%) in
the Salvation Army Australian residential AOD treatment populations. Much higher
than the rate reported in the United States of America 30-years ago (45%; Jainchill,
1994). The Salvation Army Australian residential AOD treatment populations endorse
a large number of mental disorder symptoms from a wide spectrum of mental disorders when surveyed with short screening instruments. Psychotic disorders may be
present in this population at a much higher rate than reported previously in either
treatment or non-treatment populations (Jainchill, 1994; Morgan et al., 2011). Comprehensive mental disorder assessment with semi-structured clinical interviews is
necessary to accurately ascertain the identity and needs of this population.
+
+
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Chapter+3+Study+2+
1."Introduction"
Study 2 is predominantly a psychometric validation study. It is aimed at validating
and comparing the ability of five commonly used screening instruments to detect cooccurring mental disorders in residential alcohol and other drug program participants.
This will provide much-needed evidence for residential alcohol and other drug treatment services to base their screening practices, assisting with both instrument selection and cut off score decisions. Several of the results from Study 1, however, warranted follow up and thus there is also an additional prevalence/taxonomy aspect to
Study 2 that was aimed at clarifying the results of Study 1.
In residential alcohol and other drug treatment the prevalence of mental disorder comorbidity was until recently unknown. Study 1 suggested comorbidity might be
present at rates even higher than that found across treatment modalities taken together
(64-71%) (Mortlock, Deane, & Crowe, 2011; J. Ross et al., 2005). If accurate, the estimates from Study 1 represent a significant increase in comorbid psychopathology
since studies conducted into the residential AOD treatment population nearly fortyyears ago (when the rate was 45% in an American therapeutic community population,
Jainchill, 1994). In Study 1 participants in residential AOD treatment in Australia endorsed experiencing on average more than 10 symptoms of mental disorder when administered a short survey (Mortlock et al., 2011). This is double the rate of symptom
endorsement found in either an American therapeutic community setting (5.1) or an
American prison setting (4.2) using the same measure. It is also possible that psychotic disorders exist in this subpopulation at rates many times those found in the general
population (up to 35%) (Grella & Stein, 2006; Mortlock et al., 2011).
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If found to be accurate, the prevalence and taxonomy of mental disorder
comorbidity estimated in Study 1 would have marked implications for services. It is
possible that the 35% of clients in Study 1 who reported “seeing things no one else
could see and/or hearing things no one else could hear” could be reporting these
symptoms as secondary to substance use disorders. However, even if half of these reports were due to primary psychosis that would still represent 17.5% of residential
AOD clients suffering a current comorbid psychotic disorder. It has been thought previously that clients with such severe mental disorders only presented to – and certainly should only be treated by – specialist mental health services, not AOD services
(see, for e.g., the four quadrants of care conceptualisation that classifies clients of the
AOD and mental health systems into four categories based upon symptom severity in
Center for Substance Abuse Treatment, 2005). If clients with psychosis are frequently
presenting to residential AOD treatment services serious thought needs to be given to
the training needs of the workers in those services and additionally the need to improve and standardize service access to specialist psychiatric consultants.
The figures in Study 1, however, are only estimates based upon short screening measures. Short screening measures lack the ability, for example, to tease out and
discriminate between symptoms representative of primary psychoses and those secondary to substance use disorders. They also don’t determine whether all criteria for a
disorder are met, or make an assessment of functional impairment to determine how
relevant to treatment the comorbidity is. In order to clarify the prevalence and taxonomy of comorbidity in residential treatment services – and the identity and needs of
the population within these services – a study that utilizes a full diagnostic interview
is necessary.
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It has been known for some time that successful early identification of mental
disorder comorbidity is the first step in achieving better outcomes for the co-occurring
disorder population (Croton, 2005b; Ziedonis et al., 2005). This has led to government funding and guidelines aimed at improving the identification of those with both
a mental disorder and a substance use disorder in treatment settings. Resources have
been published that review the screening measures currently available to detect cooccurring mental disorders (Center for Substance Abuse Treatment, 2005; Croton,
2007; Dawe et al., 2002). Guidelines have been published both nationally and internationally that advocate routine screening for mental disorder comorbidity. (Center for
Substance Abuse Treatment, 2005; Dawe et al., 2002; Gordon, 2008; Hawkings &
Gilburt, 2004; Health Canada, 2002; Institute of Medicine, 2006; Mills et al., 2010;
NSW Health, 2000; Substance Abuse and Mental Health Services Administration,
2002). Yet despite the guidelines, reviews, and increasing awareness of the prevalence and harms associated with undetected COD, the ongoing failure of substance
misuse treatment systems to recognize co-occurring mental disorders is well documented (Croton, 2007; Donald et al., 2005; Hu et al., 2006; Lubman et al., 2008).
Various reasons have been proposed why substance misuse treatment systems are
continuing to fail to recognize co-occurring mental disorders. One major barrier to
improving the identification of clients with co-occurring disorders in these systems to
date has been a lack of appropriate research aimed at validating and comparing the
various screening instruments available to detect co-occurring disorders. A review of
the validation research conducted to date revealed a dearth of applicable research and
significant methodological issues and inconsistencies among the studies that have
been conducted. Comparative studies that compare multiple measures’ performance
against a recognized criterion measure are rare and they have not been conducted
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within residential alcohol and other drug services. The studies that have been conducted at best reported a truncated set of statistical analyses inadequate to properly
ascertain screening instrument performance, and at worst utilised methodologies that
invalidated their results and revealed a significant lack of understanding of the underlying statistical analyses involved.
As noted previously, it is highly preferable that screening measures are validated within the treatment modality in which they will be used (Castel et al., 2008).
Measures validated in a different treatment modality or in several different treatment
modalities aggregated as a whole simply will not perform as indicated and cannot be
generalized beyond the study conducted. The underlying prevalence and taxonomy of
disorder in a population affects the performance of screening measures, including the
sensitivity, specificity, positive and negative predictive values and odds ratios and the
area under the curve score. Cut off scores may not be the same in different populations. Therefore validation results produced by jumbling settings/populations together
will not apply accurately to any one setting/population disaggregated from such a
mistakenly homogenized whole (Brenner & Gefeller, 1997). As a result, there is a
need for studies that validate and compare commonly available screening measures in
each of the various treatment modalities that exist within substance misuse treatment
systems.
In the current study the treatment modality is residential alcohol and other
drug treatment. A detailed description of the sample demographic information allows
further clarity about the context in which these results can be applied.
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"
2."Methods"
2.1+Participants+
+
+
+
+
144+Clients+
Approached
+
+
+
+
+
+
+
124+Agreed+to+
20+Did+Not+Agree
Participate
+
+
+
+
+
121+Completed+
117+Completed+4+
120+Completed+
65+Completed+
Four+Screening+
Screening+Inst.+&+
+
SCID
ASI
Instruments
SCID
+
+
+
!!!!!!!!!Figure'1.!Study!2!Recruitment!and!Participation!Rate.!
+
+

63+Completed+
SCID+&+ASI

The study was conducted across four of The Salvation Army’s alcohol and other drug
recovery service centers located in New South Wales and the Australian Capital Territory, Australia during 2010-2011. Participants were randomly selected from among
all AOD service clients within four weeks of their admission date using a random
number generator (http://www.random.org). All participants had already gone through
withdrawal management previous to admission to the program. The only inclusion
criterion was that potential participants were within four weeks of admission and all
had an equal chance of being included in the study. Sample size and power calculation were determined in accordance with the procedure described by Hajian-Tilaki
(2011) under the “Sample size in estimating the proportion of binary outcome – descriptive study” subheading. Using an estimated prevalence of 70% (based upon study
1 results), 90% power may be achieved with 95% confidence with a minimum sample
size of 80.67 (to two decimal places). One-hundred and twenty-four participants
agreed to participate in the study out of 144 clients approached, easily meeting this
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requirement and giving a participation rate of 86%. Of the 124 alcohol and other drug,
residential, recovery service clients who agreed to participate, 121 participants completed four screening instruments, 120 participants completed SCID-I/P interviews
and 117 participants completed both the four screening instruments and a SCID-I/P
interview. Of the four participants who did not complete a SCID-I/P interview, two
participants stopped participating due to emotional difficulties experienced during the
interview or active psychosis, one participant had to be sedated by the service at the
time the interview was to be conducted and one participant went to the gym. One
screening measure, the Addiction Severity Index Psychiatric Status Domain, was collected by caseworkers at the services and unfortunately valid data was only available
for 65 of the above participants on this measure, of which 63 had also completed a
SCID-I/P interview. This was due mainly to staff failing to enter data into the data
management system or failing to administer the measure. University of Wollongong
Human Research and Ethics Committee approval was gained for the study and all participation followed an informed consent process with participants.
The 124 participants who took part in the study were 84% male and 16% female. Ages ranged from 18.25 to 63.75 years, averaging 36.56 years old (SD =
10.03). Alcohol was the primary drug of concern for 77 participants (62%), followed
by amphetamines for 18 participants (14.5%), cannabis for 6 participants (5%) and
heroin/methadone/other opiates for 7 participants (5.6%).
+

2.2+Materials+
The following interview and self-report mental disorder screening instruments were
administered:
Structured Clinical Interview for DSM-IV-TR Axis I Disorders - Research Version, Patient Edition (SCID-I/P)

!

99!

The SCID-I/P was used as a criterion measure to establish the rate and taxonomy of
co-occurring Axis I mental disorders (SCID-I/P, 1/2007 Revision, First, Spitzer, et al.,
2002). The SCID-I/P is considered the gold standard in diagnosing mental disorders, a
large number of studies testify to its reliability and validity (First, Gibbon, Spitzer, &
Williams, 2002). Structured clinical interviews such as the SCID-I/P have been reported to be more sensitive to the presence of comorbid mental disorders than unstructured clinical interviews (Grove & Meehl, 1996; Zimmerman & Mattia, 1999).
The SCID-I/P (First, Spitzer, et al., 2002) was administered and rated by a doctoral
psychology student who had received intensive training in conducting SCID-I/P interviews.
Addiction Severity Index – Psychiatric Status Domain (ASI).
The Addiction Severity Index is a semi-structured interview and was administered by
trained caseworkers at the recovery services within 1-2 weeks of participant admission to treatment as part of a routine intake assessment. As mentioned previously the
Addiction Severity Index (McLellan et al., 1992; McLellan et al., 1980) is the most
used measure in research into substance abuse outcomes (Doub, 2001). It has been
extensively validated, including within COD populations generally (Hodgins & ElGuebaly, 1992). In the present study only the Psychiatric Status domain of the interview version of the fifth edition of the Addiction Severity Index is reported.
Mental Health Screening Form III (MHSF-III).
The MHSF-III (Carroll & McGinley, 2001) is the same instrument as was used in
Study 1.
Self

Reporting

Questionnaire

20

Revised

(SRQ-20R)

and

the

Self Reporting Questionnaire 25 Revised (SRQ-25R).
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The Self Reporting Questionnaire was designed by the World Health Organisation to
screen for psychiatric disturbance in primary health care settings, especially in developing countries (Beusenberg & Orley, 1994). As mentioned previously, originally, the
Self Reporting Questionnaire contained 25 questions, 20 related to neurotic symptoms, four concerning psychotic symptoms and one question asking about epileptictype fits or convulsions (Beusenberg & Orley, 1994). This measure is known as the
Self Reporting Questionnaire 25 (SRQ-25). An adaptation of the SRQ-25 that used
only the 20 questions related to neurotic symptoms was used by Lee et al., (2007) as
part of the Psycheck mental disorder screening package. In this version, known as the
Self Reporting Questionnaire 20 – Revised (SRQ-20R), questions were adapted to the
AOD treatment environment by the addition of an extra column that asks respondents
to indicate whether the problem they have reported has also occurred at a time when
they were not using drugs or alcohol. In the present study, the SRQ-20R and the five
additional questions covering psychosis and epilepsy that together constitute the
SRQ-25 and modified in the same way were administered separately to facilitate a
comparison of the performance of the SRQ-20R and what effectively became the Self
Reporting Questionnaire 25 – Revised (SRQ-25R) measures in the population of interest.
Modified Mini-Screen (MMS).
The Modified Mini Screen (MMS) was created by the New York State Office of
Mental Health and the New York State Office of Alcohol and Substance Abuse Services, (with expert consultation), to remedy the lack of validated measures available
to base a systemic decision rule to refer people with substance use problems in public
sector settings for further mental health assessment (Alexander et al., 2008). The
MMS is a combination of gateway questions taken from the Diagnostic and Statistical
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Manual for Mental Disorders–IV–TR (American Psychiatric Association, 2000), the
Structured Clinical Interview for DSM–III–R Non-Patient Edition (Spitzer et al.,
1988), and the Mini International Neuropsychiatric Interview (Sheehan et al., 1998).
There are 22 self-report items designed to identify persons in need of further assessment for mood, anxiety and/or psychotic disorders in a variety of settings including
research studies (Brandau et al., 2005; Connecticut Department of Mental Health and
Addiction Services, 2007). The MMS has been validated in a combined addiction,
social services and corrections population and demonstrated good internal consistency
(Cronbach’s alpha 0.92), inter-rater agreement (92%) and one-week, test-retest reliability (79%) (Alexander et al., 2008).

2.3+Procedure+
Participants were administered the ASI within 1-2 weeks of admission to treatment as
part of a routine intake assessment. Within four-weeks of admission to treatment diagnostic and self-report data were collected as part of a larger study assessing the
psychometric validity of measures of mental disorder and mental health in a residential AOD treatment population. Randomly selected participants participated in two
research sessions two-days apart. In a diagnostic interview session participants were
administered the SCID-I/P (First, Spitzer, et al., 2002). In the other session participants were administered the MHSF-III (Carroll & McGinley, 2001), the MMS
(Brandau et al., 2005), the Psycheck version of the SRQ-20R (Lee et al., 2007) and
the five additional questions that with the SRQ-20R combine to form the SRQ-25R
(Beusenberg & Orley, 1994). Information from one session was not consulted when
conducting the other session. The data was entered into SPSS v. 21 for analysis.
+
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2.4+Data+Analysis+
A Receiver Operating Characteristic (ROC) curve analysis was conducted on all of
the short screening instruments to determine their diagnostic validity using the SCIDI/P as a criterion measure for caseness. Sensitivity, specificity, accuracy, positive and
negative predictive values and positive and negative odds ratios were calculated for
each measure across a range of different cut off scores along with an area under the
curve (AUC) score that goes across all cut off scores. The number of clients indicated
for further assessment and the number of disordered cases correctly identified by each
measure at each cut off score is also noted to facilitate a proper analysis of the real
world results of screening with each measure at each cut off score.
ROC-AUC results usually vary between 0.50 and 1.0. A ROC-AUC score of
0.50 represents a line with a slope of 1 and indicates a complete lack of predictive
ability, (it is the equivalent of chance, a 50/50 result) (Bisoffi et al., 2000). Results
between 0.70 and 0.80 represent good accuracy (Cacciola et al., 2008). Greater than
0.80 represent reasonable to excellent accuracy and results above .90 excellent to outstanding accuracy (Cacciola et al., 2008; J. A. Swartz, 2007).
Inter-rater reliability was established by an independent clinical and research
psychologist reviewing audiotape recordings of ten randomly selected SCID-I/P interviews. Ten was a modest sample but the overall rate of agreement on whether a
current diagnosis was present was substantial at 90%, Kappa = 0.78 (p = .011). The
rates for specific categories of disorder were, affective disorder 90%, Kappa = 0.80 (p
= .01); anxiety disorder 80%, Kappa = 0.615 (p = .035); and a current psychotic disorder 100%, Kappa = 1.00 (p = .002) (all within past 30 days).
!
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3."Results"
According to the Structured Clinical Interview for DSM-IV-TR Axis I Disorders Research Version, Patient Edition (First, Spitzer, et al., 2002), 105 of the 120 participants (87.5%) who answered the SCID/IP had a lifetime comorbid Axis I mental disorder. Eighty-eight of 120 participants (73.33%) had a current (30-day prevalent)
comorbid Axis I mental disorder. Among the 73.3% of participants who had a current
comorbid disorder, 1.67 comorbid mental disorders were present for each participant
on average (in addition to their substance use disorder(s)). The taxonomy of these 30day prevalent comorbid Axis I mental disorders is listed in Table 20 below:
Table 20. Comorbid Axis I Mental Disorder Prevalence.
Disorder
Major Depressive Disorder
Dysthymic Disorder
Bipolar I Disorder
Other Bipolar Disorders
Other Mood Disorders
ANY MOOD DISORDER
Generalized Anxiety Disorder
Posttraumatic Stress Disorder
Panic Disorder
Agoraphobia w/o History Panic
Social Phobia
Specific Phobia
Obsessive Compulsive Disorder
Other Anxiety Disorder
ANY ANXIETY DISORDER
Schizoaffective Disorder
Schizophrenia
Other Psychotic Disorder
ANY PSYCHOTIC DISORDER
Binge Eating Disorder
Anorexia Nervosa
Hyperchondriasis
ANY OTHER DISORDER
+

Valid N
38/120
18/120
10/120
10/120
2/120
67/120
28/120
21/120
12/120
4/120
12/120
10/120
4/120
4/120
55/120
10/120
7/120
6/120
23/120
2/120
2/120
1/120
5/120

Percentage
31.67%
15.00%
8.33%
8.33%
1.67%
55.83%
23.33%
17.50%
10.00%
3.33%
10.00%
8.33%
3.33%
3.33%
45.83%
8.33%
5.83%
5.00%
19.17%
1.67%
1.67%
0.83%
4.17%

The mean total scores, minimum scores, maximum scores and standard deviations for
the five screening instruments validated in this study are listed in Table 21 below:
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Table 21. Mean Total Scores, Range and Standard Deviations for Five Screening Instruments.
Measure
Mental Health Screening Form III
Modified Mini Screen
Self Reporting Questionnaire 20 Revised
Self Reporting Questionnaire 25 Revised
Addiction Severity Index

N
121
121
121
121
65

Min.
0
0
0
0
0

Max.
17
20
20
21
.88

Mean
9.14
8.74
7.15
8.05
0.41

SD
3.65
5.16
5.05
5.47
0.22

Note. N = number of participants who validly completed the measure, Min = minimum score, Max = maximum score, SD =
Standard deviation.

+

The performance of the five short screening measures with reference to a
SCID-I/P diagnosis as the criterion for caseness is reported in Table 22 below. The
measure, sample and cut off score used are listed, followed by the sensitivity, specificity, accuracy, positive and negative predictive values, positive and negative odds
ratios, the number of participants the measure indicated required further assessment
and how many of the truly disordered cases the measure correctly identified at each
cut off score. The rows with bold font indicate each measure’s most accurate cut off
score or the highest aggregate of sensitivity and specificity scores. As will be discussed, although this accuracy statistic is traditionally relied upon, it does not necessarily indicate the best cut off score to use with a measure, or which is the best measure to use, as it is merely a statistic that fails to consider the context of screening or
the real world results of each measure at each cut off score.
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Table 22. Performance of Five Short Screening Measures with Reference to SCID-I/P.
Measure/Cut Score
MHSFIII (N=117)
Cut Off 3
Cut Off 6
Cut Off 9
Cut Off 11
Cut Off 12

Sensitivity

Specificity

Accuracy

PPV.

NPV.

P.ODD

N.ODD

Ind.

Corr.ID

100.0
96.5
61.6
41.9
34.9

16.1
38.7
71.0
87.1
93.5

58.1
67.6
66.3
64.5
64.2

76.8
81.4
85.5
90.0
93.8

100.0
80.0
40.0
35.1
34.1

1.19
1.57
2.12
3.25
5.37

0.00
0.09
0.54
0.67
0.70

112/117
102/117
62/117
40/117
32/117

86/86
83/86
53/86
36/86
30/86

MMS (N=117)
Cut off 3
Cut Off 5
Cut Off 6
Cut Off 7
Cut Off 8
Cut Off 9
Cut Off 10

97.7
93.0
84.9
77.9
72.1
61.6
53.5

38.7
61.3
61.3
71.0
74.2
83.9
90.3

68.2
77.15
73.1
74.45
73.15
72.75
71.9

82.4
86.95
85.9
88.2
88.6
91.4
93.9

85.7
76.0
59.4
53.7
48.9
44.1
41.2

1.59
2.40
2.19
2.69
2.79
3.83
5.52

0.06
0.11
0.25
0.31
0.38
0.46
0.51

102/117
92/117
85/117
76/117
70/117
58/117
49/117

84/86
80/86
73/86
67/86
62/86
53/86
46/86

SRQ20-R (N=117)
Cut Off 2
Cut Off 3
Cut Off 4
Cut Off 5
Cut Off 6
Cut Off 7
Cut Off 9

90.7
87.2
82.6
77.9
73.3
67.4
50.0

41.9
54.8
64.5
77.4
83.9
87.1
90.3

66.3
71.0
73.55
77.65
78.6
77.25
70.15

81.3
84.3
86.6
90.5
92.6
93.5
93.5

61.9
60.7
57.1
55.8
53.1
49.1
39.4

1.56
1.93
2.33
3.45
4.55
5.22
5.15

0.22
0.23
0.27
0.29
0.32
0.37
0.55

96/117
89/117
82/117
74/117
68/117
62/117
46/117

78/86
75/86
71/86
67/86
63/86
58/86
43/86

SRQ25-R (N=117)
Cut off 2
Cut Off 3
Cut Off 4
Cut Off 5
Cut Off 6

90.7
89.5
86.0
80.2
76.7

29.0
38.7
54.8
71.0
83.9

59.85
64.1
70.4
75.6
80.3

78.0
80.2
84.1
88.5
92.95

52.9
57.1
58.6
56.4
56.5

1.28
1.46
1.90
2.77
4.76

0.32
0.27
0.26
0.28
0.28

100/117
96/117
88/117
78/117
71/117

78/86
77/86
74/86
69/86
66/86
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Table 22 Con’d. Performance of Five Short Screening Measures with Reference to SCID-I/P.
Measure/Cut Score
Cut Off 7
Cut Off 9
ASI (N=62)
Cut Off .1636
Cut Off .2371
Cut Off .3477
Cut Off .3788
Cut Off .4008
Cut Off .6348

Sensitivity
73.3
55.8

Specificity
83.9
90.3

Accuracy
78.6
73.05

PPV.
92.6
94.1

NPV.
53.1
42.4

P.ODD
4.55
5.75

N.ODD
0.32
0.49

Ind.
68/117
51/117

Corr.ID
63/86
48/86

91.3
89.1
67.4
63.0
60.9
23.9

29.4
52.9
64.7
76.5
82.4
94.1

60.35
66.43
66.05
69.75
71.65
59.0

77.8
83.7
83.8
87.9
90.3
91.7

55.6
64.3
42.3
43.3
43.75
31.4

1.29
1.89
1.91
2.68
3.46
4.05

0.29
0.21
0.50
0.48
0.47
0.81

53/62
48/62
36/62
32/62
30/62
11/62

41/45
40/45
30/45
28/45
27/45
10/45

Note. PPV. = Positive Predictive Value, NPV. = Negative Predictive Value, P.ODD. = Positive Odds Ratio, N.ODD. = Negative Odds Ratio, Ind. = number of participants who screened positive as requiring further
assessment, Corr.ID = number of clients with COD correctly identified, MHSF-III = Mental Health Screening Form III, MMS = Modified Mini Screen, SRQ-20R = Self-Reporting Questionnaire 20 Revised, SRQ-25R
= Self-Reporting Questionnaire 25 Revised, ASI = Addiction Severity Index Psychiatric Status Domain Composite Score, The most accurate cut off score for each instrument is highlighted in bold font.
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The receiver operating characteristic curve comparing four of the five measures is below in
Figure 2, (this excludes the ASI Psychiatric Status Domain because it had a significantly
smaller valid N).

!
Figure 2. Receiver operating characteristic curves for four screening measures directly compared in the same
residential alcohol and other drug service population.
!
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The Receiver Operating Characteristic Area Under the Curve (ROC-AUC) scores for those
four measures are in Table 23.
Table 23. Directly Compared Area Under the Curve Scores for Four Screening Instruments.
Measure
MHSF-III
MMS
SRQ-20R
SRQ-25R

AUC (N=117)
.754
.837
.814
.815

!

AUC = Area Under the Curve Score, MHSF-III = Mental Health Screening Form III, MMS = Modified Mini Screen, SRQ-20R = Self
Reporting Questionnaire 20 Revised, SRQ-25R = Self Reporting Questionnaire 25 Revised.

!
!
4.!Discussion!
There are very high levels of psychiatric comorbidity and psychiatric severity in the Salvation Army Australian, AOD residential treatment services. Eighty-seven point five percent of
participants received a lifetime comorbid Axis I mental disorder diagnosis on the SCID-I/P
and 73.3% met criteria for the current (30-day) period. Current mood disorders were most
prevalent (56%) followed by current anxiety disorders (46%) and current psychotic disorders
(19%). The prevalence and taxonomy of comorbid mental disorders discovered in this residential treatment population with a semi-structured clinical interview confirms earlier research into this population utilizing short screening measures (see Study 1, and Mortlock et
al., 2011). Mental disorder comorbidity appears worse in Australian, the Salvation Army residential alcohol and other drug treatment centres when compared with the last prevalence
studies conducted in therapeutic communities in the United States of America during the
1970s and 1980s (Jainchill, 1994). Current psychotic disorders are also present in a significantly higher proportion of the population in this residential treatment modality (19%) than
was previously reported to be the case elsewhere (2.51%, Jainchill, 1994). Psychotic disorders constituted more than one-in-four disorders detected (26.14%), a startling result similar
to that reported by Grella and Stein (36%) (2006). Whether this increase in the reported
prevalence of psychotic disorders in residential alcohol and other drug treatment services is
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due to the emergence of pseudoephedrine-based amphetamines and the drug ice, as well as
cannabis of far greater potency, is a question of aetiology. As already noted in the aetiology
section above, methodologically sound evidence of a causal relationship between substance
abuse and mental disorders does not exist at the current time.
When compared with previous research, the current study’s population endorsed a
notably higher mean total number of psychiatric symptoms on several of the short screening
measures. Previous validation research on the Modified Mini Screen across a spectrum of
settings returned a mean total score of 7.48 (SD=5.77) (Alexander et al., 2008). The mean
total MMS score in the current study was 8.74 (SD=5.16). Previous research using the Mental Health Screening Form-III reported mean total scores of 5.1 (SD=4.0) (Carroll &
McGinley, 2001) and 4.2 (SD=4.3) (Ruiz et al., 2009) in therapeutic community and prison
substance abuse populations respectively. The mean total MHSF-III score in the current
study was 9.14 (SD=3.65), roughly double those previously reported rates and close to results reported in Study 1 (10.60, SD=4.07, Mortlock et al., 2011). The Salvation Army recovery services in Australia have an open door policy for individuals with comorbidity and
do not attempt to exclude people unless they are too disruptive or unwell to be satisfactorily
treated in their centers. In addition there is evidence that the Salvation Army residential recovery services have individuals with more severe levels of need for treatment across the
range of domains measured by the Addiction Severity Index compared to participants in other residential services who completed the standardized ASI (Deane, Kelly, Crowe, Coulson,
& Lyons, 2013). Results of the present study, however, are similar to those that have focused
on heroin users (J. Ross et al., 2005), and suggest that in residential AOD treatment there is
significantly higher rates of mental disorder comorbidity and severity than in other treatment
modalities. To some extent this is a positive since it indicates that those with the highest need
are accessing more intensive treatment. The ability of residential alcohol and other drug ser-
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vices to adequately treat a population with the needs indicated by the prevalence and taxonomy of mental disorder comorbidity reported above is another question, to be discussed below.
There was sufficient variation in the performance of the five screening measures to
suggest some might be more effective in residential treatment settings than others depending
upon the goals of screening. Accuracy across the measures varied by more than 12% at each
measure’s statistically most accurate cut off score and ranged from 67.6% to 80.3%. Area
under the receiver operating characteristic curve scores ranged from .73 to .84. Importantly,
in real world terms the number of clients with current co-occurring mental disorders missed
by each screening measure at its most accurate cut off score varied widely from just three
missed cases of comorbidity to 23 missed cases. This latter figure not only represented a
failure to detect 26.74% of comorbid clients, but one that occurred at the measure in question’s statistically most accurate cut off score, the score usually reported and relied upon uncritically by validation studies.
The need to consider all of the indicators of instrument performance provided by the
analysis in the context of screening is highlighted by this study’s findings. Too much screening instrument validation research simply reports the sensitivity, specificity and overall accuracy figures without adequate analysis, and without reporting and analyzing the additional
statistics that reveal how the screening instrument achieved this performance. Typically nor
do screening instrument validation studies examine how these statistics translate into real
world performance via the screening task in question. Such a truncated analysis, decontextualized from the screening task, in the current study would suggest the Self Reporting Questionnaire 20 Revised and Self Reporting Questionnaire 25 Revised had the highest accuracy
figures (78.6% & 80.3%) and therefore must be the best measures for the task at hand. How-
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ever, it was these two measures that failed to detect the most cases of comorbidity in the
study, failing to identify 26.74% and 23.27% of cases respectively.
A cursory analysis of only the usual statistics divorced from the context of the screening task at hand could conclude the Self Reporting Questionnaire measures were good at ruling out cases that did not have COD, (that these measures achieved their accuracy through
high specificity), and that they were optimal. However, when the aim of the actual task of
screening for co-occurring mental disorders is brought into view, (detecting as many clients
with COD as is reasonably practiceable), it should immediately be noted these measures
were not sensitive to detecting clients that did have COD at their statistically most accurate
cut off scores, (scores that delivered sensitivity of only 73.3% & 76.7% respectively). Commentators have rightly opined that the most important characteristics of a mental disorder
screening measure are sensitivity and negative predictive value, (the latter often not even reported by validation studies, its crucial importance to not missing clients with comorbidity
apparently not being understood). The value of sensitivity (detecting true cases) over specificity in the context of screening for co-occurring mental disorders has been recognized for
many years. In 1979 Rounsaville and others wrote (p. 226):!
The purpose of screening instruments is to detect those clients… [who warrant] further extensive clinical evaluation… Sensitivity is vital to insure [sic] that clients who have depression
are adequately treated while specificity is less crucial, being important mainly to reduce the
number of unnecessary evaluations that will be performed on clients without the disorder.

Sensitivity should always be preferred over specificity when analyzing screening instrument
performance when the task is detecting cases of mental disorder comorbidity. If a screening
instrument achieves its statistical maximum accuracy at a low sensitivity score, this figure
should be disregarded and the instrument’s accuracy at an acceptable (90%+) sensitivity be
examined.
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The negative predictive value is the proportion of cases indicated by a measure as negative for mental disorder that actually are truly negative for mental disorder. Zimmerman and
others (2004) explain with regard to negative predictive value that:
From a clinical perspective it is most important that the diagnostic aid have good sensitivity,
and corresponding high negative predictive value. With high negative predictive value, the
clinician can be confident that when the test indicates that the disorder is not present there is
little need to inquire about that disorder’s symptoms (p. 185).

In addition to lacking sensitivity for detecting those with a COD, a close analysis of the negative predictive value scores for the SRQ-20R and SRQ-25R revealed that despite high specificity scores, these measures actually were not very efficient at identifying those without a
comorbid mental disorder either, they just (over) identified so many respondents as being
negative that they also managed to pick up a lot who were truly negative. The SRQ-20R was
only correct about a client’s negative status 61.9% of the time and the SRQ-25R was only
correct 52.9% of the time. This means these measures falsely screened a client as negative
for comorbid mental disorder and not needing any further investigation when that client was
actually positive for comorbid mental disorder nearly 40% and 50% of the time respectively.
What the above results demonstrate for research studies validating screening instruments is the importance of reporting more than just the sensitivity, the specificity, the accuracy (aggregate) and area under the curve score. Unless the additional indicators of instrument performance such as negative predictive values are also reported, a proper picture of
how an instrument has performed the way it has cannot be gained.
In this study a similarly cautionary tale is told against taking an under-analyzed, truncated set of statistics at face value by two additional pieces of information that are critical to
report when undertaking a screening instrument validation. These two additional scores are
the proportion of clients indicated for further assessment by a measure at a given cut off
score and the number of true cases actually detected (and missed) at that cut off score. These
real world results of how the screening instruments in question actually performed at the task
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at hand are critical to report because they reveal how the statistics translate to real world clinical utility. They are an aid to not being deceived by statistical performance that does not
translate to real world clinical utility. An aid that is important in this study.
An analysis of the performance of the Modified Mini Screen (MMS) and the Mental
Health Screening Form III (MHSF-III) measures as compared to the two Self Reporting
Questionnaire (SRQ-20R & SRQ-25R) measures is illustrative. At face value, the MMS and
the MHSF-III were statistically less accurate than the two Self Reporting Questionnaire
measures. Yet when the real world results are examined, the Modified Mini Screen only
missed six cases out of 86 present (a 6.98% failure rate). The Mental Health Screening Form
III only missed three cases out of 86 present (a 3.49% failure rate). This is possible because
the MMS, whilst only returning the third highest accuracy figure of the measures behind the
two Self Reporting Questionnaire measures (77.15%), did so with the second highest sensitivity to the detection of COD (93.0%) and the second highest negative predictive value of
any of the measures (76%). The MHSF-III returned the smallest “accuracy” statistic
(67.6%), but it did so whilst displaying the highest sensitivity (96.5%), the highest negative
predictive value (80%), the highest negative odds ratio (0.09) and thereby it correctly identified the highest number of true cases (83/86). In contrast to the Self Reporting Questionnaire
measures that achieved their statistical accuracy through over-identifying clients as negative
for disorder (which afforded high specificity at the expense of many false negatives and low
sensitivity), the MMS and MHSF-III achieved their greatest accuracy through high sensitivity and high negative predictive value. This means the MMS and MHSF-III were accurate
because they were sensitive enough to identify most cases of comorbidity and when they actually indicated a client as negative for disorder, they were right more than three-quarters of
the time. In this study’s sample, the above figures and the importance of sensitivity and
negative predictive value translated to real world performance where the SRQ-25R actually
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missed 20 disordered cases out of 86 present, (a 23.26% failure rate) whilst being statistically
the “most accurate” measure. The SRQ-20R failed to detect 23 of 86 disordered cases present, (a 26.74% failure rate) whilst statistically being the second “most accurate”.
The question of whether the MMS or the MHSF-III is a better measure becomes a
question of resource allocation. The MHSF-III did perform more sensitively at each measure’s most accurate cut off score, but at the expense of referring nearly every client for further assessment (102 of 117). The MMS achieved its performance while only referring 92 of
117 clients for further assessment. When compared with the MHSF-III it also had a higher
positive odds ratio (2.40 vs. 1.57) and higher ROC-AUC score (.837 vs. .754). As noted by
Castel and others (2008):!
… a screening instrument is needed to help to select those clients who would benefit from a
comprehensive psychiatric assessment and those for which it is not needed. Logically, the final decision should be based not only on the results of a screening instrument, but also on the
available resources for subsequent assessment for diagnostic verification (p. 65).

Previous research on the MMS recommended a cut off score of six and suggested that
when a score equal to or less than five was obtained, no further action or assessment is needed (Frieden, Plapinger, Tom, & King, 2007). This paper validates the MMS as best able to
detect the need for further assessment in residential alcohol and other drug treatment populations using a cut off score of five or more, a reduction in the cut off score of one point that
increases sensitivity and accuracy. The MHSF-III performed best at a cut off score of six in
the current study. It has been recommended at this cut off score and a cut off score of three
previously (Sacks, Melnick, Coen, Banks, Friedmann, Grella, & Knight, 2007; Sacks,
Melnick, Coen, Banks, Friedmann, Grella, Knight, et al., 2007).
If sheer sensitivity was the most important requirement, reducing the cut off score on
the MMS from five to three would see the MMS correctly identify one more case than the
MHSF-III whilst referring the same number of clients for further assessment (102 of 117). In
fact, lowering the cut off score on the MMS from five to three would see the MMS out-
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perform the MHSF-III on every statistic except specificity where they would be tied (at
38.7%). However, that would be at the expense of referring nearly every client for assessment. In a substance treatment screening context where access to follow up psychiatric services and funding can be difficult and limited, the MMS seems the more preferable measure
at a cut off score of five due to its greater efficiency at this cut off score. Either of these highly sensitive measures, however, could be used.
These results provide a cautionary tale to those conducting and interpreting psychometric validation study results. In this instance a cursory view of only the usual statistics would
completely mislead the reader to believe that the SRQ-20R and SRQ-25R are the more accurate measures. A full analysis of all the indicators of instrument performance and their real
world clinical utility, however, tells a very different story. The Self Reporting Questionnaire
measures missed around one-in-four disordered cases because they lacked sensitivity and
negative predictive value. They were clearly outperformed at the task of screening by the
more sensitive measures. This highlights the importance of reporting all of the available parameters and carefully considering the statistics with regard to the real world clinical utility
and performance of the measures.
Given the high rate of current (30-day) psychotic disorders found in this population
(>19%), it came as no surprise the SRQ-25R performed better than the SRQ-20R. The reinstatement of the five questions aimed at detecting psychoticism and epilepsy in the SRQ-25R
increased the sensitivity of this measure without detracting from its specificity compared to
the SRQ-20R. The SRQ-20R and SRQ-25R performed exactly the same in detecting single
affective disorders and single anxiety disorders. Where the two measures differed was in detecting those with multiple affect and anxiety disorders, (where the SRQ-25R picked up one
additional case missed by the SRQ-20R), and in detecting those with psychotic disorders
(where the SRQ-25R picked up twice as many true cases as the SRQ-20R). Generally it
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should be noted that the two Self Reporting Questionnaire measures were the only measures
that failed to detect a psychotic disorder in the study and they were also the only two
measures that failed to detect a client with multiple comorbid axis I disorders (with the SRQ20R failing to detect up to four disorders in a single case). The failure of the Self Reporting
Questionnaire measures to detect psychotic disorders cannot be attributed to the SRQ-20R’s
lack of items designed to probe this type of psychopathology alone. This is because the
SRQ-25R also missed two psychotic disorder cases despite having four questions specifically aimed at detecting them. This lack of sensitivity to psychotic disorders combined with these measures’ failure to detect multiple, multiply-disordered comorbid cases indicates something additional may be contributing to their poorer performance. It is possible that the
method, which requires clients to first indicate whether they have experienced a particular
problem and then additionally to go back over their answers once they have gotten to the end
of the measure to further indicate if they have experienced that problem at time when they
were not using alcohol or other drugs, might be problematic. Whilst the aim of differentiating between symptoms that are primary in nature or secondary and due to alcohol and/or
drug use is clear in theory, in practice it confused a lot of clients and required frequent explanation, sometimes multiple times. As a result, whilst clearly there is a problem with the
SRQ-20R lacking any items that probe for psychotic disorders, there may also be an additional problem with the clinical utility of both the SRQ-20R and the SRQ-25R measures as
they appear difficult for clients to understand. Given the very serious nature and consequences of failing to detect either a co-occurring psychotic disorder or clients with multiple disorders of several different types, the SRQ-20R, the SRQ-25R and other screening measures
that do not screen for psychotic disorders, or that lack sensitivity, cannot be recommended
for use in residential alcohol and other drug treatment settings.
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Unfortunately after Study 1 where a self-report version of the Addiction Severity Index
Psychiatric Status domain suffered from a poor completion rate, (raising doubts about the
utility of this measure in this population), we again had trouble with the interview version of
this measure in Study 2. This time the nature of the measure itself cannot be blamed. Recovery service staff was expected to complete full Addiction Severity Index interviews with all
incoming clients as part of the service’s routine intake procedures. However, in the current
sample they failed to complete this task about 50% of the time. Anecdotal reports indicated
that this was occasionally due to some interviews occurring outside of the time frame for the
research (i.e., too late). As a result, it is still unknown whether there is a problem with the
nature of the ASI measure or other organizational issues. Consequently, the validation results we have for the ASI come from a much smaller sample. The smaller sample is effectively different to the sample used to validate the other four screening measures and so the
figures reported for the ASI are preliminary and although similar, they are not directly comparable.

4.1$Limitations$
There were several limitations to Study 2. Firstly, diagnostic interviews were conducted by a
single interviewer. Despite excellent inter-rater reliability when validated, the single interviewer design may subtly effect the reliability and validity of the results (Horowitz,
Siegelman, & Inouye, 1979). Secondly, only Axis I disorders were assessed. None of the
self-report questionnaires are designed to detect personality disorders. As a result Axis II
comorbidity is unknown. Thirdly, the study was conducted in four residential alcohol and
other drug treatment services in New South Wales and the Australian Capital Territory. Although participants were selected randomly the sample may not generalize to all residential
alcohol and other drug treatment participants nationally or internationally. Lastly, there was a
relatively small sample size in both the not mentally disordered group and in groups with
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specific diagnoses. A larger study would strengthen the results, particularly on a disorder-bydisorder basis.
!
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Implications$&$Future$Directions$ $
Comorbid mental disorders are highly prevalent in residential alcohol and other drug treatment services. More than seven-in-ten clients (73.33%) entering residential alcohol and other
drug treatment had a current comorbid axis I mental disorder. Many of the remaining one-infour clients who did not meet all criteria for a current disorder satisfied criteria for a past disorder and/or had a current subclinical disorder that was clinically relevant and justified
treatment intervention (Haver, 1997). Psychotic disorders were currently present in more
than 19% of participants according to a semi-structured clinical interview where all criteria
were met and time was taken to carefully tease out and exclude cases that could be drugrelated or that were in remission. Nineteen percent was a conservative estimate for current
comorbid psychotic disorders and that is almost one-in-five clients presenting to residential
recovery services for treatment.
Both the prevalence and taxonomy of comorbid mental disorders revealed in this thesis
have a number of implications for residential alcohol and other drug treatment services and
for future co-occurring disorder research. It has previously been noted by researchers that
chemically dependent persons present with a variety of disorders across a wide spectrum of
diagnoses (Carroll & McGinley, 1998). In the 2007 guidelines for the Victorian Dual Diagnosis Initiative it was argued that a criteria of screening instrument selection is that the instrument must screen for the gamut of possible disorders and it was also noted that many
screening instruments fail to screen for psychotic disorders (Croton, 2007). The prevalence
and taxonomy of co-occurring mental disorders reported in this thesis strongly demonstrate
the need to use screening measures that screen for “lower prevalence” disorders, such as
psychotic disorders in this population. These disorders may be low prevalence in the general
population at large, (0.45%, Morgan et al., 2011), but the results in this thesis support earlier
research (Grella & Stein, 2006; Mortlock et al., 2011) and demonstrate psychotic disorders
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are highly prevalent in the residential alcohol and other drugs treatment population (>19%).
As noted by Degenhardt and others (2005):
Psychotic disorders have a lower prevalence than other forms of mental illness such as depression and anxiety disorders, yet they impose a considerable public health burden because
of their impact on sufferers and their families (Keith, Regier, & Rae, 1991). Persons with psychotic disorders also utilise a disproportionately high segment of health services (p. v).

Screening instruments that fail to screen for psychotic disorders cannot be recommended for
use to detect co-occurring mental disorders in residential alcohol and other drug program
participants.
A connected implication flowing from the results reported in this thesis is that the accuracy of conceptualisations, such as the four quadrants of care model, is in question (Center
for Substance Abuse Treatment, 2005; Ries, 2008). The four quadrants of care model proposes clients with more severe psychopathology (should) only present to and are treated by
specialist mental health services whereas alcohol and other drug services (should) only receive clients with “high prevalence” disorders such as depression and anxiety. In Study 1
more than 35% and 70% of 278 residential substance abuse treatment clients endorsed questions indicating they had suffered hallucinations and delusions respectively. Nine percent of
those participants in Study 1 also indicated they had previously been diagnosed with schizophrenia or psychosis. In Study 2 19.33% of 120 different clients met all criteria for diagnosis
of a current psychotic disorder according to a standardized, semi-structured clinical interview. These studies and earlier research, such as that conducted by Grella and Stein (2006)
and Ross and others (J. Ross et al., 2005), are evidence that clients with severe psychopathology are presenting to residential AOD services in significant numbers. Prevalence and
taxonomy studies need to be conducted in other treatment modalities to ascertain whether
this is the case across the substance misuse treatment system or is particular to the residential
alcohol and other drug treatment modality, (as current evidence suggests it may be). The
findings in Study 1 and Study 2, taken together with previous research, suggest that tradi-
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tional thinking about what sort of clients present to which parts of the mental health and substance misuse treatment systems may be erroneous. If found to be the case, this has significant implications for the alcohol and other drug treatment industry. The need for a significant
increase in access to specialist mental disorder service providers, a significant increase in
mental disorder qualifications and greater mental disorder training among alcohol and other
drug treatment workers may be warranted.
In a review of a number of studies that surveyed current access to specialised psychiatric staff in the substance misuse treatment services in America, Flynn and Brown (2008)
conclude that although evidence exists for an association between on site psychiatric staff
and better treatment outcomes, such as retention and reduced substance use, the utility of
such staff is moot because of their limited availability to public treatment programs. The research relied upon by these authors included research that reported a current dearth of postgraduate specialist mental health staff in the industry, a level of staff turnover so high that it
jeopardized treatment program stability, and an inability to fill existing positions with staff
competent to fill them due to an inability to offer appropriate remuneration. These authors
reported results indicating that substance misuse treatment services do not have adequate access to specialised mental health services (Flynn & Brown, 2008). Flynn and Brown conclude:
In brief, there is the suggestion that the level of staff, often seen as the most critical resource
needed for the implementation of intensive and complex interventions for clients manifesting
COD, is in short supply in substance abuse treatment programs. Moreover, there appears little
reason for optimism that this situation will change any time soon (Flynn & Brown, 2008, p.
41).

Thankfully, direct employment of specialised psychiatric staff by substance misuse
treatment providers is not the only means of securing access to specialised psychiatric services. Edward and others (2012) showed the importance of networking between the AOD
and mental health treatment systems as a means of providing integrated treatment for cooccurring disorders in Australia. These authors advocated collaboration and clear channels of
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communication between alcohol and other drug treatment services and mental disorder
treatment services so that opportunities for secondary consultation are taken advantage of
and “dual diagnosis capability” becomes part of the core business of both services. Whilst
reporting some success in this endeavour, these authors noted that:
as illustrated by the case studies presented here, it appears that the structure and constraints of
current mental health service provision mean that it is not always possible for mental health
services to respond to invitations of shared care of dually diagnosed clients. Additionally,
AOD services face similar barriers to integrated care. This requires something of a cultural
shift on the part of AOD and mental health clinicians. This cultural shift needs to be articulated in organisational policy directions and funding agreements that support the shift from segregated, stand-alone services to fully integrated dual diagnosis care for clients, families and
carers (Edward et al., 2012, p. 21).

An inability to attract and retain access to appropriately qualified and specialised psychiatric staff is a major concern for substance misuse treatment services. The results of this
thesis demonstrate there is also a need for greater AOD treatment staff training in mental
disorders to maximize the utility of existing staff. In one study of 3,972 clients entering outpatient substance misuse treatment, counselors under-rated the need for mental health services in 32% of clients who reported psychiatric problems (Mericle et al., 2012). Thirty-six
percent of these (essentially) unidentified co-occurring disorder clients had also indicated the
importance of obtaining treatment for their mental health problems (Mericle et al., 2012).
The authors hypothesized that the failure to recognize client concerns as symptoms of
comorbid mental disorders may have been due to the lack of personnel with clinical backgrounds and advanced degrees in substance abuse treatment settings (Mericle et al., 2012).
The speculative association by these authors of staff qualification/training levels with the
problem of under-identification of comorbidity warrants future research. The need to upskill
existing staff with higher qualifications and training in the area of mental disorder in the
AOD treatment system is apparent, but the real question is, “How much more training?” Is it
enough to upskill existing staff with diploma-level qualifications or are degree-qualified staff
needed in much greater numbers than industry funding currently supports? To answer this
important question first research needs to determine what the current qualification levels are
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in the substance abuse treatment industry in Australia. Then the existence of any demonstrable link between these levels of staff qualification/training and the identification and treatment of comorbidity should be investigated. There are already studies that suggest increasing
the qualification levels and training of staff may increase the efficacy of treatment (Alterman
et al., 2001; Grella & Stein, 2006).
Significant mental disorder demands are being placed upon residential alcohol and other drug treatment services. The studies in this thesis provide data to indicate the importance
of screening as a necessary efficient means of allocating scarce mental disorder resources in
this context. Several studies have demonstrated individuals manifesting low to moderate levels of mental disorder comorbidity appear to respond positively to the nonspecialized treatment provided by AOD services (Flynn & Brown, 2008). The same studies, however, show
that those with moderate to severe mental disorder comorbidity do not respond positively
and require specialized treatment (Flynn & Brown, 2008). One of the tasks of screening is to
differentiate between these two groups so that treatment services can identify the COD clients who require specialized treatment resources. These resources are scarce at the current
time and screening is therefore ‘a single, critical step in the provision of quality care for cooccurring mental health and substance use disorders, and must be integrated into treatment
settings with an eye to the constraints and pressures on clients, staff and agencies’
(Alexander et al., 2008, p. 115).
From a statistical/methodological standpoint, nearly 25-years ago Hsiao and others
wrote that (1989, p. 667):!
Receiver operating characteristic methods are descriptive graphic tools that provide a way to
assess and compare the performances of different diagnostic techniques. They are, if appropriately used, a potentially powerful tool for examining how biological and psychological
measures relate to diagnosis. These methods can never be better than the data to which they
are applied, and they can be of no use at all if those data are not available. In the future, if
ROC is to fulfill its promise, researchers will have to present the full range of their data rather
than just means, SDs, and sensitivity and specificity at a single cutoff point. Presentation of an
ROC curve, assessment of sensitivity and specificity at multiple cutoff points, or, better yet,
the actual data themselves, will be essential.
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Twenty-five years later studies are still reporting a truncated array of statistics on screening
measure performance. There is a need for psychometric validation studies to be conducted in
different treatment modalities to compare the popular and freely available screening
measures in different substance using populations. But these validation studies must report a
full array of statistics about each measure and they must include a report of the real world
performance, the actual clinical utility of each measure. It is only when treatment services
are possessed of all this information that they will be able to make a properly informed decision about which screening measure is the best for them and at what cut off score.
In summary, future research must concentrate upon improving the evidence-base for
alcohol and other drug treatment services so they have proper research evidence upon which
to base their screening and treating practices. Future research should survey the prevalence
and taxonomy of co-occurring disorders in different treatment modalities. Future research
should assess the performance of popular and freely available screening instruments in different treatment modalities. The current availability of specialised mental disorder services
must be ascertained and when known, the potential efficacy of improved access to such services, along with different levels of improved mental disorder qualifications and training for
existing AOD treatment staff, should all be tested. Lastly, future research must evaluate the
effects of better identifying and meeting the mental disorder needs of those seeking treatment
for alcohol and other drugs.
!
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Appendix$A$
Table 24. Nomenclature changes in DSM-5 (Peele et al., 2013)
DSM-IV-TR
Dementia
Alcohol-induced persistent amnestic disorder
“Mood” in the title of many disorders
Nicotine
General medical condition
(Does not have the word “Probably” in the
name of any Disorders)
(Does not have the word “Possible” in the name
of any Disorder
Autistic disorder
Dissociative fugue
Social phobia
Dysthymia
Hypochondriasis
Pedophilia
Transvestic fetishism
Exhibitionism
Female sexual arousal disorder
Male orgasmic disorder
Dyspareunia
Frotteurism
Stuttering
Transient tic disorder
Chronic motor or vocal tic disorder
Sleep terror disorder
Sleepwalking disorder
Feeding disorder of infancy or early childhood
Reading disorder
Mathematics disorder
Disorder of written expression
Phonology disorder
Narcolepsy

Breathing-related sleep disorder

DSM-5
Neurocognitive disorder
Alcohol-induced major cognitive disorder,
amnestic confabulatory type
“Depressive” or “Bipolar”
Tobacco
Another medical condition
“Probably” added to the name of some neurocognitive disorders
“Possible” added to the name of some neurocognitive disorders
Autism spectrum disorder
Dissociative amnesia with dissociative fugue
Social anxiety disorder
Persistent depressive disorder
Illness anxiety disorder
Pedophilic disorder
Transvestic disorder
Exhibitionistic disorder
Female sexual interest/arousal disorder
Delayed ejaculation
Genito-pelvic pain/penetration disorder
Frotteuristic disorder
Fluency disorder
Provisional tic disorder
Persistent motor or tic disorder
Non-rapid eye movement sleep arousal disorder, sleep terror type
Non-rapid eye movement sleep arousal disorder, sleepwalking type
Avoidant/restrictive food intake disorder
Specific learning disorder, with impairment in
reading
Specific learning disorder, with impairment in
mathematics
Specific learning disorder, with impairment in
written expression
Speech sound disorder
Five types: autosomal dominant cerebellar
ataxia and narcolepsy; autosomal dominant
narcolepsy, obesity, and type 2 diabetes;
narcolepsy without cataplexy but with hypocretin deficiency; narcolepsy with cataplexy
but without hypocretin deficiency; narcolepsy
secondary to another medical condition
Central sleep apnea

DSM-IV-TR = Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (American Psychiatric Association,
2000), DSM-5 = Diagnostic and Statistical Manual of Mental Disorders, fifth edition (American Psychiatric Association, 2013).
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Table 25. New Disorders in DSM-5 (Peele et al., 2013)
New Disorder
Social communication
Disruptive mood dysregulation
Premenstrual dysphoric
Hoarding
Excoriation
Disinhibited social engagement
Binge eating
Central sleep apnea
Sleep-related hypoventilation
Rapid eye movement sleep behaviour
Restless legs
Caffeine withdrawal
Cannabis withdrawal
Neurocognitive disorder with Lewy body disease, major and mild
Ten “mild” neurocognitive disorders
Thirty-eight “other disorders”a
Thirty “unspecified disorders”a
a

“Other disorder” and “unspecified disorder” in DSM-5 replace “Not Otherwise Specified” in DSM-IV-TR.
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Appendix$B$
CINAHL Plus with Full Text
(screen* + psychology 1957-2014: 126, screen* + alcohol and other drug 1957-2014: 82;
screen* + substance use 1957-2014: 588; prevalence + psychology 1957-2014: 111; prevalence + alcohol and other drug 1957-2014: 126; prevalence + substance use 1957-2014: 853;
co-occurring disorders 1957-2014: 366; dual diagnosis 1957-2014: 483; alcohol and other
drug 1957-2014: 282; substance use + psychology 1957-2014: 98; mental health + substance
use 1957-2014: 1103; comorbidity + psychology 1957-2014: 14; comorbidity + alcohol and
other drug 1957-2014: 31; comorbidity + substance use 1957-2014: 292; psychometric +
psychology 1957-2014: 127; psychometric + alcohol and other drug 1957-2014: 14; psychometric + substance use 1957-2014: 85; receiver 1957-2014: 199; roc 1957-2014: 174; cut
off 1957-2014: 291).
PsycINFO
(screen* + psychology 1860-2014: 301; screen* + alcohol and other drug 1860-2014: 63;
screen* + substance 1860-2014: 694; prevalence + psychology 1860-2014: 173; prevalence
+ alcohol and other drug 1860-2014: 43; prevalence + substance 1860-2014: 1006; cooccurring disorders 1860-2014: 802; dual diagnosis 1860-2014: 2737; alcohol and other drug
1860-2014: 2528; substance + psychology 1860-2014: 3135; mental health + substance
1860-2014: 9753; comorbidity + psychology 1860-2014: 624; comorbidity + alcohol and
other drug 1860-2014: 171; comorbidity + substance 1860-2014: 5783; psychometric + psychology 1860-2014: 2444; psychometric + alcohol and other drug 1860-2014: 37; psychometric + substance 1860-2014: 703; receiver 1860-2014: 292; roc 1860-2014: 145; cut off
1860-2014: 113).
PsycARTICLES
(screen* + psychology 1860-2014: 175; screen* + alcohol and other drug 1860-2014: 36;
screen* + substance 1860-2014: 87; prevalence + psychology 1860-2014: 125; prevalence +
alcohol and other drug 1860-2014: 65; prevalence + substance 1860-2014: 80; co-occurring
disorders 1860-2014: 183; dual diagnosis 1860-2014: 274; alcohol and other drug 18602014: 7965; substance + psychology 1860-2014: 340; mental health + substance 1860-2014:
479; comorbidity + psychology 1860-2014: 43; comorbidity + alcohol and other drug 18602014: 41; comorbidity + substance 1860-2014: 60; psychometric + psychology 1860-2014:
319; psychometric + alcohol and other drug 1860-2014: 47; psychometric + substance 18602014: 94; receiver 1860-2014: 20; roc 1860-2014: 9; cut off 1860-2014: 2).
MEDLINE with Full Text
(screen* + psychology 1946-2014: 7768; screen* + alcohol and other drug 1946-2014: 185;
screen* + substance 1946-2014: 2052; prevalence + psychology 1946-2014: 6595; prevalence + alcohol and other drug 1946-2014: 325; prevalence + substance 1946-2014: 2639;
co-occurring disorders 1946-2014: 378; dual diagnosis 1946-2014: 643; alcohol and other
drug 1946-2014: 388; substance + psychology 1946-2014: 6854; mental health + substance
1946-2014: 2395; comorbidity + psychology 1946-2014: 1835; comorbidity + alcohol and
other drug 1946-2014: 96; comorbidity + substance 1946-2014: 896; psychometric + psychology 1946-2014: 4151; psychometric + alcohol and other drug 1946-2014: 20; psychometric + substance 1946-2014: 215; receiver 1946-2014: 1417; roc 1946-2014: 994; cut off
1946-2014: 1091).
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ScienceDirect
(screen* + psychology 1822-2014: 946; screen* + alcohol and other drug 1822-2014: 1460;
screen* + substance 1822-2014: 3935; prevalence + psychology 1822-2014: 785; prevalence
+ alcohol and other drug 1822-2014: 1647; prevalence + substance 1822-2014: 1869; cooccurring disorders 1822-2014: 133; dual diagnosis 1822-2014: 216; alcohol and other drug
1822-2014: 130; substance + psychology 1822-2014: 1372; mental health + substance 18222014: 1784; comorbidity + psychology 1822-2014: 337; comorbidity + alcohol and other
drug 1822-2014: 571; comorbidity + substance 1822-2014: 839; psychometric + psychology
1822-2014: 933; psychometric + alcohol and other drug 1822-2014: 210; psychometric +
substance 1822-2014: 324; receiver 1822-2014: 1800; roc 1822-2014: 454; cut off 18222014: 1486).
Web of Science
(screen* + psychology 1965-2014: 142; screen* + alcohol and other drug 1965-2014: 210;
screen* + substance 1965-2014: 2143; prevalence + psychology 1965-2014: 94; prevalence
+ alcohol and other drug 1965-2014: 382; prevalence + substance 1965-2014: 1630; cooccurring disorders 1965-2014: 608; dual diagnosis 1965-2014: 1007; alcohol and other drug
1965-2014: 869; substance + psychology 1965-2014: 131; mental health + substance 19652014: 2003; comorbidity + psychology 1965-2014: 19; comorbidity + alcohol and other drug
1965-2014: 150; comorbidity + substance 1965-2014: 1073; psychometric + psychology
1965-2014: 241; psychometric + alcohol and other drug 1965-2014: 31; psychometric + substance 1965-2014: 181; receiver 1965-2014: 25,681; roc 1965-2014: 2062; cut off 19652014: 2859).
Scopus
(screen* + psychology 1960-2014: 1625; screen* + alcohol and other drug 1960-2014: 376;
screen* + substance 1960-2014: 3821; prevalence + psychology 1960-2014: 1322; prevalence + alcohol and other drug 1960-2014: 549; prevalence + substance 1960-2014: 3240;
co-occurring disorders 1960-2014: 640; dual diagnosis 1960-2014: 1173; alcohol and other
drug 1960-2014: 970; substance + psychology 1960-2014: 1867; mental health + substance
1960-2014: 3199; comorbidity + psychology 1960-2014: 312; comorbidity + alcohol and
other drug 1960-2014: 176; comorbidity + substance 1960-2014: 1188; psychometric + psychology 1960-2014: 1190; psychometric + alcohol and other drug 1960-2014: 32; psychometric + substance 1960-2014: 265; receiver 1960-2014: 34,178; roc 1960-2014: 1872; cut
off 1960-2014: 3212).
Many individual searches were also done in various databases including on individual
screening instruments, major prevalence studies such as the ECA, NCS and Australian
MHWB 1& 2. Additionally “seminal” sources were often forwards searched as well with all
sources that had cited such works also researched.
!
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Appendix$C$
Research Office use only
HE 08/297
UNIVERSITY OF WOLLONGONG/ILLAWARRA AREA HEALTH SERVICE

Human Research Ethics Committee
INITIAL APPLICATION FOR APPROVAL TO UNDERTAKE
RESEARCH INVOLVING HUMAN PARTICIPANTS
(A separate application is required for each project)
Please answer questions in terms understandable to the layperson.
1.

Descriptive Title of Project:
Mental health screening within residential drug and alcohol rehabilitation.

2.

7 line summary of project aims:
This project will examine the relationship between a series of screening measures used within
residential drug and alcohol treatment. It will include screens for mental health, Alexithymia,
emotional control and wellness. The relationship between the screening measures and individual reactions to music will also be examined. Results will be used to inform assessment, treatment planning and treatment services (e.g. cue exposure) within substance abuse treatment facilities.

3.

Name
Position/Appointment
Chief Investigator(s)

Institution

Qualifications
(Academic or Professional)

Dr Peter Kelly (PhD Clin. Psych, BSc)
Research Assistant
Illawarra Institute for Mental Health
University of Wollongong
Prof Frank Deane (PhD, Dip. Clin. Psych)
Director
Illawarra Institute for Mental Health
School of Psychology
University of Wollongong
Kane Mortlock (BA, LLB, BPsyc)
PhD candidate
Illawarra Institute for Mental Health
School of Psychology
University of Wollongong
Address for Correspondence (1st named investigator):
Illawarra Institute for Mental Health
Building 22
University of Wollongong
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Wollongong, NSW 2522
Contact Phone Number: 0403 541 306
4.

Fax: (02) 4221 5585

Email: pkelly@uow.edu.au

Where will potential participants be approached by the researchers to seek their participation in the research and where will research activities involving participants be conducted:
Caseworkers of the Salvation Army Bridge program will be informed of the proposed study by
the researchers via a presentation at their team meetings. Clients will be informed of the study
in their house meeting where the study will be conducted. A participant information sheet (Appendix A) will be provided along with contact details so that the clients can contact the researcher if there are any further questions. Researchers will be on site at the time of distributing the questionnaires and they will be the only other people present in the room at the time
of the questionnaires’ completion. This allows the opportunity for the client to refuse to participate outside of direct contact with his/her caseworker. The Salvation Army will not provide
the researcher with any confidential information regarding the potential participant. The research team will distribute the survey on site. Once the survey is completed, all clients will be
instructed to put it into a sealed envelope. That way, clients can either refuse to participate or
put the incomplete survey in the envelope.

Purpose and Funding of Project
5.a Is this: Yes Staff Research (University of Wollongong)
______Staff Research (Illawarra Area Health Service)
Yes
Student Research (Post grad. degree or subject)
Course undertaken PhD (Psychology)
Unit/ Faculty/Department School of Psychology HBS
Supervisor Prof Frank Deane & Dr. Trevor Crowe
______Other (Please specify e.g. for external people who want to research Uni
students or IAHS clients)
5.b

What is the source and amount of funding from all sources for this research?

Source (Name of Organisation / Funding Scheme)
The Salvation Army

Amount
$397,000

5.c

Is there any affiliation or financial interest between the sponsor/funding body and the
researcher(s) or supervisor associated with this research? If Yes, Please declare.
No

5.d

Are there any conditions placed on this research by the funding body? (please provide
details)
No

5.e

Is a copy of the HREC approval to be forwarded to the Granting Body?

Yes

If YES, please advise of any deadlines:
No deadline, but provided to the funding body before the research is commenced.
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6.

Has this research project been reviewed by any other Institutional Ethics Committee?
(for example multi-centre research)
No
If YES, include a copy of any correspondence the sponsor or researcher has entered into
with the other Ethics Committee(s) to this point.

7.

Research Categories
Please mark the research categories relevant to this research proposal. See guidelines for
descriptions of the categories. At least one category should be marked for each grouping.
For "Other", please specify.
If your research only involves participants and research procedures from a-d under
A Participants and B Research Procedures Used, it may be open to expedited review by
the Chair of the HREC. In that case, submit only one copy of your application (please see
guidelines regarding expedited review).

A

Participants
a.
b.
c.
d.
e.
f.
g.
h.
i.
j.
k.
l.
m.

Healthy members of the community
University students
Employees of a specific company/organisation
Members of a specific community group, club or association
Clients of a service provider
Health Service clients (e.g. users/clients of a health service)
School children
Hospital in-patients
Clinical clients (e.g. patients)
Aboriginal/Torres Strait Islander people
Members of socially disadvantaged groups
Cadavers/ cadaveric organs
Other:

Expected age(s) of participants – please circle one or more
Children (under 14)

B

Adults (> 18) YES

Research procedures used
a.
b.
c.
d.
e.
f.
g.
h.
i.
j.
k.

!

Young people (14-18)

Anonymous questionnaires/ surveys
Coded (potentially identifiable) questionnaires/ surveys
Identifiable questionnaires/ surveys
Examination of student work, journals etc
Examination of medical, educational, personnel or other confidential records
Observation (overt)
Observation (covert)
Interviews (structured or unstructured)
Telephone interviews
Procedures involving physical experiments (e.g. exercise, reacting to computer images)
Procedures involving administration of substances (e.g. drugs, alcohol, food)
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l.

C

8.a

m.
n.

Physical examination of participants (including eg. blood glucose, blood pressure
and temperature monitoring)
Collection of body tissues or fluid samples
Surgical procedures

o.

Other:

Research areas
a.
b.
c.
d.

Qualitative research
Social Science research
Humanities research
Educational research

e.
f.
g.
h.
i.
j.
k.
l.
m.!
n.!

Health research
Psychological research
Comparison or evaluation of drugs or surgical or other therapeutic devices
Comparison or evaluation of clinical procedures
Comparison or evaluation of counselling or training methods
Investigation of the effects of an agent (drug or other substance)
Investigation of bio-mechanical processes
Biomedical research
Epidemiology
Genetic research

o.

Other:

Does the project involve the use of drugs?
NO
If YES give details:
Is the research clarified as a:
CTN Trial
CTX Trial

8.b

Other (Please detail)

Does the project involve the use of a surgical or other therapeutic device? (please detail)
NO

8.c

If you answered YES to 8a. or 8b., is there any business or similar association between
the researcher and the supplier of a drug or surgical or other therapeutic device to be
used in the trial? (please detail).
NA
If you answered YES to 8a. or 8b., please include the budget for this trial including information about capitation fees, payments to researchers, institutions or organisations
involved in the research, current and consequential costs and costs which may be incurred by participants.
Please include evidence of arrangements to ensure adequate compensation to participants
for any injury suffered as a result of participation in the trial. (Indemnification forms
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and, if the research is being undertaken in a private practice, evidence of adequate and
appropriate insurance coverage)
NA
9.

Justify the design of your proposed research and describe what you want participants to
do.
Please provide an explanation, in terms understandable by a non-expert reader. For student researchers, please provide (in no more than 2 pages) the background to this project
(Attach extra sheets if necessary)

Background
The current research is in two parts.
Mental health screening
The Illawarra Institute for Mental Health (iiMH) has been contracted by The Salvation Army to develop, trial and integrate mental health screening tools across their residential sites. The Salvation
Army provides a range of long-term, residential treatment services for people with substance abuse
problems. Although recommended as best practice, The Salvation Army does not currently use mental health screening procedures within their organisation.
35% to 89% of individuals seeking treatment from alcohol and other drug (AOD) services also have a
co-occurring mental health disorder (Hides, et al., 2007). Problems facing people with comorbidity
include: poorer treatment response (Grella & Stein, 2006), higher rates of relapse, more hospital visits, increased involvement in violence, family difficulties, homelessness (Brunette, et al., 2004) and
HIV (Adams, 2008). It has also been acknowledged that clients with comorbidity have received poor
care due to gaps in service provision (Adams, 2008). Accurate and effective identification of mental
illness comorbidity is the first step to a comprehensive needs assessment that can be readily transferred into effective, individualised and collaborative care planning to better meet the needs of this
population. Recent research conducted by Corey Keyes, (see 2002, 2005, 2006, 2008), however, has
empirically disproven the notion that the absence of mental illness can be equated with the presence
of mental health in epidemiological, youth and cross-cultural populations. Keyes’ research has
demonstrated that mental illness and mental health are distinct, only moderately correlated construct
domains in these populations. Keyes’ empirical revelation indicates systematic procedures to screen
AOD clients for mental illness comorbidity and the treatment protocols used to treat them are in need
of comprehensive review in terms of scope, aims and purpose. It may no longer be enough to identify which clients have co-occurring mental illness. Clients’ mental health may also need to be assessed and the information fed into the treatment planning process.
The Addiction Severity Index (ASI; McLellan, 1980) is the most widely used structured interview
within substance abuse treatment settings. This scale includes several items that screen for possible
co-morbid mental illness problems. A previous evaluation indicates that these items provide good
sensitivity (Cacciola, Peceoraro & Alterman, 2008). Another screening scale, The Mental Health
Screening Form – III (MHSF–III; Carroll & McGinley, 2000), has also been widely used within both
treatment and research settings. The current study aims to examine if the sensitivity of these measures
can be improved if they are administered concurrently. This study also aims to compare instruments
that screen for mental illness with Keyes’ measure of mental health to determine whether the absence
of mental illness may be equated with the presence of mental health or a two factor model is to be
preferred. Keyes’ measure of mental health, The Mental Health Continuum – Short Form (MHC–SF;
Keyes, 2006), has not been used in an AOD residential treatment or co-occurring disorder populations.
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Emotional control and cue exposure
Effective drug and alcohol treatment should focus on the prevention of further relapse. This typically
involves identifying the person’s high-risk situations / triggers and preparing the person to manage
these events. Cue exposure has consistently been recommended as an important treatment approach
within the substance abuse field (Otto, Powers & Fischmann, 2005). It involves directly exposing the
patient to situations that the person would normally associate with their substance of abuse (e.g., drug
using equipment, emotions associated with drug use). The goal of exposure is to break the patient’s
bond between these events / emotions and their drug use. Whilst laboratory studies have consistently
demonstrated that cue exposure is an important component of relapse prevention training (Siegel &
Ramos, 2002), this has typically not translated into routine practice. This is likely to be associated
with ethical issues associated with cue exposure (i.e. using illicit substances, bringing substances of
abuse into drug free environments) and practical difficulties (i.e. difficulties accessing the person’s
local pub).
Poor emotion regulation is generally associated with poorer outcomes for individuals with substance
misuse problems (e.g. Bonn-Miller, Vujanovic & Zvolensky, 2008; Fox, Axelrod, Paliwal & Sinha,
2007; Fox & Sinha, 2008). For example, approximately 50% of substance abuse patients returning to
residential treatment report their previous relapse was the direct result of trying to cope with negative
emotions (Fernandez-Montalvo, et al., 2007). Similarly, individuals scoring highly on Alexithymia
scales are at higher risk of relapse following substance abuse treatment (Loas, et al., 1997). It is important that cue exposure activities address negative emotions. The use of music for cue exposure in
residential treatment settings is likely to be extremely beneficial for this purpose. Music has been
successfully used in laboratory-based studies to induce both positive and negative mood states (Martin, 1990). Its effects occur quite quickly (within 10 minutes) and 75% of participants report changes
in mood in clinical studies (see Martin, 1990). Additionally, most patients have access to music, and
cue exposure homework activities could be developed with relative ease. Whilst music has been
promoted for use in substance abuse treatment settings (Dingle, Gleadhill & Baker, 2008), very limited research has been conducted to examine the relationship between mood and substance abuse
treatment.
The study is exploratory in nature and seeks to examine the degree to which substance abuse patients
report that music influences their mood. It will also compare differences in individuals’ reactions to
music with patients’ self-rated emotional control ratings.
Research plan
a)! Research design
A cross-sectional design will be used. Participants will be at different stages of their 10-month
treatment program. All measures will be quantitative self-report questionnaires.
b)! Participants
The sample will consist of individuals attending the Salvation Army Bridge residential rehabilitation program located in, Townsville (n = 32), Brisbane (n = 90), Gold Coast (n = 55), Lake
Macquarie (n = 104), Sydney (n = 110), Blue Mountains (n = 17), Central Coast (n = 40) and
Canberra (n = 40). We anticipate at least 70% of these residents to participate. All individuals
will be diagnosed with an alcohol and/or substance misuse problem. Participants may also be
diagnosed with a co-occurring mental illness problem (e.g. depression, anxiety, psychotic disorder).
c)! Treatment Condition
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Clients will be attending the Salvation Army Bridge program. The program is 10 months in
length, with participants completing a 6-stage, group-based treatment process. The treatment
programs provide a combination of skills training, psycho-education, 12-step based interventions and individual counseling.
d) Measures
The measures outlined in the section below have all been combined into one questionnaire, the ‘Men%
tal! Health! Screening! and! Emotional! Control’. The questionnaire takes approximately 60 minutes
and contains 188 items.
Background Information and drug and alcohol use
Basic demographic information will be collected. This will include age, weeks in the program, gender and The Salvation Army centre they are attending. We will also collect information on the person’s drug and alcohol history. This will include the length of time the person has had a substance
misuse problem, the types of drugs the person has used in the previous 12-months, the substance the
person considers their primary drug of choice, frequency of drug use and if they have ever received
treatment before. We will ask clients to specify any previous mental illness diagnoses, how well their
current service is meeting their mental health needs and if they have suffered any of the poorer treatment responses and outcomes traditionally associated with co-occurring AOD and mental illness disorders previously.
Desires for Alcohol Questionnaire – Strong Desire Subscale (DAQ; Clark, 1994). This is a selfreport questionnaire that measures an individual’s current desire for alcohol. The questionnaire consists of three subscales (negative reinforcement, strong desire, mild desire). This scale was modified
for this study in order to assess drug and alcohol desires. An example is the statement ‘My desire to
drink now seems overwhelming’ was adjusted to ‘My desire to drink and/or use drugs now seems
overwhelming’.
Mental Health Screening
Mental Health Screening Form – III (MHSF-III; Carroll & McGinley, 2000) - The Mental Health
Screening Form – III is designed as a mental illness screening device for clients seeking admission to
substance abuse treatment programs. Each MHSF-III question is answered either “yes” or “no.” All
questions reflect the respondent’s entire life history; therefore all questions begin with the phrase
“Have you ever...”. The MHSF-III features a “Total Score” line to reflect the total number of “yes”
responses. The maximum score on the MHSF-III is 18 (question 6 has two parts). This feature permits programs to do research and program evaluation on the mental illness-chemical dependence interface for their clients. The first four questions on the MHSF-III are not unique to any particular
mental illness diagnosis; however, questions 5 through 17 reflect symptoms associated with the following diagnoses/diagnostic categories: Q5, Schizophrenia; Q6, Depressive Disorders; Q7, Posttraumatic Stress Disorder; Q8, Phobias; Q9, Intermittent Explosive Disorder; Q10, Delusional Disorder;
Q11, Sexual and Gender Identity Disorders; Q12, Eating Disorders (Anorexia, Bulimia); Q13, Manic
Episode; Q14, Panic Disorder; Q15, Obsessive-Compulsive Disorder; Q16, Pathological Gambling;
and Q17, Learning Disorder and Mental Retardation.
Mental Health Continuum – Short Form (MHC – SF; Keyes, 2006) - The Mental Health Continuum
– Short Form is a measure of mental health that consists of 14 items. It measures the degree of (1)
Emotional Well Being (items 1–3) as defined in terms of positive affect/satisfaction with life; (2) Social Well Being (items 4–8) as described in Keyes’s (1998) model of Social Well Being (one item on
each of the dimensions of social acceptance, social actualization, social contribution, social coherence and social integration); and (3) Psychological Well Being (items 9–14) as described in Ryff’s
(1989) model (including one item on each of the dimensions of autonomy, environmental mastery,
personal growth, positive relations with others, purpose in life and self-acceptance). The MHC–SF
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allows a diagnosis to be made of the level of mental health an individual enjoys from languishing
mental health to flourishing mental health.
Addiction)Severity)Index)–)Self)Report!(ASI–SRr!Rosen,!Henson,!et!al.,!2000)!–!The!Addiction!SeverA
ity!Index!(ASIr!McLellan,!et!al.,!1980)!is!the!most!widely!published!substance!abuse!assessment.!For!
the!purposes!of!this!study!we!will!be!using!the!‘Your!Health’!section!of!the!self!report!version.!PreviA
ous! research! indicates! that! the! ASI! provides! good! sensitivity! and! specificity! to! identify! coAoccurring!
mental!illness!problems!(Cacciola,!Pecoraro,!&!Aterman,!2008).!

Alexithymia and Emotional Regulation
The Toronto Alexithymia Scale (TAS-20; Bagby, et al., 1992) is a widely used self-report measure of
Alexithymia. The scale is 20-items in length and provides independent measures of (1) Difficulties in
Identifying Feelings; (2) Difficulties in Describing Feelings; and (3) Externally Orientated Thinking.
Difficulties in Emotion Regulation Scale (DERS; Gratz & Roemer, 2004) – this is a 36-item selfreport measure that provides a total score of emotional regulation and 6-subscale scores (Nonacceptance of Emotional Response; Difficulties Engaging in Goal Directed Behaviour; Impulse Control
Difficulties; Lack of Emotional Awareness; Limited Access to Emotion Regulation Strategies; and
Lack of Emotional Clarity). The scale has previously been used with substance abuse populations
(e.g. Bonn-Miller, Vujanovic, & Zvolensky, 2008; Fox, Paliwal & Sinha, 2007).
A 53-item scale was developed for the purposes of this study to examine the relationship between
emotions and (a) using drugs and/or alcohol; and (b) listening to music. The emotions used in the
scale were selected from a previous survey examining emotions and music (Juslin & Laukka, 2004).
Music
Music Experience Questionnaire (MEQ; Werner, Swope & Heide, 2006). The MEQ is a 53-item self
report measure of individual differences in reaction to music. It is comprised of 6 independent subscale scores (Commitment to Music; Innovative Musical Aptitude; Social Uplift; Affective Reactions; Positive Psychotropic Effects; and Reactive Musical Behaviour).
See Appendix B for copies of the measures.
e)

Procedures

Assessment protocol
The process will first involve informing staff members of the study through a presentation in
their weekly staff meetings. Following this staff will then inform the clients of the study in the
clients ‘house meeting’. Questionnaires will then be distributed and completed by the clients
who are willing to participate. All clients will be provided with a participant information sheet.
Researchers will be on site at the time when clients are completing the questionnaires.
10.

Please provide a brief statement of the ethical considerations relevant to the proposed
research; specifically in relation to the participants’ welfare, rights, beliefs, perceptions,
customs and cultural heritage both individual and collective. (Attach an extra sheet if
necessary)
Informed consent – It is important that clients are aware of their freedom of choice to participate or refuse participation in this study. For this to be made certain clients will be approached
about this study through the Salvation Army staff so clients do not feel pressured by the re-
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searchers to participate. Salvation Army staff will be instructed to reinforce to the clients that
participation is voluntary and there will be no negative repercussions for refusing to participate.
Also clients will also be given the option of refusing participation through the researchers being the ones to hand out the questionnaires and be present while they are completed, in the instance they don’t want to refuse through Salvation Army staff. A third option for clients to refuse participation is by not completing the survey and placing it in an anonymous envelope.
This will allow clients to refuse participation without informing Salvation Army staff or the researchers. Clients will be made aware of this before they receive their survey and envelope.
We have used the same research protocol previously and clients did return blank surveys indicating that they felt comfortable to refuse participation.
Confidentiality – To ensure confidentiality consent forms will not be used. Rather the
following statement will be included on the participant information sheet “In order to
protect your privacy we will not request your written consent to participate in this study,
instead by completing and returning this questionnaire you will be providing your consent to participate in this study. If you do not wish to participate in this study you can
either: (1) Discuss this with the Salvation Army staff; (2) Discuss this with one of the
researchers; and/or (3) Return the incomplete questionnaire in the envelope provided.”
The surveys will be collected directly by researchers from the University of Wollongong and
no individual data will be given to the case managers or the service. The researchers will be on
site to collect the data and clients will also be given the option of posting their survey directly
to the researchers at the University of Wollongong with their provided reply-paid envelope.
All information will be stored securely at the University of Wollongong.
11.

Referring to the categories of participants to be involved in this project identified in question 7, above, What is the rationale for selecting participants from this/these group/s?
We are interested in identifying co-occurring mental illness problems within residential drug
and alcohol rehabilitation programs. The study will use clients who are currently attending these programs.

12.

How will potential participants be approached initially and informed about the project?
Please explain in detail and include copies of any letters, advertisements or other recruitment information. (e.g. direct approach to people on the street, mail-out to potential
participants through an organisation, posters or newspaper advertisements, etc)
Salvation Army staff will be informed of the proposed study by one of the researchers via a
presentation at a team meeting.
Clients will initially be informed of the study by Salvation Army staff. A participant information sheet (Appendix A) will be provided with contact details so if a client has further questions they can contact the researcher. This allows the opportunity for the client to refuse to participate outside of direct contact with Salvation Army staff.
We believe the safest approach to clients will be through Salvation Army staff. The staff will
be instructed to reinforce to the clients that participation is voluntary and there will be no negative repercussions for refusing to participate. Also clients will be given the option of refusing
participation through the researchers, in the instance they don’t want to refuse through their
caseworker. Clients will first be asked to put their survey in a provided envelope on completion. This allows a third option for clients to refuse participation by not completing the survey
and placing it in an anonymous reply-paid envelope. This means that clients have the option to
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refuse participation without contacting their caseworker or the researchers. Clients will be
made aware of this option by Salvation Army staff before they receive their survey and envelope.
13.

How many participants in total do you anticipate will be involved in the project? If the
research has several stages involving different participants, please provide the total number of participants expected as well as the number of participants involved in each stage.
There are at total of 488 beds in the rehabilitation centres throughout NSW, QLD and the ACT,
however not all of these beds are always occupied. Therefore with an estimated 70% participation rate it is expected there will be around 340 clients involved in the study.
Participant Consent
Attach copies of any letters of invitation, information packages, consent forms,
proxy/substitute consent forms, debriefing information, identification cards, contact detail cards, etc.

14 a. Is it anticipated that all participants will have the capacity to consent to their participation in the research?
Yes
If NO, please explain why (e.g. children, incompetent participants, etc.) and explain how
proxy or substitute consent will be obtained from the person with legal authority to consent on behalf of the participant (see Guidelines).
14 b. For participants who have the capacity to consent, how does the process ensure that informed consent is freely obtained from the participant?
To enter the Bridge program clients will have undergone a supervised detoxification programme prior and will have already been assessed as having appropriate psychological stability. As previously noted, the consent process allows clients to refuse consent through discussing participation with Salvation Army staff or via a third party (the researchers). Also if participants do not wish to participate they are given the option of placing the incomplete survey in a
blank reply-paid envelope which will be kept separate from the consent form which will be returned before the survey is completed. This means there will be no way of identifying those
who chose not to participate because no name will be identified on the survey. This also gives
clients the option of posting the envelope, allowing them to time to decide whether they wish
to participate and complete the survey.
14 c. Will written consent from participants be obtained?
No
If NO, please explain why it would be inappropriate or unethical to seek written evidence
of consent to this project.
By not obtaining written consent we eliminate any possible method of identifying any particular individual with their time in a residential drug and alcohol rehabilitation program. Also as
the study does not require identifying information collection of such information would be
both redundant and an unnecessary risk to the participant’s privacy.
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15.

Are any participants in a dependent relationship with the researcher, the institution or
the funding body (for example the researcher’s clinical clients or students; employees of
the institution; recipients of services provided by the funding body)? If so, what steps will
be taken to ensure that participants are free to participate or refuse to participate in the
research?
The clients will be in a clinical relationship with the Salvation Army staff who will inform
them of the study. As noted it will be clearly emphasised that participation is voluntary. In addition, the client will be provided with an option of contacting (or asking to be contacted by)
the researchers so they have the opportunity to refuse to participate without having to do so directly with the caseworker.

16.

How does the project address the participants’ freedom to discontinue participation?
Will there be any adverse effects on participants if they withdraw their consent and will
they be able to withdraw data concerning themselves if they withdraw their consent?
Once participants have completed their questionnaire and passed it on to researchers there will
be no option to withdraw their data (as we do not have identifying information). Clients will be
informed of this in their participant information sheet before completing the survey. Also clients will be made aware of their options to refuse participation before completing and returning
the questionnaire.

17.!

Does the project involve withholding relevant information from participants or deceiving
them about some aspect of the research?
No
If YES, what is the justification for this withholding or deception and what steps will be
taken to protect the participants’ interest in having full information about their participation?

18.

Will participants be paid or offered any form of reward or benefit (monetary or otherwise) for participation in the research? If so, please detail and provide a justification for
the payment, reward or benefit.
No

19.

Confidentiality:
What measures will be taken to protect the privacy of individual subjects in terms of the
test results and other confidential data obtained (both in recording the data and in its
publication)?
As consent forms will not be collected there will be no means by which the data collected can
be attributed to an individual. Therefore data that is recorded and published will have no link to
individual participants.

20.

Will information collected from data or interview be published?
Yes
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If YES, please indicate what form this will take (Please note that any further use of information which may identify a participant is conditional upon the participant’s permission for such use):
No individual identifying data will appear in any reports from the study. Data will be published
in group form only. The data will be used for the purposes of research student theses and potentially publication in scholarly journals and conference presentations. A report will also be
written for the Salvation Army.
21.

Will any part of the research activities be placed on an audiotape, film, photograph or
video-tape?
No
To what purpose will the audiotape, film, photograph or video-tape be used?
For what audience(s) will the audiotape, film, photograph or video-tape be exhibited?

22.

How will the data (including questionnaires, surveys, computer data, tapes, transcripts
and specimens) be held securely, during and on completion of the project?
Confidential data will be stored securely at the Illawarra Institute for Mental Health, it will be
stored in locked filing cabinets and at the completion of the project will be held in a locked
storage room.
Please confirm that original data will be held securely for a minimum of 5 years (15 years
for clinical research).
Clinical research data will be securely stored for 15 years.
If NO, please give reasons why it would be unethical to store the data for this period.

23.

Does the project involve the use of invasive procedures (e.g. blood sampling) or the risk of
physical harm or emotional distress?
Yes
If YES, give details:
Explain how the risks of harm or distress will be minimised. In the case of risks of emotional distress, what provisions have been made for an exit interview or the necessity of
counselling?
Clients may experience mild distress from answering questions about cravings for drugs or alcohol, or by questions about past situations in which another individual has offended them. In
the unlikely event that emotional distress occurs in response to some of the study questions
there will be provision for participants to meet with one of the counselling staff who are available at the treatment centre.

!

152!

24.

Does this project involve obtaining information (e.g. data) of a private nature from any
Commonwealth/State/Local Government Department or any other Agency, including
health records from Area Health Services.
No
If YES, which Department (s)/Agency?
Please include copies of any correspondence regarding permission to access this information from a responsible officer of the Agency and complete a Privacy Guideline Form
(available from Ethics Officer).

25.

Does the research intend to determine whether illegal activity has occurred or anticipate
that participants may reveal information about criminal activity?
Yes
If YES, how do you propose to respond to the legal issues raised?
There are questions in the survey that relate to clients’ past drug use which may involve clients
providing responses on past illegal substance use. Clients will be informed through their participant information sheet that any reports of current or past drug use will not be reported to the
authorities or the Salvation Staff. Also clients’ names will not be associated with their data
from their questionnaire so no data can be traced to an individual client.

! !
As!this!research!is!concerned!with!substance!use!the!researchers!will!not!report!
any!illegal!drug!use.!

26.

Period of Research Clearance Requested (Please specify as near as possible 'start' and
'finish' dates for the conduct of research):
FROM: 15/11/08

27.

TO: 15/11/09.

Any research project that involves the collection of data should be designed so that it is
capable of providing information that can be analysed to achieve the aims of the project.
Usually, although not always, this will involve various important statistical issues. It is
important that the design and analysis be properly planned in the early stages of the project. You should seek statistical advice. The University of Wollongong has a Statistical
Consulting Service that provides such advice to research students and staff undertaking
research.
Are statistical issues relevant to this project?
Yes
If so, have you discussed this project with the Statistical Consulting Service? No
Statistical staff from the School of Psychology, will be consulted regarding the design of this
study if required.

28.

!

Does this project involve the collection or use of personal health information or information relating to the provision of a health service to an individual? This includes general information such as a gymnasium would collect as well as information collected for a
medical purpose.
If so, you need to complete the Initial Application Form Part 2 – Privacy Addition for
Health Information. For additional information regarding this please read the document
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‘Health Records and Privacy Act’ and the NSW Privacy Commissioners’ Statutory
guidelines on research. Both documents are available from the HREC webpage.
Yes

NSW HEALTH
HEALTH ETHICS BRANCH
PRIVACY ADDITION TO HREC APPLICATION FORM
The Health Records and Information Privacy Act 2002 commences on 1 September 2004.
The Act creates a scheme to regulate the collection, use and disclosure of personal health information. It requires personal health information to be handled in accordance with 15
Health Privacy Principles (HPPs) set out in the Act. It is necessary for you to complete this
part of the application form in order to ensure:
•!
•!
•!

You and the [name of institution] comply with the Act;
This HREC can properly assess your research under the Act;
This HREC can meet its statutory obligations to report to the Privacy Commissioner on its activities
under the Act.

Please read the Statutory Guidelines made under the Act entitled Health Records and Information Privacy Act
2002 (NSW): Statutory Guidelines on Research which can be found on the website of Privacy NSW. This website can be accessed through www.lawlink.nsw.gov.au. Reading these documents will assist you in completing
this section of the application form.
Q1. Does this project involve the collection, use, or disclosure of personal health information which is identified, or from which the identity of the person can be reasonably
ascertained?

Yes!–!you!must!complete!this!section!of!the!application!form.!Go!to!question!2.!
!

29.

!

No – you do not need to complete this section of the application form. Go to [insert next
section of your standard HREC application form]

Comments. If you would like to make any comment about the application or the application process please do so.
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DECLARATION BY CHIEF INVESTIGATOR
I, the undersigned, have read the current National Statement on Ethical Conduct in Research Involving Humans:
http://www.health.gov.au/nhmrc/publications/synopses/e35syn.htm
and accept responsibility for the conduct of the research activities detailed in this application in accordance with the principles contained in the National Statement and any
other conditions laid down by the University of Wollongong's Human Research Ethics
Committee.
Chief Investigator's signature/s:
Date:
If the Chief Investigator is a student include:
Supervisor's signature:
Date:
Signature/s of other researcher/s: (The first named researcher will assume responsibility
for the project in the absence of the Chief Investigator)
Date:
DECLARATION BY HEAD OF UNIT
As Head of Unit I have responsibility for ensuring that Occupational Health and Safety
(OHS) issues surrounding research in the Unit are addressed.
(please tick all relevant boxes)
___
___
___
___
___

I am satisfied that a general risk assessment for the research project addressed in this
application has been completed adequately
I will ensure that a risk assessment specific to this application will be completed prior to
commencing the activities described in this application
I will ensure that there exist appropriate mechanisms to address potential OHS issues
that may arise and I have responsibility for implementing those mechanisms
I will ensure that mechanisms exist for ongoing assessment of the OHS issues related to
this research
This research involves use of radiation, chemicals or biohazards. A Risk Assessment has
been conducted and is attached to this application
Head of Unit’s Signature.................................................Date........................
NOTE: RESEARCH MUST NOT COMMENCE UNTIL APPLICATION HAS BEEN
FULLY APPROVED.

!
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CHECKLIST
Applications should be sent to the Ethics Officer, Human Research Ethics Committee, Office of
Research, University of Wollongong, Northfields Ave, Wollongong NSW 2522
Original Ethics Application plus appropriate number of copies (See Guidelines)
Consent Form(s)
Participant Information Sheet/Package
Copies of Questionnaire(s)/Survey(s) or Interview Questions
Copies of all documents and other material used to inform potential participants
about the research including advertisements and letters of invitation.
Evidence of permission to conduct research in locations not associated with the
University of Wollongong
Evidence of approval/rejection by other HREC(s), including comments and requested alternations to the protocol
Any form requiring signature by the HREC (one copy)
For Clinical Trials : Application Form (original +14 copies), Patient
Information Package (14 copies), Consent Forms (14 copies), Indemnity Form (14
copies), Protocols (14 copies), Advertisement (14 copies), Summary Sheet (14 copies), Budget (14 copies), Insurance information (if in Private Practice) (14 copies),
Investigator’s Brochure (5 copies), CTN or CTX Form (1 original copy)
Form Revised Jan 2003

!
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University of Wollongong
Client Participant Information Sheet
Lake Macquarie Recovery Service Centre:

Mental Health and Substance Abuse Problems
Who is doing the study?
Dr Peter Kelly, Prof Frank Deane and Mr Kane Mortlock will be conducting this research project. Aspects of
this research will be used for Mr Mortlock’s doctorial thesis.
What is the study about?
The study aims to examine the proportion of people in residential drug and alcohol rehabilitation who also
have a mental health problem. Studies have found that people with both drug and alcohol and mental health
problems can do much worse than those with drug and alcohol problems alone. For this reason it is important
to identify how many people in drug and alcohol treatment services also have mental health problems so more
can be done to help this group. It will also examine people’s different reactions to music. We are looking at this
because music has been found to effect people’s moods in different ways and may have the potential to be useful in therapy.!
What do I need to do?
The first thing you need to do is carefully read this ‘participant information sheet’ making sure you understand
what is required. In order to protect your privacy we will not request your written consent to participate in this
study, instead by completing and returning this questionnaire you will be providing your consent to participate
in this study. If you do not wish to participate in this study you can either:
1. Discuss this with the Salvation Army staff
2. Discuss this with one of the researchers
3. Return the incomplete questionnaire in the envelope provided.
It is anticipated that completion of this questionnaire will take approximately 60 minutes. If you would like
further information on the study you can also contact Dr Kelly or Prof Deane at the University of Wollongong
by calling 02 4221 4207.
Is there any risk or burden if I decide to participate?
The main burden will be related to the time it takes to complete the assessment. There is a very small risk that
you might think some of the questions in the questionnaires are too personal or distressing. Example items are:
“Have you ever been advised to take medication for anxiety, depression, hearing voices, or for any other emotional problem?” and to what extent do you “want to drink/use drugs so much I can taste it.” However, in addition to your right not to participate in the survey, you also have the right to refuse to answer any specific questions that you find too personal or distressing and if any of the questions cause you any distress the Salvation
Army staff will also be available to assist you.!
Also because your name will not appear on any part of the questionnaire there will be no option to withdraw
any information provided at a later date. If you choose not to participate in the study, this will in no way have
an effect on your relationship with your support or treatment services or the University of Wollongong. Participation is entirely voluntary.
Are there any benefits expected?
People often find that when they complete the questionnaires it helps them reflect on their progress and clarify
what it is about treatment that is helping them. Also the information from this study will hopefully contribute
to improving the treatment program and complimenting already existing research.
How will my information be collected and used?
You will be required to complete a questionnaire which will involve completing a written survey. Information
from this survey will be kept confidential. All questionnaire material will be stored securely at the University of
Wollongong. The information may be used for publication in scholarly research journals, reports to the Salvation Army, student theses, and conference presentations. You will not be identifiable in any publications.
What if I have more questions?

!

157!

You may have additional questions that you wish to ask about the research before you decide whether to participate. You can contact Dr Kelly or Prof Deane at the University of Wollongong by calling 02 4221 4207. If you
have any concerns or complaints regarding the way in which the research is or has been conducted, you can
contact the Secretary of the University of Wollongong Human Research Ethics Committee on Phone: (02)
4221 4457, Fax: (02) 4221 4338 email: research@uow.edu.au

!
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Mental!Health!Screening!and!Emotional!Control!
!

1.! What!is!your!age?!………………..!
!

2.! How!many!weeks!have!you!been!in!the!program!for?!………………!
!

3.! What!gender!are!you?!(Circle)!!!

1.!Male!!

!

2.!

Female!

!

4.! What!program!are!you!attending?!(circle)!
Gold Coast

Brisbane

Townsville

Canberra

Central
Coast

Sydney

Morisset

Blue
Mountains

5.! How long have you had drug and/or alcohol problems? ___________Years
!

6.! In!the!12!months!before!you!entered!treatment!what!substances!had!you!used?!
(You!may!tick!multiple!drugs)!
!
Heroin!!
!
!
!
!
!
!
!1!
!
Marijuana/Cannabis! !
!
!
!
!
!2!
Amphetamines!(e.g.!speed,!ice,!crystal!methyl)!
!
!3!
!
Alcohol!
!
!
!
!
!
!
!4!
!
Ecstasy!
!
!
!
!
!
!
!5!
!
Cocaine!
!
!
!
!
!
!
!6!
!
Other(s)!
!
!
!
!
!
!
!7!
If!Other(s)!Please!Specify!
! _____________________________________________________________!
!

7.! What!do!you!consider!your!primary!drug!of!concern?!(Please!specify!just!one)!
____________________________________________
8.! Before entering treatment, how often would you take this drug? (tick)

Once$a$month$
$
More$than$once$a$month$
At$least$once$a$week$
Daily$ $
$
$
More$than$once$a$day$

$
$
$
$
$

$
$
$
$
$

$
$
$
$
$

$
$
$
$
$

!1$
!2$
!3$
!4$
!5$

9.! Have you ever previously sought treatment for your current drug problem?

YES!
NO!

!
!

!1!
!2!

!

10.! Have you ever received treatment for a mental health problem?
YES
"1
NO
"2

11.!If YES, what diagnosis did you receive? ………………………
12.!How well is the service meeting your mental health needs currently?
Not at all

Slightly

Moderately

Considerably

Extremely

13.!Have you experienced any of the following drug-and-alcohol-related things previously?
Relapse

!

Hospitalisation

Violence

Family difficulties

Homelessness
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DAQ
A craving refers to the thoughts and feelings associated with an urge or desire to drink or use drugs.
The following questions in this section relate specifically the time since you’ve been in the residential treatment program. Please indicate your agreement to the following statements by circling the
most appropriate number on the scale following the statement
!
Strongly
disagree

Strongly
agree

1.

I want to drink/use drugs so much I can taste
it.

1

2

3

4

5

6

7

2.

My desire to drink/ use drugs now seems
overwhelming

1

2

3

4

5

6

7

3.

I would do almost anything to have a drink/ take
1
some drugs right now

2

3

4

5

6

7

4.

I would feel as if all the bad things in my life
had disappeared if I drank/used drugs now

1

2

3

4

5

6

7

5.

Even major problems in my life would not
bother me if I drank/used drugs now

1

2

3

4

5

6

7

6.

I would feel less worried about my daily problems if I drank/used dugs now

1

2

3

4

5

6

7

7.

Drinking/using drugs would be satisfying now

1

2

3

4

5

6

7

8.

Drinking/using drugs would be pleasant now

1

2

3

4

5

6

7

!
!
!

TAS%20!
Please!rate!how!strongly!you!agree!with!the!following!statements.!
!
!
!

1.! I!am!often!confused!about!what!emotion!
I!am!feeling.!
2.! It!is!difficult!for!me!to!find!the!right!words!
for!my!feelings.!
3.! I!have!physical!sensations!that!even!
doctors!don’t!understand.!
4.! I!am!able!to!describe!my!feelings!easily.!
5.! I!prefer!to!analyse!problems!rather!than!
just!describe!them!
6.! When!I!am!upset,!I!don’t!know!if!I!am!
sad,!frightened,!or!angry.!

!

Strong%
ly!disa%
gree!

Disa%
gree!

Unsure!

Agree!

Strong%
ly!agree!

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5
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!
!

Strong%
ly!disa%
gree!

Disa%
gree!

Unsure!

Agree!

Strong%
ly!agree!

1

2

3

4

5

1

2

3

4

5

9.! I!have!feelings!that!I!can’t!quite!identify.!

1

2

3

4

5

10.!Being!in!touch!with!emotions!is!essential.!

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

13.!I!don’t!know!what’s!going!on!inside!me.!

1

2

3

4

5

14.!I!often!don’t!know!why!I!am!angry.!

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

7.! I!am!often!puzzled!by!sensations!in!my!
body!
8.! I!prefer!to!just!let!things!happen!rather!
than!to!understand!why!they!turned!out!
that!way.!

11.!I!find!it!hard!to!describe!how!I!feel!about!
people.!
12.!People!!tell!me!to!describe!my!feelings!
more.!

15.!I!prefer!talking!to!people!about!their!daily!
activities!rather!than!their!feelings.!
16.!I!prefer!to!watch!“light”!entertainment!
shows!rather!than!psychological!dramas.!
17.!It!is!difficult!for!me!to!reveal!my!innerA
most!feelings,!even!to!close!friends.!
18.!I!can!feel!close!to!someone,!even!in!
moments!of!silence.!
19.!I!find!examination!of!my!feelings!useful!in!
solving!personal!problems.!
20.!Looking!for!hidden!meanings!in!movies!
or!plays!distracts!from!their!enjoyment.!

!
!
!
What!is!your!favourite!style!of!music?!………………………………..!
!
!
In!the!past,!to!what!extent!have!the!following!emotions!triggered!you!to!use!your!main!drug!of!
choice?!
!
!
Very!
Small! Unsure! Large!
Very!
!
small!
extent!
extend!
large!
extent!
extent!

1.! Sadness!

1

2

3

4

5

2.! Anger!

1

2

3

4

5

3.! Anxiety!

1

2

3

4

5

4.! Happiness!/!Joy!

1

2

3

4

5

5.! Love!

1

2

3

4

5

!
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!
!

6.! Calmness!

Very!
small!
extent!

Small!
extent!

Unsure!

Large!
extend!

Very!
large!
extent!

1

2

3

4

5

!
!
!
To!what!extent!is!music!capable!of!leading!you!to!experience!the!following!emotions?!
!
!
!

Very!
small!
extent!

Small!
extent!

Unsure!

Large!
extend!

Very!
large!
extent!

7.! Sadness!

1

2

3

4

5

8.! Anger!

1

2

3

4

5

9.! Anxiety!

1

2

3

4

5

10.!Happiness!/!Joy!

1

2

3

4

5

11.!Love!

1

2

3

4

5

12.!Calmness!

1

2

3

4

5

!
!
MEQ!

This!questionnaire!concerns!the!place!of!music!in!your!life.!!Questions!concern!your!
thoughts!about!music,!your!feelings!about!it,!your!reactions!to!it,!and!how!it!relates!to!your!
activities.!!There!are!no!right!or!wrong!answers!to!these!questions.!!After!reading!each!
question!carefully,!indicate!how!true!it!is!of!your!experience!and!behaviour,!using!the!followA
ing!scale:!
!

1.! I!can!easily!improvise!on!an!inA
strument!without!having!music!
in!front!of!me.
2.! I!frequently!hear!songs!in!my!
head.
3.! I!feel!more!integrated!(more!
“together”)!when!I!hear!certain!
kinds!of!music.
4.! I!often!sing,!hum,!or!whistle!
along!with!recorded!music.
5.! I!would!never!want!to!listen!to!
the!same!piece!of!music!twice!
in!a!row.
6.! When!I’m!enjoying!music!with!
other!people!I!feel!like!we’re!

!

Very!
untrue

Some%
what!
untrue

Equally!
true!
and!un%
trueY!
unsure

Some%
what!
true

Very!
true

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5
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Very!
untrue

Some%
what!
untrue

Equally!
true!
and!un%
trueY!
unsure

Some%
what!
true

Very!
true

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

speaking!the!same!language.
7.! I’ve!had!musical!experiences!
that!have!changed!my!whole!
mood.
8.! I!enjoy!singing!in!the!shower!or!
bath.
9.! I!sometimes!spend!more!money!
than!I!can!afford!to!attend!a!
musical!performance.
10.!It!is!hard!for!me!to!keep!the!
beat!when!dancing.
11.!Music!unites!my!mind!and!my!
body.
12.!A!song!has!never!made!me!feel!
joyous.
13.!I!like!listening!to!music!that!has!
a!message.
14.!There’s!nothing!more!powerful!
than!singing!a!beloved!song!
with!other!people.
15.!Listening!to!music!is!a!very!priA
vate!experience!for!me.
16.!I!wish!my!family!had!sung!toA
gether!more!when!I!was!growA
ing!up.
17.!I!have!perfect!pitch.
18.!When!they!are!done!well,!I!find!
patriotic!songs!very!stirring.
19.!I!wish!music!had!been!more!a!
part!of!my!childhood.
20.!I!have!never!been!physically!
stirred!up!by!music.
21.!Music!is!the!most!important!
thing!in!my!life.
22.!Music!helps!me!forget!my!
cares.
23.!Totally!new!tunes,!that!I’ve!
never!heard!before,!sometimes!
pop!into!my!head.
24.!I!can!hardly!resist!dancing!to!
certain!music.
25.!Music!gives!me!a!sense!of!purA
pose!and!movement.
26.!The!experience!of!music!brings!
me!closer!to!a!higher!power.
27.!I!am!especially!response!to!the!
beat!or!rhythm!in!music.

!
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Very!
untrue

Some%
what!
untrue

Equally!
true!
and!un%
trueY!
unsure

Some%
what!
true

Very!
true

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

33.!Music!never!affects!my!feelings.

1

2

3

4

5

34.!Music!has!no!place!in!my!life.

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

28.!People!have!applauded!my!perA
formance!of!music.
29.!I!enjoy!making!up!or!composing!
tunes,!songs!or!musical!pieces.
30.!I!have!a!good!sense!of!pitch.
31.!I!easily!get!“lost”!in!the!depth!of!
my!concentration!on!music.
32.!I!often!find!myself!swaying!in!
tune!with!music!to!which!I’m!lisA
tening.

35.!Music!helps!me!get!out!of!myA
self.
36.!Certain!music!draws!me!strongA
ly!to!dance.
37.!I!have!made!sacrifices!in!my!life!
in!the!pursuit!of!music.
38.!I!follow!the!details!of!certain!
musical!performers’!lives.
39.!I!love!some!kind!of!music.
40.!Sometimes!I!spend!too!much!
money!on!musical!recordings!or!
music!videos.
41.!It’s!important!for!me!to!see!muA
sic!being!performed!and!not!just!
hear!it.
42.!Music!!helps!me!not!feel!so!
lonely.
43.!Often!I!tap!my!feet!or!hands!
along!with!music!I’m!hearing.
44.!I!am!better!able!to!face!the!
world!after!enjoying!music.
45.!The!emotional!side!of!music!
makes!me!uncomfortable.
46.!There!are!some!kinds!of!music!
that!I!really!detest.
47.!I’ve!been!both!aroused!and!satA
isfied!by!a!musical!experience.
48.!Music!gives!a!sense!of!order!to!
my!life.
49.!I’m!pretty!good!at!improvising!
music,!either!in!my!head!or!on!
an!instrument.
50.!Hearing!a!song!will!sometimes!

!
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bring!to!my!mind!a!period!of!my!
life.
51.!Music!can!influence!my!emoA
tions.
52.!Life!would!be!meaningless!to!
me!without!music.
53.!I’ve!had!experiences!of!ecstasy!
while!listening!to!music.

Very!
untrue

Some%
what!
untrue

Equally!
true!
and!un%
trueY!
unsure

Some%
what!
true

Very!
true

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

!
!
DERS!

Please!indicate!how!often!the!following!statements!apply!to!you!by!writing!the!appropriate!
number!from!the!scale!below!on!the!line!beside!each!item:!
!

!

Almost!
never!
(0%10%)!

Some%
times!

About!
half!
time!

Most!of! Almost!
the!time! always!
(66%90%)! (91%100%)!

(11%35%)!

1
1

2
2

3
3

4
4

5
5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1
1
1
1

2
2
2
2

3
3
3
3

4
4
4
4

5
5
5
5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

(36%65%)!

1.! I!am!clear!about!my!feelings.!
2.! I!pay!attention!to!how!I!feel.!
3.! I!experience!my!emotions!as!
overwhelming!and!out!of!conA
trol.!
4.! I!have!no!idea!how!I!am!feeling.!
!
5.! I!have!difficulty!making!sense!
out!of!my!feelings.!
6.! I!am!attentive!to!my!feelings.!
7.! I!know!exactly!how!I!am!feeling.!
8.! I!care!about!what!I!am!feeling.!
9.! I!am!confused!about!how!I!feel.!
10.!When!I’m!upset,!I!acknowledge!
my!emotions.!
11.!When!I’m!upset,!I!become!anA
gry!with!myself!for!feeling!that!
way.!
12.!When!I’m!upset,!I!become!emA
barrassed!for!feeling!that!way.!
13.!When!I’m!upset,!I!have!difficulty!
getting!work!done.!
14.!When!I’m!upset,!I!become!out!
of!control.!
15.!When!I’m!upset,!I!believe!that!I!
will!remain!that!way!for!a!long!
time.!
16.!When!I’m!upset,!I!believe!that!
I’ll!end!up!feeling!very!deA
pressed.!

!
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!

Almost!
never!
(0%10%)!

Some%
times!

(11%35%)!

About!
half!
time!

Most!of! Almost!
the!time! always!
(66%90%)! (91%100%)!

(36%65%)!

17.!When!I’m!upset,!I!believe!that!
my!feelings!are!valid!and!imA
portant.!
18.!When!I’m!upset,!I!have!difficulty!
focusing!on!other!things.!
19.!When!I’m!upset,!I!feel!out!of!
control.!
20.!When!I’m!upset,!I!can!still!get!
things!done.!
21.!When!I’m!upset,!I!feel!ashamed!
with!myself!for!feeling!that!way.!
22.!When!I’m!upset,!I!know!that!I!
can!find!a!way!to!eventually!feel!
better.!
23.!When!I’m!upset,!I!feel!like!I!am!
weak.!
24.!When!I’m!upset,!I!feel!like!I!can!
remain!in!control!of!my!behavA
iors.!
25.!When!I’m!upset,!I!feel!guilty!for!
feeling!that!way.!
!
26.!When!I’m!upset,!I!have!difficulty!
concentrating.!
27.!When!I’m!upset,!I!have!difficulty!
controlling!my!behaviors.!
28.!When!I’m!upset,!I!believe!that!
there!is!nothing!I!can!do!to!
make!myself!feel!better.!
29.!When!I’m!upset,!I!become!irriA
tated!with!myself!for!feeling!that!
way.!
30.!When!I’m!upset,!I!start!to!feel!
very!bad!about!myself.!
31.!When!I’m!upset,!I!believe!that!
wallowing!in!it!is!all!I!can!do.!
32.!When!I’m!upset,!I!lose!control!
over!my!behaviours.!
33.!When!I’m!upset,!I!have!difficulty!
thinking!about!anything!else.!
34.!When!I’m!upset,!I!take!time!to!
figure!out!what!I’m!really!feelA
ing.!
35.!When!I’m!upset,!it!takes!me!a!
long!time!to!feel!better.!
36.!When!I’m!upset,!my!emotions!
feel!overwhelming.!

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

!
MHSF%III!

!
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Please&rate&Yes&or&No&to&the&following&questions.&Please&note,&each&item&refers&to&your&entire&life&history,&not&
just&your&current&situation,&this&is&why&each&question&begins&–&“Have&you&ever&….”&
&

1)! Have you ever talked to a psychiatrist, psychologist, therapist, social workYES& NO&
er or counsellor about an emotional problem?&
2)! Have you ever felt you needed help with your emotional problems, or have
you had people tell you that you should get help for your emotional prob- YES& NO&
lems?&
3)! Have you ever been advised to take medication for anxiety, depression,
YES& NO&
hearing voices, or for any other emotional problem?&
4)! Have you ever been seen in a psychiatric emergency room or been hospitalYES& NO&
ised for psychiatric reasons?&
5)! Have you ever heard voices no one else could hear or seen objects or things
YES& NO&
which others could not see?&
!

!

6)! a) Have you ever been depressed for weeks at a time, lost interest or pleas- YES! NO!
ure in most activities, had trouble concentrating and making decisions or !
!
thought about killing yourself?
!
!
b) Did you ever attempt to kill yourself?
&

YES& NO&

7)! Have you ever had nightmares or flashbacks as a result of being involved in
some traumatic/terrible event? For example, warfare, gang fights, fire, do- YES& NO&
mestic violence, rape, incest, car accident, being shot or stabbed?&
8)! Have you ever experienced any strong fears? For example, of heights, insects, animals, dirt, attending social events, being in a crowd, being alone, YES& NO&
being in places where it may be hard to escape or get help?&
9)! Have you ever given in to an aggressive urge or impulse, on more than one
occasion, that resulted in serious harm to others or led to the destruction of YES& NO&
property?&
10)!Have you ever felt that people had something against you, without them
necessarily saying so, or that someone or some group may be influencing or YES& NO&
trying to influence your thoughts or behaviour?&
11)!Have you ever experienced any emotional problems associated with your
YES& NO&
sexual interests, your sexual activities, or your choice of sexual partner?&
12)!Was there ever a period in your life where you spent a lot of time thinking
and worrying about gaining weight, becoming fat, or controlling your eating? For example, by repeatedly dieting or fasting, engaging in much exer- YES& NO&
cise to compensate for binge eating, taking enemas, or forcing yourself to
throw up?&

!
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13)!Have you ever had a period of time when you were so full of energy and
your ideas came very rapidly, when you talked nearly non-stop, when you
YES& NO&
moved quickly from one activity to another, when you needed little sleep,
and believed you could do almost anything?&
14)!Have you ever had spells or attacks when you suddenly felt anxious, frightened, uneasy to the extent that you began sweating, your heart began to beat
YES& NO&
rapidly, you were shaking or trembling, your stomach was upset, you felt
dizzy or unsteady, as if you would faint?&
15)!Have you ever had a persistent, lasting thought or impulse to do something
over and over that caused you considerable distress and interfered with
normal routines, work, or your social relations? Examples would include
YES& NO&
repeatedly counting things, checking and rechecking on things you had
done, washing and rewashing your hands, praying, or maintaining a very
rigid schedule of daily activities from which you could not deviate?&
16)!Have you ever lost considerable sums of money through gambling or had
problems at work, in school, with your family and friends as a result of your YES& NO&
gambling?&
17)!Have you ever been told by teachers, guidance counselors, or others that
YES& NO&
you have a special learning problem?&
!
!

!
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MENTAL!HEALTH!CONTINUUM!–!SHORT!FORM!(MHC!–!SF)!
The&following&questions&are&about&how&you&have&been&feeling&in&the&past&month.&Please&place&a&check&mark&in&
the&box&that&best&represents&how&often&you&have&felt&each&feeling.&
!

In!the!past!month,!how!often!
did!you!feel!…!!
&

1.&happy&

!
!
NEVER!
(0)!

ONCE!
OR!
TWICE!
(1)!

ABOUT!
ONCE!A!
WEEK!
(2)!

2!OR!3! ALMOST!
TIMES!A! EVERY!
WEEK!
DAY!
(3)!
(4)!

!
EVERY!
DAY!
(5)!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

&
&

2.&interested&in&life&
&

&

3.&satisfied&
&

&

4.&that&you&had&something&
important&to&contribute&to&
society&
&

&

5.&that&you&belonged&to&a&
community&(like&a&social&group,&your&
neighbourhood,&your&city)&
&

&

6.&that&our&society&is&becoming&a&betR
ter&place&for&people&
&

&

7.&that&people&are&basically&
good&
&

&

8.&that&the&way&our&society&
works&makes&sense&to&you&
&

&

9.&that&you&liked&most&parts&of&your&
personality&
&
&

10.&good&at&managing&the&
responsibilities&of&your&daily&life&
&

&

11.&that&you&had&warm&and&
trusting&relationships&with&
others&
&

&

12.&that&you&have&experiences&that&
challenge&you&to&grow&and&become&a&
better&person&
&

&

13.&confident&to&think&or&
express&your&own&ideas&and&
opinions&
&

&

14.&that&your&life&has&a&sense&of&direcR
tion&or&meaning&to&it&
&

©2006!Corey!L.!M.!Keyes.!For!permission,!please!contact!Dr.!Keyes!at!corey.keyes@emory.edu!!
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ADDICTION!SEVERITY!INDEX!–!SELF!REPORT!(ASI%SR)!PART!II:!YOUR!HEALTH!
&
&

7.&How&many&days&have&you&experienced&medical&problems&in!the!past!30!days?&&
&&&&&(Do&not&include&ailments&directly&caused&by&drugs/alcohol,&except&for&serious&ailments&&
!
&&&&&that&would&continue&even&if&you&were&abstinent&–&for&example,&cirrhosis&of&the&liver,& &&&&&&&&&&&&&&&Number!of!Days&
&&&&&abscesses&from&needles,&etc.)&
&

8.&How&troubled&or&bothered&have&you&been&by&these&medical&problems&in!the!past!30!days?&
!!!!!!!!!!!!Not!at!all!!!!!!!!!Slightly!

!!!!!!Moderately! !!!!!!!!Considerably!

!!!!!Extremely!

!

9.&How&important&to&you&now&is&treatment&for&these&medical&problems?&
!!!!!!!!!!!!Not!at!all! !!!!!!!!Slightly!

!!!!!!Moderately! !!!!!!!!!Considerably!

!!!!!!Extremely!

!
!

10.&&
In!the!past!30!days,!have&you&had&a&significant&
period&of&time&in&which&you&have:&
!
&

a.&Experienced&serious&depression,&hopelessness,&
&&&&loss&of&interest,&difficulty&with&daily&functioning?&

Only!when!high,!
or!in!withdrawal!
from!alcohol/drugs!

NO!

YES!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

!

&
&

b.&Experienced&serious&anxiety/tension,&uptight,&
&&&&unreasonably&worried,&inability&to&feel&relaxed?&
&
&

c.&Experienced&hallucinations&–&saw&things&or&heard&
&&&&voices&that&were&not&there?&
&
&

d.&Experienced&trouble&understanding,&concentrating,&
&&&&or&remembering?&
&
&

11.&
!

In!the!past!30!days,!did&you&have&a&significant&period&(it&may&have&
been&the&direct&result&of&alcohol/drug&use)&in&which&you&have:&

YES!

!
&

a.&Experienced&trouble&controlling&violent&behaviour,&including&episodes&
&&&&of&rage,&or&violence?&
&
&

b.&Experienced&serious&thoughts&of&suicide&(seriously&considered&a&plan&
&&&&for&taking&your&life)?&
c.&Attempted&suicide?&

&
&

NO!

!

!

!

!

!

!

!

!

&
&

&
&

12.&In!the!past!30!days,&how&many&days&have&you&experienced&these&
&&&&&&psychological&or&emotional&problems?&
&
&
&

&

Number!of!Days&

&
&

13.&How&much&have&you&been&troubled&or&bothered&by&these&psychological&or&emotional&problems&&
&&&&&&&in!the!past!30!days?!
Not!at!all!
!Slightly!!!!!!!!!!!!!!!!!Moderately! !!!!!!Considerably!
!Extremely!
&

!
!

14.&How&important&to&you&now&is&treatment&for&these&psychological&or&emotional&problems?&
Not!at!all!
!Slightly! !!!!!!!!!!!!!!!!Moderately! !!!!!!Considerably!
!Extremely!
!
&

15.&In!the!past!30!days,&have&you&been&prescribed&medication&for&
&&&&&&any&psychological&or&emotional&problems?& &
&
&

&NO!!!!!!! !!!!!!!!!!!!YES!

&

!
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If!completing!this!survey!raises!any!emotional!issues!with!you!we!strongly!encourage!that!
you!discuss!this!with!your!support!worker.!
!
Thank!you!for!completing!the!survey.!
!
!
!

!

171!

Appendix$D$
HE08/297!
!
th
!
17 !November!2008
!
Chairperson!
Human!Research!Ethics!Committee!
University!of!Wollongong!
!
!
Ethics!Number:!
HE08/297!
Project!Title:!!Mental)health)screening)within)residential)drug)and)alcohol)rehabilitation!
!
Thank&you&for&providing&a&prompt&response&to&our&application.&We&have&carefully&attended&to&each&aspect&of&
the&committees’&concerns&as&outlined&below.&
&
1.! Provide!a!longer!outline!of!the!purpose!of!the!study!on!the!information!sheet.!
&
The&following&passage&has&been&inserted&into&the&participant&information&sheet,&(attached&in&full&as&appendix&
A),&to&enlarge&upon&our&outline&of&the&purpose&of&the&study:&
!
What%is%the%study%about?%
The% study% aims% to% examine% the% proportion% of% people% in% residential% drug% and% alcohol% rehabilitation% who% also%
have%a%mental%health%problem.%Studies%have%found%that%people%with%both%drug%and%alcohol%and%mental%health%
problems%can%do%much%worse%than%those%with%drug%and%alcohol%problems%alone.%For%this%reason%it%is%important%
to% identify% how% many% people% in% drug% and% alcohol% treatment% services% also% have% mental% health% problems% so%
more%can%be%done%to%help%this%group.%It%will%also%examine%people’s%different%reactions%to%music.%We%are%looking%
at%this%because%music%has%been%found%to%effect%people’s%moods%in%different%ways%and%may%have%the%potential%to%
be%useful%in%therapy.%%
&
&
2.! Extend!the!amount!of!time!it!takes!to!complete!the!survey!on!the!information!sheet.!!
!
The&advice&on&the&estimated&amount&of&time&it&takes&to&complete&the&survey&has&been&extended&from&40&
minutes&to&60&minutes.&&
&
&
3.! Provide!examples!of!“sensitive!questions”!on!the!participant!information!sheet.!
&
The&participant&information&sheet&has&had&the&following&paragraph&added&that&includes&two&items&that&could&
be&construed&as&“sensitive”:&
&
There%is%a%very%small%risk%that%you%might%think%some%of%the%questions%in%the%questionnaires%are%too%personal%or%
distressing.%Example%items%are:%“Have%you%ever%been%advised%to%take%medication%for%anxiety,%depression,%hearG
ing%voices,%or%for%any%other%emotional%problem?”%and%to%what%extent%do%you%“want%to%drink/use%drugs%so%much%
I%can%taste%it.”%However,%in%addition%to%your%right%not%to%participate%in%the%survey,% you%also%have%the%right%to%
refuse% to% answer% any% specific% questions% that% you% find% too% personal% or% distressing% and% if% any% of% the% questions%
cause%you%any%distress%the%Salvation%Army%staff%will%also%be%available%to%assist%you.%
&
&
4.! To!ensure!clients!have!the!freedom!to!not!participate,!only!have!researchers!in!the!room!when!clients!
are!completing!the!surveys.&
&&
At&the&time&when&clients&are&completing&the&surveys&only&researchers&will&be&in&the&room.&
&

!
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In& addition& to& the& concerns& raised& by& the& committee& we& would& like& to& add& an& additional& 2& questions& to& the&
survey&to&examine&the&participants’&perceptions&of&how&well&their&mental&health&needs&are&being&met&by&their&
drug&and&alcohol&treatment&service&currently&and&what,&if&any,&poorer&treatment&outcomes&traditionally&assoR
ciated&with&drug&and&alcohol&and&mental&illness&comorbidity&they&have&experienced&previously.&The&items&are&
as&follows:&
&

14.!How$well$is$the$service$meeting$your$mental$health$needs$currently?$
$

Not!at!all!

!!!Slightly!

!!!Moderately! !!!!!!!Considerably!

!!Extremely!

$
15.!Have$you$experienced$any$of$the$following$drugKandKalcoholKrelated$difficulties$preK
viously?$
$

Relapse!!!!!!!Hospitalisation!!!!!!!!Violence!
!Family!difficulties!
!Homelessness!
&
We&would&appreciate&it&if&you&could&let&us&know&if&these&revisions&have&adequately,&addressed&the&CommitR
tee’s&concerns&as&soon&as&possible&in&order&to&finalise&dates&for&the&data&collection.&
&
Yours&sincerely,&
Professor&Frank&Deane&
University&of&Wollongong&
&
&

University!of!Wollongong!
Client!Participant!Information!Sheet!
Lake!Macquarie!Recovery!Service!Centre:!!
!

Mental!Health!and!Substance!Abuse!Problems!
!

Who!is!doing!the!study?!!
Dr!Peter!Kelly,!Prof!Frank!Deane!and!Mr!Kane!Mortlock!will!be!conducting!this!research!project.!AsA
pects!of!this!research!will!be!used!for!Mr!Mortlock’s!doctorial!thesis.!
!

What!is!the!study!about?!
The!study!aims!to!examine!the!proportion!of!people!in!residential!drug!and!alcohol!rehabilitation!who!also!
have! a! mental! health! problem.! Studies! have! found! that! people! with! both! drug! and! alcohol! and! mental!
health!problems!can!do!much!worse!than!those!with!drug!and!alcohol!problems!alone.!For!this!reason!it!
is!important!to!identify!how!many!people!in!drug!and!alcohol!treatment!services!also!have!mental!health!
problems!so!more!can!be!done!to!help!this!group.!It!will!also!examine!people’s!different!reactions!to!muA
sic.!We!are!looking!at!this!because!music!has!been!found!to!effect!people’s!moods!in!different!ways!and!
may!have!the!potential!to!be!useful!in!therapy.!
!

What!do!I!need!to!do?!
The first thing you need to do is carefully read this ‘participant information sheet’ making sure you understand
what is required. In order to protect your privacy we will not request your written consent to participate in this
study, instead by completing and returning this questionnaire you will be providing your consent to participate
in this study. If you do not wish to participate in this study you can either: !
1. Discuss this with the Salvation Army staff!
2. Discuss this with one of the researchers!
3. Return the incomplete questionnaire in the envelope provided.
It is anticipated that completion of this questionnaire will take approximately 60 minutes. If you would like
further information on the study you can also contact Dr Kelly or Prof Deane at the University of Wollongong
by calling 02 4221 4207.!
Is!there!any!risk!or!burden!if!I!decide!to!participate?!
The! main! burden! will! be! related! to! the! time! it! takes! to! complete! the! assessment.! There! is! a! very!
small! risk! that! you! might! think! some! of! the! questions! in! the!questionnaires! are! too! personal! or! disA
tressing.! Example! items! are:! “Have! you! ever! been! advised! to! take! medication! for! anxiety,! depresA
sion,! hearing! voices,! or! for! any! other! emotional! problem?”! and! to! what! extent! do! you! “want! to!
drink/use!drugs!so!much!I!can!taste!it.”!However,!in!addition!to!your!right!not!to!participate!in!the!surA
!

!
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vey,!you!also!have!the!right!to!refuse!to!answer!any!specific!questions!that!you!find!too!personal!or!
distressing! and! if! any! of! the! questions! cause! you! any! distress! the! Salvation! Army! staff! will! also! be!
available!to!assist!you.!
Also because your name will not appear on any part of the questionnaire there will be no option to withdraw
any information provided at a later date. If you choose not to participate in the study, this will in no way have
an effect on your relationship with your support or treatment services or the University of Wollongong. Participation is entirely voluntary.
Are!there!any!benefits!expected?!
People!often!find!that!when!they!complete!the!questionnaires!it!helps!them!reflect!on!their!progress!
and!clarify!what!it!is!about!treatment!that!is!helping!them.!!Also!the!information!from!this!study!will!
hopefully! contribute! to! improving! the! treatment! program! and! complimenting! already! existing! reA
search.!
!

How!will!my!information!be!collected!and!used?!
You!will!be!required!to!complete!a!questionnaire!which!will!involve!completing!a!written!survey.!!InA
formation!from!this!survey!will!be!kept!confidential.!All!questionnaire!material!will!be!stored!securely!
at! the! University! of! Wollongong.! The! information! may! be! used! for! publication! in! scholarly! research!
journals,!reports!to!the!Salvation!Army,!student!theses,!and!conference!presentations.!You!will!not!be!
identifiable!in!any!publications.!
!

What!if!I!have!more!questions?!
You! may! have! additional! questions! that! you! wish! to! ask! about! the! research! before! you! decide!
whether! to! participate.! You! can! contact! Dr! Kelly! or! Prof! Deane! at! the! University! of! Wollongong! by!
calling! 02! 4221! 4207.! If! you! have! any! concerns! or! complaints! regarding! the! way! in! which! the! reA
search!is!or!has!been!conducted,!you!can!contact!the!Secretary!of!the!University!of!Wollongong!HuA
man! Research! Ethics! Committee! on! Phone:! ! (02)! 4221! 4457,! Fax:! (02)! 4221! 4338! ! ! email:! re%
search@uow.edu.au!

!
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Appendix$E$
Research Office use only
HE 09/224
UNIVERSITY OF WOLLONGONG/ILLAWARRA AREA HEALTH SERVICE

Human Research Ethics Committee
INITIAL APPLICATION FOR APPROVAL TO UNDERTAKE
RESEARCH INVOLVING HUMAN PARTICIPANTS
(A separate application is required for each project)
Please answer questions in terms understandable to the layperson.
1.

Descriptive Title of Project:
The!Salvation!Army!Recovery!Service!Centres:!Validation!of!Mental!Disorder!and!Mental!
Health!Screening!Measures!!

2.

7 line summary of project aims:
This! project! will! first! examine! the! sensitivity,! specificity! and! overall! accuracy! of! a! number! of!
screening!measures!designed!to!detect!mental!disorder!amongst!individuals!with!alcohol!and!
other!drug!problems.!The!project!will!also!investigate!the!psychometric!validity!and!reliability!of!
a! measure! of! mental! health.! Results! will! be! used! to! inform! assessment,! treatment! planning!
and!treatment!outcome!measurement!within!substance!abuse!treatment!facilities.!

3.

Name
Position/Appointment
Chief Investigator(s)

Institution

Qualifications
(Academic or Professional)

Kane!Mortlock!(BA,!LLB!(Hons),!BPsyc!(Hons))!
PhD!candidate!!
Illawarra!Institute!for!Mental!Health!
School!of!Psychology!
University!of!Wollongong! !
!
Prof!Frank!Deane!(PhD,!Dip.!Clin.!Psych)!
Director!
Illawarra!Institute!for!Mental!Health!
School!of!Psychology!
University!of!Wollongong!
!
Dr!Trevor!Crowe!(PhD)!
Research!Fellow!
Illawarra!Institute!for!Mental!Health!
University!of!Wollongong!

Address for Correspondence (1st named investigator):
Illawarra!Institute!for!Mental!Health!
Building!22!!
University!of!Wollongong!
Wollongong,!NSW!2522!

Contact Phone Number: 0422!589!549 Fax:!(02)!4221!5585!!Email: ksm22@uow.edu.au
!
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Other Participating Researchers: (names/address/contact details of other researchers
working on this project)
!
Dr!Peter!Kelly,!Associate!Fellow,!Illawarra!Institute!for!Mental!Health,!Building!22,!University!of!
Wollongong,!NSW!2522.

4.

Where will potential participants be approached by the researchers to seek their participation in the research and where will research activities involving participants be conducted:
Supervisors!and!caseworkers!of!the!Salvation!Army!Bridge!program!will!be!informed!of!the!
proposed!study!by!the!researchers.!!Clients!will!be!informed!of!the!study!in!their!“house”!meetA
ing!(located!in!the!residential!treatment!facility)!where!they!will!be!notified!of!a!sign!up!sheet!
available!to!sign!up!for!the!study.!!A!participant!information!sheet!(Appendix!A)!will!be!provided!
along!with!contact!details!so!that!the!clients!can!contact!the!researcher!if!there!are!any!further!
questions.!!This!will!allow!the!opportunity!for!the!client!to!refuse!to!participate!outside!of!direct!
contact!with!his/her!caseworker.!!The!chief!investigator!will!be!on!site!at!The!Salvation!Army!
Recovery!Service!Centres!to!conduct!the!research!and!will!be!the!only!other!person!present!in!
the!room!at!the!time!the!research!is!conducted.!!!

Purpose and Funding of Project
5.a Is this: YES Staff Research (University of Wollongong)
______Staff Research (Illawarra Area Health Service)
YES Student Research (Post grad. degree or subject)
Course undertaken: PhD (Psychology)
Unit/ Faculty/Department School of Psychology/HBS
Supervisor Prof Frank Deane & Dr Trevor Crowe
______Other (Please specify e.g. for external people who want to research Uni
students or IAHS clients)
5.b

What is the source and amount of funding from all sources for this research?

Source (Name of Organisation / Funding Scheme)
The Salvation Army

5.c
!

5.d
!

5.e

!

Amount
$397 000

Is there any affiliation or financial interest between the sponsor/funding body and the
researcher(s) or supervisor associated with this research? If Yes, Please declare.
NO!

Are there any conditions placed on this research by the funding body? (please provide
details) YES/NO
NO!

Is a copy of the HREC approval to be forwarded to the Granting Body?
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!

YES!!

If YES, please advise of any deadlines:
!
No!deadline,!but!provided!to!the!funding!body!before!the!research!is!commenced.!

6.
!

Has this research project been reviewed by any other Institutional Ethics Committee?
(for example multi-centre research)
NO!

If YES, include a copy of any correspondence the sponsor or researcher has entered into
with the other Ethics Committee(s) to this point.
7.

Research Categories
Please mark the research categories relevant to this research proposal. See guidelines for
descriptions of the categories. At least one category should be marked for each grouping.
For "Other", please specify.
If your research only involves participants and research procedures from a-d under
A Participants and B Research Procedures Used, it may be open to expedited review by
the Chair of the HREC. In that case, submit only one copy of your application (please see
guidelines regarding expedited review).

A

Participants
a.
b.
c.
d.
e.

Healthy members of the community
University students
Employees of a specific company/organisation
Members of a specific community group, club or association
Clients of a service provider

f.
g.
h.
i.
j.
k.
l.
m.

Health Service clients (e.g. users/clients of a health service)
School children
Hospital in-patients
Clinical clients (e.g. patients)
Aboriginal/Torres Strait Islander people
Members of socially disadvantaged groups
Cadavers/ cadaveric organs
Other:

Expected age(s) of participants – please circle one or more
Children (under 14)

B

Adults (> 18)

Research procedures used
a.
b.
c.
d.
e.
f.

!

Young people (14-18)

Anonymous questionnaires/ surveys
Coded (potentially identifiable) questionnaires/ surveys
Identifiable questionnaires/ surveys
Examination of student work, journals etc
Examination of medical, educational, personnel or other confidential records
Observation (overt)
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g.
h.
i.
j.

m.
n.

Observation (covert)
Interviews (structured or unstructured)
Telephone interviews
Procedures involving physical experiments (e.g. exercise, reacting to computer images)
Procedures involving administration of substances (e.g. drugs, alcohol, food)
Physical examination of participants (including eg. blood glucose, blood pressure
and temperature monitoring)
Collection of body tissues or fluid samples
Surgical procedures

o.

Other:

k.
l.

C

8.a
!

Research areas
a.
b.
c.
d.

Qualitative research
Social Science research
Humanities research
Educational research

e.
f.
g.
h.
i.
j.
k.
l.
o.!
p.!

Health research
Psychological research
Comparison or evaluation of drugs or surgical or other therapeutic devices
Comparison or evaluation of clinical procedures
Comparison or evaluation of counselling or training methods
Investigation of the effects of an agent (drug or other substance)
Investigation of bio-mechanical processes
Biomedical research
Epidemiology
Genetic research

o.

Other:

Does the project involve the use of drugs?
NO!

Is the research clarified as a:
CTN Trial
CTX Trial
8.b
!

8.c

!

Other (Please detail)

Does the project involve the use of a surgical or other therapeutic device? (please detail)
NO!

If you answered YES to 8a. or 8b., is there any business or similar association between
the researcher and the supplier of a drug or surgical or other therapeutic device to be
used in the trial? (please detail).
N/A!

If you answered YES to 8a. or 8b., please include the budget for this trial including information about capitation fees, payments to researchers, institutions or organisations

!
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involved in the research, current and consequential costs and costs which may be incurred by participants.
Please include evidence of arrangements to ensure adequate compensation to participants
for any injury suffered as a result of participation in the trial. (Indemnification forms
and, if the research is being undertaken in a private practice, evidence of adequate and
appropriate insurance coverage)
!

9.

N/A!

Justify the design of your proposed research and describe what you want participants to
do.
Please provide an explanation, in terms understandable by a non-expert reader. For student researchers, please provide (in no more than 2 pages) the background to this project
(Attach extra sheets if necessary)
The!current!research!is!in!two!parts.!!
!
Mental!disorder!screening!
!
The!Illawarra!Institute!for!Mental!Health!(iiMH)!has!been!contracted!by!The!Salvation!Army!to!
develop,!trial!and!integrate!mental!disorder!screening!tools!across!their!residential!sites!and!to!
improve!treatment!offered!to!clients!in!The!Salvation!Army!alcohol!and!other!drug!recovery!
services!generally.!The!Salvation!Army!provides!a!range!of!longAterm,!residential!treatment!
services!for!people!with!substance!abuse!problems.!Although!screening!for!coAoccurring!menA
tal!disorder!is!recommended!as!best!practice,!there!is!no!definitive!guidance!provided!by!existA
ing!research!as!to!which!mental!disorder!screening!instrument!should!used.!A!preliminary!
screening!instrument!has!been!instituted!as!a!temporary!measure!until!the!proposed!research!
can!report!on!which!instrument!is!most!accurate!at!identifying!mental!disorder!comorbidity!in!a!
residential,!alcohol!or!other!drug!recovery!service!population.!!
!
It!has!been!acknowledged!that!clients!with!comorbid!mental!disorders!and!substance!misuse!
have!received!poor!care!due!to!gaps!in!service!provision!(Adams,!2008r!Harris!&!Edlund,!
2005).!Not!treating!coAoccurring!disorders!“contributes!to!some!of!the!most!intractable!and!exA
pensive!social!problems”!(Davis!et!al.,!2006,!p.!263).!In!Australia!the!historical!inadequacy!of!
treatment!for!this!population!was!targeted!by!the!Australian!Government’s!National!ComorbidiA
ty!Initiative,!which!allocated!$17.9!million!over!seven!years!to!address!the!treatment!of!this!
population.!The!emphasis!of!this!initiative!under!which!funding!for!the!proposed!research!is!
auspiced!is!upon!the!importance!of!identifying!and!effectively!managing!clients!who!are!expeA
riencing!both!a!substance!use!disorder(s)!and!a!mental!disorder(s)!in!treatment!settings!(AusA
tralian!Institute!of!Health!and!Welfare,!2009).!
!
Problems!facing!the!significant!number!of!people!with!comorbidity!include!poorer!treatment!reA
sponse!and!an!inability!to!maintain!functional!stability!(Grella!&!Stein,!2006r!Ziedonis!&!Stern,!
2001),!higher!rates!of!relapse!(Swofford,!Kasckow,!SchellerAGilkey,!&!Inderbitzin,!1996),!more!
hospital!visits!(Haywood!et!al.,!1995),!increased!involvement!in!violence!(Swartz!et!al.,!1998),!
family!difficulties!and!limited!social!relationships,!increased!unemployment,!victimisation!
(Goodman,!Rosenberg,!Mueser,!&!Drake,!1997),!incarceration!(Abram!&!Teplin,!1991),!homeA
lessness!(Drake,!Osher,!&!Wallach,!1991),!HIV!(Adams,!2008r!Brunette,!Mueser,!&!Drake,!
2004r!Ziedonis!&!Stern,!2001)!and!Hepatitis!C!(Rosenberg!et!al.,!2001).!In!2005,!in!most!cases!
in!Australia!where!a!mental!or!behavioural!disorder!was!recorded!as!the!underlying!cause!of!
death,!the!abuse!of!psychoactive!substances!such!as!alcohol!and!heroin!was!also!involved!
(Australian!Institute!of!Health!and!Welfare,!2008).!
!
The!accurate!identification!of!mental!disorder!comorbidity!is!an!important!step!towards!improvA
ing!treatment!for!this!population!(Ziedonis!et!al.,!2005).!Yet!there!is!no!consensus!about!which!
screening!instrument!to!use!to!identify!mental!disorder!comorbidity!in!alcohol!and!other!drug,!
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residential,! treatment! service! populations! (Maisto! &! Kivlahan,! 2007).! There! is! no! adequate!
base! of! research! evidence! upon! which! to! build! a! consensus.! Clinicians! often! miss! the! coA
occurrence!of!mental!disorders!and!substance!use!disorders!because!of!an!absence!of!routine!
screening!(Donald,!Dower,!&!Kavanagh,!2005).!Few!screening!instruments!have!been!tested!
against! one! another! directly! in! the! same! population! to! obtain! data! on! their! relative! accuracy.!
Two!exceptions!are!studies!by!Sacks!et!al.,!(2007)!which!compared!two!instruments!in!a!prisA
on!population!and!by!Lee!et!al.,!(2007)!which!compared!two!different!instruments!in!an!AustralA
ian! population! but! changed! one! of! them! from! Likert! to! dichotomous! scoring! and! reported! no!
sensitivity,!specificity!or!accuracy!figures.!No!comparative!studies!of!all!the!major!screening!inA
struments! have! been! conducted! in! Australian! populations.! The! research! data! on! existing! inA
struments! has! been! obtained! separately! in! different! populations! and! only! one! of! them! has!
been!conducted!in!Australia!(see!the!abovementioned!Lee!et!al.,!2007).!!
!
One! aim! of! the! present! study! is! to! address! this! research! gap! to! help! determine! the! best! inA
strument!to!screen!for!mental!illness!comorbidity!in!Australian,!alcohol!and!other!drug,!residenA
tial!treatment!populations.!To!facilitate!this!aim!clients!will!be!administered!a!number!of!the!maA
jor!screening!instruments!designed!to!detect!mental!disorder.!A!semiAstructured,!clinical!diagA
nostic!interview!(SCIDA1)!will!then!also!be!administered!to!provide!a!criterion!measure!against!
which!to!evaluate!the!sensitivity!of!the!various!screening!instruments!at!identifying!mental!disA
order,!the!specificity!of!the!various!screening!instruments!at!correctly!ruling!out!those!who!are!
not! mentally! disordered,! and! the! overall! accuracy! of! the! instruments! (obtained! by! combining!
the!previous!two!elements).!Comparing!the!various!screening!instruments!directly!against!each!
other! in! a! single! population! will! provide! evidence! about! which! mental! disorder! screening! inA
strument!is!the!most!accurate!at!identifying!mental!disorder!comorbidity!in!Australian,!alcohol!
and!other!drug,!residential!recovery!services.!This!is!information!the!entire!addictionAtreatment!
industry!could!benefit!from.!
!

Mental health screening
In!addition!to!the!accurate!identification!of!pathologyAfocused!mental!illness,!wellnessAoriented!
mental!health!is!also!being!recognized!as!an!important!construct!in!the!treatment!of!both!menA
tal! disorders! and! drug! and! alcohol! disorders! (Corrigan! &! Ralph,! 2005r! Davidson! &! White,!
2007r! Miller! &! Miller,! 2009).! The! latest! theoretical! models! proposed! as! a! framework! within!
which!to!treat!coAoccurring!disorders!include!wellnessAoriented!mental!health!concepts!in!addiA
tion!to!pathologyAfocused!mental!illness!concepts!(see,!for!e.g.,!Davidson!et!al.,!2008r!Gagne,!
White,!&!William,!2007).!The!Surgeon!General!of!the!United!States!of!America,!defined!mental!
health!as:!
the successful performance of mental function, resulting in productive activities,
fulfilling relationships with other people, and the ability to adapt to change and to
cope with adversity; from early childhood until late life, mental health is the
springboard of thinking and communication skills, learning, emotional growth, resilience and self-esteem (US Department of Health and Human Services, 1999, p.
6).
Contrastingly,!mental!illness!is!
the term that refers collectively to all mental disorders. Mental disorders are health
conditions that are characterised by alterations in thinking, mood or behaviour (or
some combination thereof) associated with distress and/or impaired functioning
(US Department of Health and Human Services, 1999, p. 6)

Recent! empirical! research! conducted! by! Corey! Keyes! suggests! mental! illness! (illnessA
oriented!constructs!such!as!distress!and!deficits!in!functioning)!and!mental!health!(wellnessA
oriented!and!successfulAfunctioning!constructs!such!as!happiness!and!purpose!in!life)!are!difA
ferent! latent! constructs.! The! implication! is! that! treatment! aimed! at! mental! disorder! alone! is!
inadequate!as!a!prescription!to!obtain!mental!health!(2005).!Keyes!found!that!the!absence!of!
mental! illness! does! not! equate! to! the! presence! of! mental! health! in! epidemiological! populaA
tions!and!that!the!worst!psychosocial!dysfunction!was!suffered!by!those!both!mentally!ill!and!
low! on! mental! health! (termed! “flounderers”)! (2002,! 2005).! People! with! mental! illness,! but!
medium!to!high!mental!health!(described!as!the!“purely!mentally!ill”!and!“strugglers”)!suffered!
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much! less! psychosocial! dysfunction! (Keyes,! 2002,! 2005).! The! implications! of! this! research!
are!that!it!may!no!longer!be!enough!to!identify!which!clients!have!coAoccurring!mental!disorA
der.! Clients’! mental! health! may! also! need! to! be! assessed! and! the! information! fed! into! the!
treatment!planning!process.!!
!
It! is! possible! that! it! is! coAoccurring! disorder! clients’! mental! health! in! combination! with! their!
mental!illness!that!is!associated!with!their!psychosocial!dysfunction,!not!their!mental!illness!
alone.!It!may!be!possible!to!alleviate!significant!psychosocial!dysfunction!and!reverse!tradiA
tionally!poor!treatment!outcomes!by!raising!mental!health!irrespective!of!client!mental!illness!
status.!This!possibility!is!particularly!important!to!alcohol!and!other!drug,!residential!rehabiliA
tation!services!that!often!lack!the!expertise!to!administer!specific,!best!practice!interventions!
for!each!type!of!mental!disorder.!Measuring!mental!health,!in!a!clinical!population!may!proA
vide!the!data!necessary!to!provide!new!integrated!treatments!consistent!with!recent!advocaA
cy!and!theoretical!models!(see,!for!e.g.,!Davidson!et!al.,!2008r!Davidson!&!White,!2007r!MilA
ler!&!Miller,!2009).!!
!
The! first! step! is! to! assess! the! validity! and! reliability! of! Keyes’! measure! in! a! clinical! populaA
tion.!TestAretest!reliability!analyses!require!a!coded,!potentially!identifiable!method!so!that!the!
same!clients!can!be!administered!the!same!measure!on!two!separate!occasions.!!
Research!plan!
!
a)!Research!design!
!
A!crossAsectional!design!will!be!used.!Participants!will!be!interviewed!within!one!month!of!inA
take.!Each!participant!will!be!interviewed!over!two!separate!sessions!to!facilitate!testAretest!
data!and!guard!against!results!from!an!instrument!informing!an!interview!or!vice!versa.!AddiA
tionally,!some!archival!data!from!the!generic!intake!process!will!be!accessed!including!inforA
th
mation!gathered!using!the!full!Addiction!Severity!Index!5 !Edition!(McLellan!et!al.,!1995)!and!
the! Depression,! Anxiety! and! Distress! Scale! –! 21! (DASS,! Lovibond! &! Lovibond,! 1995).!
Measures!used!in!the!two!sessions!will!be!quantitative!selfAreport!questionnaires!and!a!semiA
structured!interview.!In!one!session!participants!will!be!interviewed!using!the!Structured!ClinA
ical! Interview! for! DSMAIVATR! Axis! I! Disorders,! Research! Version,! Patient! Edition! (First,!
Spitzer,! Gobbon,! &! Williams,! 2002),! which! may! be! audioArecorded! if! participant! consent! is!
given!so!that!an!interrater!reliability!analysis!can!be!conducted.!For!the!participants,!this!auA
dio!recording!will!be!an!optional!component!and!they!will!be!able!to!do!the!study!without!conA
senting!to!this!component.!The!Mental!Health!Continuum!–!Short!Form!will!also!be!adminisA
tered! for! the! first! time! during! this! session.! In! the! other! session! participants! will! be! adminisA
tered! the! following! instruments! as! mental! illness! screening! instruments:! the! MHSFAIII,! the!
Modified!Mini!Screen!(MMS,!Alexander,!Haugland,!Lin,!Bertollo,!&!McCorry,!2008),!and!the!
World! Health! Organisation’s! SelfAReporting! Questionnaire! (SRQ,! Beusenberg! &! Orley,!
1994),!part!of!the!Psycheck!package!(see!Lee!et!al.,!2007).!Participants!will!also!be!adminisA
tered!Ryff’s!54Aitem!Scales!of!Psychological!WellABeing,!the!WHO!WellAbeing!Index!(WHOA5,!
Bech,! 1998,! 2001),! the! Short! Depression! Happiness! Scale! (SHDS,! Joseph,! 2004),! and! the!
Mental!Health!Continuum!–!Short!Form!for!a!second!time!to!test!the!validity!and!reliability!of!
the!Mental!Health!Continuum!–!Short!Form.!!
!
!
b)!Participants!
!
The!sample!will!consist!of!individuals!attending!the!Salvation!Army!Bridge!residential!rehabiliA
tation!program!located!in,!Lake!Macquarie!(n!=!104),!Sydney!(n!=!110),!Blue!Mountains!(n!=!
17),!and!Canberra!(n!=!40).!We!anticipate!at!least!70%!of!these!residents!to!participate.!!All!
individuals!will!be!diagnosed!with!an!alcohol!and/or!substance!misuse!problem.!Participants!
may!also!be!diagnosed!with!a!coAoccurring!mental!illness!problem!(e.g.!depression,!anxiety,!
psychotic!disorder).!
!
!
c)!Measures!
!

!
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The!measures!outlined!in!the!section!below!will!be!administered!in!conjunction!with!the!interA
view! and! it! anticipated! the! whole! procedure! will! take! approximately! 2! to! 2.5! hours! to! comA
plete.!
!
Background!Information!and!drug!and!alcohol!use!
!
Basic!demographic!information!will!be!collected.!This!will!include!age,!weeks!in!the!program,!
gender! and! The! Salvation! Army! centre! they! are! attending.! Information! gathered! separately!
th
during!the!intake!process!using!the!full!Addiction!Severity!Index!5 !Edition!(McLellan!et!al.,!
1995)!will!also!be!accessed!as!relevant!to!the!person’s!drug!and!alcohol!history.!This!will!inA
clude!the!length!of!time!the!person!has!had!a!substance!misuse!problem,!the!types!of!drugs!
the! person! has! used! in! the! previous! 12Amonths,! the! substance! the! person! considers! their!
primary!drug!of!choice,!frequency!of!drug!use!and!if!they!have!ever!received!treatment!beA
fore.!We!will!ask!clients!to!specify!any!previous!mental!illness!diagnoses,!how!well!their!curA
rent!service!is!meeting!their!mental!health!needs!and!if!they!have!suffered!any!of!the!poorer!
treatment!responses!and!outcomes!traditionally!associated!with!coAoccurring!AOD!and!menA
tal!illness!disorders!previously.!
!
Mental!Disorder!Screening!
!
Structured)Clinical)Interview)for)DSMDIVDTR)Axis)I)Disorders,)Research)Version,)Patient)EdiD
tion)(SCIDDIP,)First)et)al.,)2002)!–!The!Structured!Clinical!Interview!for!DSMAIV!Disorders!is!a!
semiAstructured!interview!for!making!the!major!DSMAIV!Axis!I!diagnoses.!The!SCIDAIP!is!diA
vided!into!six!selfAcontained!modules!that!can!be!administered!in!sequence:!mood!episodes,!
psychotic!symptoms,!psychotic!disorders,!mood!disorders,!substance!use!disorders,!anxiety!
disorders,!adjustment,!and!other!disorders.!The!SCIDAIP!is!widely!accepted!as!the!standard!
for!assessing!substance!use!and!mental!disorders!(Magruda,!Sonne,!Brady,!Quello,!&!MarA
tin,!2005).!A!screening!instrument!is!considered!to!be!accurate!if!it!concurs!with!the!SCIDAIP!
on!the!presence!or!absence!of!a!disorder!(Sacks,!Melnick,!Coen,!Banks,!Friedmann,!Grella,!
Knight!et!al.,!2007).!
)
)
Mental)Health)Screening)Form)–)III)(MHSFDIIIr!Carroll)&)McGinley,)2000))D!The!Mental!Health!
Screening!Form!–!III!is!designed!as!a!mental!illness!screening!device!for!clients!seeking!adA
mission!to!substance!abuse!treatment!programs.!Each!MHSFAIII!question!is!answered!either!
“yes”!or!“no.”!All!questions!reflect!the!respondent’s!entire!life!historyr!therefore!all!questions!
begin!with!the!phrase!“Have!you!ever...”.!The!MHSFAIII!features!a!“Total!Score”!line!to!reflect!
the!total!number!of!“yes”!responses.!The!maximum!score!on!the!MHSFAIII!is!18!(question!6!
has!two!parts).!This!feature!permits!programs!to!do!research!and!program!evaluation!on!the!
mental!illnessAchemical!dependence!interface!for!their!clients.!The!first!four!questions!on!the!
MHSFAIII! are! not! unique! to! any! particular! mental! illness! diagnosisr! however,! questions! 5!
through! 17! reflect! symptoms! associated! with! the! following! diagnoses/diagnostic! categories:!
Q5,!Schizophreniar!Q6,!Depressive!Disordersr!Q7,!Posttraumatic!Stress!Disorderr!Q8,!PhoA
biasr!Q9,!Intermittent!Explosive!Disorderr!Q10,!Delusional!Disorderr!Q11,!Sexual!and!Gender!
Identity! Disordersr! Q12,! Eating! Disorders! (Anorexia,! Bulimia)r! Q13,! Manic! Episoder! Q14,!
Panic! Disorderr! Q15,! ObsessiveACompulsive! Disorderr! Q16,! Pathological! Gamblingr! and!
Q17,!Learning!Disorder!and!Mental!Retardation.!
!
th
Addiction)Severity)Index)5 )Edition)–)Psychiatric)Status)Domain)(McLellan)et)al.,)1995)!–!The!
Addiction!Severity!Index!is!the!most!widely!published!substance!abuse!assessment.!The!enA
tire! measure! is! being! administered! as! part! of! The! Salvation! Army! intake! protocol.! For! the!
purposes!of!the!mental!disorder!screening!aspect!of!this!study!we!will!be!using!the!‘PsychiatA
ric! Status’! section! of! the! interview.! Previous! research! indicates! that! the! ASI! provides! good!
sensitivity!and!specificity!to!identify!coAoccurring!mental!illness!problems!(Cacciola,!PecoraA
ro,!&!Alterman,!2008).!
)
Modified) Mini) Screen) (MMS,) Alexander,) Haugland,) Lin,) Bertollo,) &) McCorry,) 2008)! –! The!
Modified!Mini!Screen!is!designed!to!identify!people!with!mental!disorder!problems!who!are!in!
treatment! for! chemical! dependency,! including! speciality! sector! substance! abuse! treatment!
settings,!shelters,!jails!and!community!outreach!programs.!The!Modified!Mini!Screen!(MMS)!
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consists!of!22!items!that!ask!about!current!symptoms!for!major!depression,!dysthymia,!suiA
cidality,! hypomania,! panic,! agoraphobia,! social! phobia,! obsessive! compulsive! disorder,!
PTSD,!psychosis!and!generalized!anxiety.!
!
World) Health) Organisation’s) SelfDReporting) Questionnaire) (SRQ20,) Beusenberg) &) Orley,)
1994),)part)of)the)Psycheck)package)(see)Lee)et)al.,)2007)!–!The!SelfAReporting!QuestionA
naire!was!originally!designed!by!Harding!et!al.!(1980)!to!study!mental!illness!in!primary!care!
in! developing! countries.! The! items! were! extracted! from! preAexisting! psychiatric! instruments!
(Ghubash,!Daradkeh,!ElARufaie,!&!AbouASaleh,!2001).!The!SRQ20!became!formally!recomA
mended!by!the!World!Health!Organization!in!1994!as!a!screen!for!common!mental!disorders!
(depression!and!anxiety)!in!primary!health!care.!
)
Mental!Health!Screening!
!
Mental) Health) Continuum) –) Short) Form) (Keyes,) 2009)) D! The! Mental! Health! Continuum! –!
Short!Form!is!a!measure!of!mental!health!that!consists!of!14!items.!It!measures!the!degree!
of!(1)!Emotional!Well!Being!(items!1–3)!as!defined!in!terms!of!positive!affect/satisfaction!with!
lifer! (2)! Social! Well! Being! (items! 4–8)! as! described! in! Keyes’s! (1998)! model! of! Social! Well!
Being!(one!item!on!each!of!the!dimensions!of!social!acceptance,!social!actualization,!social!
contribution,! social! coherence! and! social! integration)r! and! (3)! Psychological! Well! Being!
(items!9–14)!as!described!in!Ryff’s!(1989)!model!(including!one!item!on!each!of!the!dimenA
sions! of! autonomy,! environmental! mastery,! personal! growth,! positive! relations! with! others,!
purpose!in!life!and!selfAacceptance).!The!MHC–SF!allows!a!diagnosis!to!be!made!of!the!level!
of! mental! health! an! individual! enjoys! from! languishing! mental! health! to! flourishing! mental!
health.!
!
Ryff)Scales)of)Psychological)WellDBeing) –)54)(PWBD54,)Ryff,)1989)!–!Ryff’s!Scales!of!PsyA
chological! WellABeing! include! 6! subscales.! The! subscales! are! autonomy,! environmental!
mastery,!personal!growth,!positive!relations!with!others,!purpose!in!life,!and!selfAacceptance.!
!
WHO)WellDbeing)Index)(WHOD5,)Bech,)1998,)2001)!–!The!World!Health!Organisation!(WHO)!
Five!WellAbeing!Index!was!derived!from!a!larger!rating!scale!developed!for!a!WHO!project!on!
quality!of!life!in!patients!suffering!from!diabetes.!During!the!first!psychometric!evaluation,!10!
of! the! original! 28! items! were! selected! due! to! the! homogeneity! they! had! shown! across! the!
various! European! countries! participating! in! this! study! (Bech,! Gudex,! &! Staehr,! 1996).! BeA
cause!it!was!thought!positive!psychological!wellAbeing!has!to!include!positively!worded!items!
only,!these!10!items!were!then!reduced!to!five!items!(WHOAFive)!which!still!covered!positive!
mood! (good! spirits,! relaxation),! vitality! (being! active! and! waking! up! fresh! and! rested),! and!
general!interests!(being!interested!in!things).!
!
Short) Depression) Happiness) Scale) (SDHS,) Joseph,) Linley,) Harwood,) Lewis,) &) McCollam,)
2004)! –! The! SDHS! is! a! 6Aitem! short! form! of! the! 25Aitem! statistically! bipolar,! selfAreport! DeA
pression! Happiness! Scale! designed! for! the! rapid! assessment! of! depression! and! happiness!
conceived! of! as! two! poles! on! a! single! continuum.! Three! items! are! positive! and! three! items!
are!negative.)
!
Depression)Anxiety)Stress)Scale)–)21)(DASSD21,)Lovibond)&)Lovibond,)1995)))–!The!DASSA
21!is!a!shortened!form!of!the!42Aitem!Depression!Anxiety!Stress!Scale.!DASS!items!can!be!
reliably!grouped!into!three!scales:!Depression,!Anxiety!and!Stress.!The!Depression!Scale!inA
cludes! items! that! measure! symptoms! associated! with! dysphoric! mood! (e.g.,! sadness! or!
worthlessness).!The!Anxiety!Scale!measures!symptoms!related!to!physical!arousal,!panic!atA
tacks!and!fear.!The!Stress!Scale!includes!items!that!measure!tension,!irritability!and!a!tenA
dency! to! overreact! to! stressful! events! (Antony,! Bieling,! Cox,! Enns,! &! Swinson,! 1998).! This!
measure! is! being! administered! as! part! of! The! Salvation! Army! intake! protocol! and! the! data!
collected!will!be!accessed!for!the!purposes!of!this!study.!
!
See!Appendix!C!for!copies!of!all!the!written!measures!for!this!study!including!those!used!in!
the!intake!process.!!
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10.

Please provide a brief statement of the ethical considerations relevant to the proposed
research; specifically in relation to the participants’ welfare, rights, beliefs, perceptions,
customs and cultural heritage both individual and collective. (Attach an extra sheet if
necessary)
Informed)consent)–)It!is!important!that!clients!are!aware!of!their!freedom!of!choice!to!particiA
pate!or!refuse!participation!in!this!study.!!For!this!to!be!made!certain!clients!will!be!approached!
about! this! study! through! the! Salvation! Army! staff! so! clients! do! not! feel! pressured! by! the! reA
searchers!to!participate.!!Salvation!Army!staff!will!be!instructed!to!reinforce!to!the!clients!that!
participation!is!voluntary!and!there!will!be!no!negative!repercussions!for!refusing!to!participate.!!
If! potential! participants! express! an! interest! in! participating! then! a! time! to! meet! with! the! reA
searchers! will! be! arranged.! At! the! time! of! the! appointment,! prior! to! commencing,! the! inforA
mation!form!will!again!be!reviewed!and!signed!consent!obtained.!This!provides!a!second!ocA
casion!for!the!potential!participant!to!be!fully!informed!about!what!is!required!for!participation!
and!to!refuse!to!participate!if!they!choose.!The!Consent!Form!is!Appendix!B!to!this!document.!

!
Confidentiality! –! The! surveys! will! be! collected! directly! by! researchers! from! the! University! of!
Wollongong!and!no!individual!data!will!be!given!to!the!case!managers!or!the!service.!!The!reA
searchers!will!be!on!site!to!collect!the!data.!!All!information!will!be!stored!securely!at!the!UniA
versity!of!Wollongong.!All!individuals!will!be!provided!with!a!unique!identifier!so!that!once!data!
is! entered! into! the! statistical! package! there! will! be! no! identifying! information.! Questionnaires!
with!identifying!information!will!have!all!names!removed!and!replaced!with!the!unique!identifier.!
After!data!has!been!entered!into!the!statistical!packages!all!questionnaires!will!be!scanned!for!
storage! without! names! and! original! paper! versions! will! be! destroyed.! If! participants! agree! to!
have!their!interviews!audio!taped!(optional),!then!after!interrater!reliability!analyses!have!been!
conducted!the!audio!recordings!will!be!destroyed.!

11.

Referring to the categories of participants to be involved in this project identified in question 7, above, What is the rationale for selecting participants from this/these group/s?
We! are! interested! in! identifying! coAoccurring! mental! illness! problems! and! levels! of! mental!
health! within! residential! drug! and! alcohol! rehabilitation! programs.! As! outlined! in! the! introducA
tion!this!is!to!better!identify!and!then!treat!comorbid!problems.!The!study!will!use!clients!in!this!
population!who!are!currently!attending!these!programs.!

12.

How will potential participants be approached initially and informed about the project?
Please explain in detail and include copies of any letters, advertisements or other recruitment information. (e.g. direct approach to people on the street, mail-out to potential
participants through an organisation, posters or newspaper advertisements, etc)
The!Salvation!Army!staff!(predominantly!program!managers)!will!be!informed!of!the!proposed!
study!by!one!of!the!researchers.!
!
Clients! will! initially! be! informed! of! the! study! by! The! Salvation! Army! staff.! A! participant! inforA
mation!sheet!(Appendix!A)!will!be!provided!with!contact!details!so!if!a!client!has!further!quesA
tions! they! can! contact! the! researcher.! A! sign! up! sheet! will! also! be! provided! so! clients! who!
chose!to!can!volunteer!to!participate!in!the!study.!
!
We!believe!the!safest!approach!to!clients!will!be!through!Salvation!Army!staff.!!The!staff!will!be!
instructed!to!reinforce!to!the!clients!that!participation!is!voluntary!and!there!will!be!no!negative!
repercussions!for!refusing!to!participate.!!Also!clients!will!be!given!the!option!of!refusing!particA
ipation! through! the! researchers,! in! the! instance! they! don’t! want! to! refuse! through! their! caseA
worker.!
!
Once!we!have!preliminary!agreement,!the!researcher!will!arrange!to!meet!with!the!participant,!
at! that! time! the! information! sheet! will! again! be! reviewed,! an! opportunity! to! ask! further! quesA
tions!will!be!provided!and!the!consent!form!will!be!signed!if!the!participant!wants!to!proceed.!

!
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13.

How many participants in total do you anticipate will be involved in the project? If the
research has several stages involving different participants, please provide the total number of participants expected as well as the number of participants involved in each stage.
It!is!our!intention!that!a!minimum!of!100!clients!participate!in!this!study.!A!maximum!of!150!cliA
ents!would!be!interviewed.!
!

14.! Participant Consent
Attach copies of any letters of invitation, information packages, consent forms,
proxy/substitute consent forms, debriefing information, identification cards, contact detail cards, etc.
See!Appendix!B!for!a!copy!of!the!Consent!Form.!

14 a. Is it anticipated that all participants will have the capacity to consent to their participation in the research?
YES!

If NO, please explain why (e.g. children, incompetent participants, etc.) and explain how
proxy or substitute consent will be obtained from the person with legal authority to consent on behalf of the participant (see Guidelines).
14 b. For participants who have the capacity to consent, how does the process ensure that informed consent is freely obtained from the participant?
To! enter! the! Bridge! program! clients! will! have! undergone! a! supervised! detoxification! proA
gramme!prior!and!will!have!already!been!assessed!as!having!appropriate!psychological!stabilA
ity.!As!previously!noted,!the!consent!process!allows!clients!to!refuse!consent!through!discussA
ing! participation! with! Salvation! Army! staff! and! the! researchers.! The! Salvation! Army! staff! will!
emphasize! clients’! right! to! refuse! to! participate! in! the! program! and! will! assure! clients! that! no!
negative!ramifications!will!follow!them!doing!so.!Further,!when!the!researchers!first!meet!with!
the! participants,! information! about! the! study! will! again! be! reviewed! and! signed! consent! obA
tained.!This!provides!a!second!opportunity!for!questions!and!the!option!to!decline!participation.!

14 c. Will written consent from participants be obtained?
YES!

If NO, please explain why it would be inappropriate or unethical to seek written evidence
of consent to this project.
15.

Are any participants in a dependent relationship with the researcher, the institution or
the funding body (for example the researcher’s clinical clients or students; employees of
the institution; recipients of services provided by the funding body)? If so, what steps will
be taken to ensure that participants are free to participate or refuse to participate in the
research?
The!clients!will!be!in!a!clinical!relationship!with!the!Salvation!Army!staff!who!will!inform!them!of!
the!study.!As!noted!it!will!be!clearly!emphasised!that!participation!is!voluntary.!In!addition,!the!
client!will!be!provided!with!an!option!of!contacting!(or!asking!to!be!contacted!by)!the!researchA
ers! so! they! have! the! opportunity! to! refuse! to! participate! without! having! to! do! so! directly! with!
the!caseworker.!!!

!
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16.

How does the project address the participants’ freedom to discontinue participation?
Will there be any adverse effects on participants if they withdraw their consent and will
they be able to withdraw data concerning themselves if they withdraw their consent?
Participants! will! be! able! to! withdraw! their! data! at! any! point! because! they! will! be! identifiable.!
Clients!will!be!informed!of!this!in!their!participant!information!sheet!before!participating.!!

18.!

Does the project involve withholding relevant information from participants or deceiving
them about some aspect of the research?
NO.!

If YES, what is the justification for this withholding or deception and what steps will be
taken to protect the participants’ interest in having full information about their participation?
18.

Will participants be paid or offered any form of reward or benefit (monetary or otherwise) for participation in the research? If so, please detail and provide a justification for
the payment, reward or benefit.
NO.

19.

Confidentiality:
What measures will be taken to protect the privacy of individual subjects in terms of the
test results and other confidential data obtained (both in recording the data and in its
publication)?
After!data!is!entered!names!from!questionnaires!will!be!removed!and!unique!codes!used.!!IniA
tially,!names!need!to!be!used!since!contact!will!be!faceAtoAface!for!the!interview!and!there!will!
be!a!testAretest!component!to!the!study!requiring!that!time!1!and!time!2!data!be!linked.!Once!
all! data! is! entered! into! statistical! packages,! only! unique! codes! will! be! on! the! data.! QuestionA
naires! will! be! scanned! with! the! use! of! unique! identifiers! and! names! removed.! Original! paper!
versions! of! questionnaires! used! for! research! purposes! will! be! destroyed.! Only! grouped! data!
will!be!reported!in!any!publications!or!presentations!and!no!individual!will!be!identifiable.!Once!
audio!recorded!interviews!have!been!assessed!by!an!independent!rater!to!determine!interrater!
reliability!they!will!be!destroyed.!

20.

Will information collected from data or interview be published?
YES.!

If YES, please indicate what form this will take (Please note that any further use of information which may identify a participant is conditional upon the participant’s permission for such use):
No!individual!identifying!data!will!appear!in!any!reports!from!the!study.!Data!will!be!published!
in!group!form!only.!The!data!will!be!used!for!the!purposes!of!research!student!theses!and!poA
tentially! publication! in! scholarly! journals! and! conference! presentations.! A! report! may! also! be!
written!for!the!Salvation!Army.!

21.

Will any part of the research activities be placed on an audiotape, film, photograph or
video-tape?
YES.!

!
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To what purpose will the audiotape, film, photograph or video-tape be used?
Some!Structured!Clinical!Interviews!for!Diagnoses!will!be!audio!recorded!so!that!the!reliability!
of!the!interviewer!can!be!rated!against!additional!clinicians!and!reported!on!as!part!of!the!reliaA
bility!of!the!research.!This!will!be!an!“optional”!component.!Participants!will!be!able!to!do!the!
study!without!doing!this!audioArecorded!component.!
!
!

For what audience(s) will the audiotape, film, photograph or video-tape be exhibited?
Only!trained,!experienced!research!clinicians!will!review!the!audio!recordings!for!the!purposes!
of!establishing!interrater!reliability.!!
!
!
!
!
!
!

22.

How will the data (including questionnaires, surveys, computer data, tapes, transcripts
and specimens) be held securely, during and on completion of the project?
Confidential!data!will!be!stored!securely!at!the!Illawarra!Institute!for!Mental!Health,!it!will!be!
stored!in!locked!filing!cabinets!and!at!the!completion!of!the!project!will!be!held!in!a!locked!storA
age!room.!

Please confirm that original data will be held securely for a minimum of 5 years (15 years
for clinical research).
Clinical!research!data!will!be!securely!stored!for!15!years.!

If NO, please give reasons why it would be unethical to store the data for this period.
23.

Does the project involve the use of invasive procedures (e.g. blood sampling) or the risk of
physical harm or emotional distress?
YES!

If YES, give details:
Clients!may!experience!mild!distress!from!answering!questions!about!cravings!for!drugs!or!alA
cohol,!or!by!questions!about!mental!disorders.!

Explain how the risks of harm or distress will be minimised. In the case of risks of emotional distress, what provisions have been made for an exit interview or the necessity of
counselling?
As! part! of! their! assessment! and! treatment! process,! all! participants! would! have! had! similar!
questions!asked!of!them!previously.!In!this!sense!they!will!not!be!surprised!by!any!of!the!quesA
tions!in!the!research!protocol.!In!the!unlikely!event!that!emotional!distress!occurs!in!response!
to!some!of!the!study!questions!there!will!be!provision!for!participants!to!meet!with!one!of!the!
counselling!staff!who!are!available!at!the!treatment!centre.!

24.

Does this project involve obtaining information (e.g. data) of a private nature from any
Commonwealth/State/Local Government Department or any other Agency, including
health records from Area Health Services.
NO!

If YES, which Department (s)/Agency?

!
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Please include copies of any correspondence regarding permission to access this information from a responsible officer of the Agency and complete a Privacy Guideline Form
(available from Ethics Officer).
25.

Does the research intend to determine whether illegal activity has occurred or anticipate
that participants may reveal information about criminal activity ?
YES!

If YES, how do you propose to respond to the legal issues raised?
!
It!is!not!an!aim!of!this!research!to!examine!serious!criminal!activity,!but!it!is!possible!that!cliA
ents!may!identify!serious!crimes!that!they!have!committed!during!the!course!of!the!interview.!
To!minimise!the!risk!to!the!individual!client!the!following!statement!will!be!included!on!the!conA
sent!form!and!participants!will!be!reminded!about!this!issue!at!the!time!of!the!interviews.!
!
“It!is!not!a!component!of!this!research!to!examine!your!involvement!in!any!serious!criminal!acA
tivities.!If!you!choose!to!discuss!any!serious!criminal!activity!you!should!avoid!identifying!any!
specific! individuals! who! may! have! committed! crimes! in! any! way.! Serious!criminal! activity! coA
vers! offences! such! as! drug! trafficking,! serious! assaults,! sexual! assaults,! child! abuse! or! neA
glect,! murder! and! manslaughter.! It! does! not! cover! minor! possession! of! drugs.! As! this! re%
search!is!concerned!with!substance!use!the!researchers!will!not!report!any!illegal!drug!
use.”!
!!

26.

Period of Research Clearance Requested (Please specify as near as possible 'start' and
'finish' dates for the conduct of research):
FROM: 1/11/09

27.

TO: 1/11/10

Any research project that involves the collection of data should be designed so that it is
capable of providing information that can be analysed to achieve the aims of the project.
Usually, although not always, this will involve various important statistical issues. It is
important that the design and analysis be properly planned in the early stages of the project. You should seek statistical advice. The University of Wollongong has a Statistical
Consulting Service that provides such advice to research students and staff undertaking
research.
Are statistical issues relevant to this project?
YES!

If so, have you discussed this project with the Statistical Consulting Service?
The!statistical!consultants!in!the!School!of!Psychology!have!been!and!will!again!be!consulted!
regarding!the!design!and!analysis!of!this!study.!

28.

!

Does this project involve the collection or use of personal health information or information relating to the provision of a health service to an individual? This includes general information such as a gymnasium would collect as well as information collected for a
medical purpose.
If so, you need to complete the Initial Application Form Part 2 – Privacy Addition for
Health Information. For additional information regarding this please read the document
‘Health Records and Privacy Act’ and the NSW Privacy Commissioners’ Statutory
guidelines on research. Both documents are available from the HREC webpage.
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YES!

29.

Comments. If you would like to make any comment about the application or the application process please do so.
DECLARATION BY CHIEF INVESTIGATOR
I, the undersigned, have read the current National Statement on Ethical Conduct in Research Involving Humans:
http://www.health.gov.au/nhmrc/publications/synopses/e35syn.htm
and accept responsibility for the conduct of the research activities detailed in this application in accordance with the principles contained in the National Statement and any
other conditions laid down by the University of Wollongong's Human Research Ethics
Committee.
Chief Investigator's signature/s:
Date:
If the Chief Investigator is a student include:
Supervisor's signature:
Date:
Signature/s of other researcher/s: (The first named researcher will assume responsibility
for the project in the absence of the Chief Investigator)
Date:
DECLARATION BY HEAD OF UNIT
As Head of Unit I have responsibility for ensuring that Occupational Health and Safety
(OHS) issues surrounding research in the Unit are addressed.
(please tick all relevant boxes)

___
___
___
___
___

I am satisfied that a general risk assessment for the research project addressed in this
application has been completed adequately
I will ensure that a risk assessment specific to this application will be completed prior to
commencing the activities described in this application
I will ensure that there exist appropriate mechanisms to address potential OHS issues
that may arise and I have responsibility for implementing those mechanisms
I will ensure that mechanisms exist for ongoing assessment of the OHS issues related to
this research
This research involves use of radiation, chemicals or biohazards. A Risk Assessment has
been conducted and is attached to this application
Head of Unit’s Signature.................................................Date........................

NOTE: RESEARCH MUST NOT COMMENCE UNTIL APPLICATION HAS BEEN
FULLY APPROVED.
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CHECKLIST
Applications should be sent to the Ethics Officer, Human Research Ethics Committee, Office of
Research, University of Wollongong, Northfields Ave, Wollongong NSW 2522
Original Ethics Application plus appropriate number of copies (See Guidelines)
Consent Form(s)
Participant Information Sheet/Package
Copies of Questionnaire(s)/Survey(s) or Interview Questions
Copies of all documents and other material used to inform potential participants
about the research including advertisements and letters of invitation.
Evidence of permission to conduct research in locations not associated with the
University of Wollongong
Evidence of approval/rejection by other HREC(s), including comments and requested alternations to the protocol
Any form requiring signature by the HREC (one copy)
For Clinical Trials : Application Form (original +14 copies), Patient
Information Package (14 copies), Consent Forms (14 copies), Indemnity Form (14
copies), Protocols (14 copies), Advertisement (14 copies), Summary Sheet (14 copies), Budget (14 copies), Insurance information (if in Private Practice) (14 copies),
Investigator’s Brochure (5 copies), CTN or CTX Form (1 original copy)
Form Revised Jan 2003
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Appendix$F$
NSW HEALTH
HEALTH ETHICS BRANCH
PRIVACY ADDITION TO HREC APPLICATION FORM
!
!
!
The Health Records and Information Privacy Act 2002 commences on 1 September 2004. The Act creates a scheme to regulate the collection, use and disclosure of personal health information. It requires personal health information to be handled in accordance with 15 Health
Privacy Principles (HPPs) set out in the Act. It is necessary for you to complete this part of the application form in order to ensure:

•! You and the [name of institution] comply with the Act;
•! This HREC can properly assess your research under the Act;
•! This HREC can meet its statutory obligations to report to the Privacy
Commissioner on its activities under the Act.
Please read the Statutory Guidelines made under the Act entitled Health Records and Information Privacy Act 2002 (NSW): Statutory Guidelines on Research
which can be found on the website of Privacy NSW. This website can be accessed through www.lawlink.nsw.gov.au. Reading these documents will assist
you in completing this section of the application form.

Q1. Does this project involve the collection, use, or disclosure of personal health
information which is identified, or from which the identity of the person can be
reasonably ascertained?
√!

Yes!–!you!must!complete!this!section!of!the!application!form.!Go!to!question!2.!
No – you do not need to complete this section of the application form. Go to [insert
next section of your standard HREC application form]
Q2. Could the purpose of this project be served by collecting, using or disclosing
de-identified information?
Yes!–!you!should!collect,!use!or!disclose!deEidentified!information!only.!If!you!do!so,!you!do!
not!need!to!complete!this!section!of!the!application!form.!
√ No – Go to question 3.

Q3. Why can’t the purpose of the project be achieved using de-identified information?
√

!

The proposed project involves linkage of data.
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Scientific defects in the project would result if de-identified information
was used. Please provide details.

Other. Please provide details.

Go to question 4.
Q4. Are you proposing to collect, use or disclose the health information with the
consent of the individual(s) concerned?
√!

Yes!–!you!can!collect,!use!or!disclose!the!health!information!relying!on!the!‘consent!exempE
tion’!in!HPP!10!or!HPP!11.!Go!to!question!12.!
No – Go to question 5.
Best!practice!tip:!Wherever!possible,!you!should!seek!the!consent!of!the!person.!!Use!or!disclosure!authorised!by!the!person!is!alE
most!always!to!be!preferred,!provided!the!consent!is!freely!given!and!informed.!

Q5. From which organisations/bodies are you collecting personal health information? Please specify each individual hospital, other area health services and
any other organisations. If known, please name the individual custodian of this
information and the personnel in the organisation who generally have access to
the information.

Go to question 6.
Q6. Is the information being collected reasonably necessary for the project, being collected for a lawful purpose (HPP1), relevant to the project, and not excessive (HPP 2)?

!
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Yes!–!go!to!question!7.!
No – you must comply with HPP 1 and HPP 2. Refer to the Act.

Q7. Was the health information originally collected for the primary purpose of
this project?
Yes!–!you!can!use!or!disclose!the!health!information!for!the!project!relying!on!HPP!10!or!HPP!
11.! ! You! do! not! need! to! complete! any! more! questions! from! this! section! of! the! application!
form.!Go!to![insert'the'next'section'of'your'standard'HREC'application'form]!
No – Go to question 8.
Q8. Is this project directly related to the primary purpose for which the health
information was collected and would the person reasonably expect you to use or
disclose their health information for the purposes of this project?
Yes!–!please!provide!details!of!how!it!is!directly!related!!
!

!
You!can!use!or!disclose!the!health!information!for!the!project!relying!on!the!‘direct!relation!exE
emption’!in!HPP!10!or!HPP!11.!!You!do!not!need!to!answer!any!more!questions!from!this!secE
tion! of! the! application! form.! Go! to! [insert' the' next' section' of' your' standard' HREC' application'
form]!
No – Go to question 9.
Best practice tip: It is unlikely that many research activities will come within this exemption, however some compilation or analysis of
statistics activities might come within it. Using health information to compile statistics about the number of patients treated for a particular
disease within a hospital, for example, would arguably come within this exemption.

!
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Q9. Is the use or disclosure for the project authorised, required, permitted or reasonably contemplated under another law?
Yes!–!Please!provide!details.!
!
!
!
!
!
!
!
You!can!use!or!disclose!the!health!information!relying!on!the!exemption!in!HPP!10(2)!or!HPP!
11(2).!!You!do!not!need!to!answer!any!more!questions!from!this!section.!!Go!to![insert'next'sec9
tion'of'your!standard'HREC'application'form]'
No – Go to question 10.
Q10. Why is it impracticable to obtain the consent of the individual to collect, use or disclose their
health information?
The size of the population involved in the research.
The proportion of individuals who are likely to have moved or died since
the health information was originally collected.
The risk of introducing potential bias into the research, thereby affecting
the generalisability and validity of the results.
The risk of creating additional threats to privacy by having to link information in order to locate and contact individuals to seek their consent.
The risk of inflicting psychological, social or other harm by contacting individuals with particular conditions in certain circumstances.
The difficulty of contacting individuals directly when there is no existing or
continual relationship between the organisation and the individuals.
The difficulty of contacting individuals indirectly through public means,
such as advertisement and notices.
Other – please give details.

Go to question 11.

!

196!

Q11. Please provide reasons why the collection, use or disclosure of this
information is in the public interest, and why the public interest in
the project substantially outweighs the public interest in the protection of privacy.

NB: In determining whether the public interest in the project substantially outweighs the public interest in the protection of
privacy, the HREC will consider the matters listed below. Please make reference to relevant factors in your reasons.

(a)!
(b)!

(c)!
(d)!

(e)!
(f)!
(g)!
(h)!
(i)!

The degree to which the project is in the public interest
The degree to which the project is likely to contribute to:
(i)!
the identification, prevention or treatment of illness, injury or disease; or
(ii)!
scientific understanding relating to health; or
(iii)!
the protection of the health of individuals and/or communities; or
(iv)!
the improved delivery of health, disability or aged care services; or
(v)!
enhanced scientific knowledge or understanding; or
(vi)!
enhanced knowledge within the fields of social science and the humanities relating to health;
Any likely benefits to individuals, to the category of persons to which the individual(s) belong, or the wider
community that will arise from the project being undertaken in the manner proposed;
In considering benefits to the category of persons to which the individual(s) belong, specific consideration
should be given to any likely benefits to individuals that belong to certain categories where the information
may be of a particularly personal or sensitive nature; for example:
(i)!
children and young people; or
(ii)!
persons with intellectual or psychiatric disability; or
(iii)!
persons highly dependant on medical care; or
(iv)!
persons in dependant or unequal relationships; or
(v)!
persons who are members of collectivities; or
(vi)!
Aboriginal and Torres Strait Islander peoples; or
(vii)!
Persons whose information relates to their mental or sexual health
(viii)!
Persons who are incarcerated
whether the project design can be satisfied without needing to apply HPP 10(1)(f) or 11(1)(f) and the defects
in the project that might arise if the project was not conducted in the manner proposed;
the cost of not undertaking the project (to government, the public, the health care system, etc.);
the public importance of the project;
whether the risk of harm to an individual whose health information is to be collected, used or disclosed in the
project is minimal
the standards of conduct to be observed in the project, including:
(i)!
The project design and the scientific or other credentials of those involved in conducting that
project;
(ii)!
If the project involves contact with participants, the procedures or controls that will apply to
ensure participants are treated with integrity and sensitivity, including whether questions to be
asked or procedures to be employed are intrusive;
(iii)!
Whether access to health information is restricted to appropriate personnel involved in conducting the proposed study [you are asked to respond to this in question 13];
(iv)!
The procedures that are to be followed to ensure that the information will not be published in
a form that identifies particular individuals or from which an individuals or from which an individual’s identity can be reasonably ascertained [you are asked to respond to this in question
12]; and
(v)!
The procedures that are to be followed at the completion of the project to ensure that all data
containing health information are at least as secure as they were in the sources from which the
data was obtained, including the date when the data will be destroyed or returned. These procedures must be in accordance with HPP 5 [you are asked to respond to this in question 13].

Go to question 12.

!
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Q12. Please confirm that information which identifies individuals or from which an individual’s identity can reasonably be ascertained, will not be published in any generally available publication?
√

Confirmed – publication of such information is not permissible under the Act

Q13. Describe in detail the security standards that will be applied to the storage of, and access
to, the health information during the project and the proposed method of disposal of the health
information at the completion of the project.
The!surveys!will!be!collected!directly!by!researchers!from!the!University!of!Wollongong!and!no!
individual!data!will!be!given!to!the!case!managers!or!the!service.!!The!researchers!will!be!on!
site!to!collect!the!data.!!All!information!will!be!stored!securely!at!the!University!of!Wollongong.!
Questionnaires! with! identifying! information! will! have! all! names! removed! and! replaced! with! a!
unique!identifier.!All!individuals!will!be!provided!with!this!unique!identifier!so!that!once!data!is!
entered!into!the!statistical!package!there!will!be!no!identifying!information.!After!data!has!been!
entered! into! the! statistical! packages! all! questionnaires! will! be! scanned! for! storage! without!
names! and! original! paper! versions! will! be! destroyed.! If! participants! agree! to! have! their! interA
views!audio!taped!(optional),!then!after!interrater!reliability!analyses!have!been!conducted!the!
audio!recordings!will!be!destroyed.

!
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Office use only:
•! If “no” was ticked in response to question 4, mark here
should be counted for reporting question 5.

- This project

•! If the applicant was required to complete question 10 and following, mark
here
- This project should be counted in determining the number of proposals to be listed next to “yes” in reporting question 6.
•! Mark which boxes the applicant ticked in question 3.
The proposed project involves linkage of data.
Scientific defects in the project would result if de-identified information was used
Other. Give brief description……………………………………………………………….
This information should be used to answer reporting question 8.
•! Mark which boxes the applicant ticked in question 10
The size of the population involved in the research.
The proportion of individuals who are likely to have moved or died
since the health information was originally collected.
The risk of introducing potential bias into the research, thereby affecting the generalisability and validity of the results.
The risk of creating additional threats to privacy by having to link information in order to locate and contact individuals to seek their consent.
The risk of inflicting psychological, social or other harm by contacting
individuals with particular conditions in certain circumstances.
The difficulty of contacting individuals directly when there is no existing or continual relationship between the organisation and the individuals.
The difficulty of contacting individuals indirectly through public
means, such as advertisement and notices.
Other –give brief details……………………………………………………………………….
This information should be used to answer reporting question 9.
•! Note the outcome of the HREC decision
Approved including privacy aspects.
Rejected for reasons including privacy aspects.
Rejected for other reason.
Count!this!project!for!the!purposes!of!reporting)question)10,!only!if!the!first!box!is!marked.!

!
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Appendix$G$
HE09/224!
!
st
!
21 !August!2009
!
Chairperson!
Human!Research!Ethics!Committee!
University!of!Wollongong!
!
!
Ethics!Number:!
HE09/224!
Project!Title:!
The)Salvation)Army)Recovery)Service)Centres:)Validation)of)Mental)
Disorder)and)Mental)Health)Screening)Measures!
!
Thank&you&for&providing&a&prompt&response&to&our&application.&We&have&carefully&attended&to&the&Committees’&
concern&as&outlined&below.&
&
5.! Please!state!clearly!in!the!‘risks’!section!of!the!Participant!Information!Sheet!that!if!participants!do!re^
veal!information!about!criminal!activity!which!has!a!mandatory!reporting!requirement!the!researchers!
will!have!to!report!it.!
&
The&following&passage&has&been&inserted&into&the&Participant&Information&Sheet&‘risks’&section,&(attached&in&full&
as&appendix&A),&to&address&the&Committee’s&concern:&
!
It!is!not!a!component!of!this!research!to!examine!your!involvement!in!any!serious!criminal!activities.!If!
you!choose!to!discuss!any!serious!criminal!activity!you!should!avoid!identifying!any!specific!individuA
als! who! may! have! committed! crimes! in! any! way.! Serious! criminal! activity! covers! offences! such! as!
drug!trafficking,!serious!assaults,!sexual!assaults,!child!abuse!or!neglect,!murder!and!manslaughter.!
It!does!not!cover!minor!possession!of!drugs.!As!this!research!is!concerned!with!substance!use!
the!researchers!will!not!report!any!illegal!drug!use.!If!you!reveal!information!about!criminal!activiA
ty!that!has!a!mandatory!reporting!requirement,!however,!(for!e.g.,!current!criminal!activity!that!is!putA
ting!a!child!or!children!at!risk!of!harm),!the!researchers!will!have!to!report!it.!
&
We& would& appreciate& it& if& you& could& let& us& know& if& this& revision& has& adequately& addressed& the& Committee’s&
concerns&as&soon&as&possible&in&order&to&finalise&dates&for&the&data&collection.&
&
&
Yours&sincerely,&
&
&
&
&
&
Professor&Frank&Deane&
University&of&Wollongong&
&&
!

!
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Appendix$H$
University of Wollongong
Client Participant Information Sheet
The Salvation Army Recovery Service Centres:
Validation of Mental Disorder & Mental Health Screening Measures
Who is doing the study?
Mr Kane Mortlock, Prof Frank Deane and Dr Trevor Crowe will be conducting this research project. Aspects
of this research will be used for Mr Mortlock’s doctoral thesis.
What is the study about?
The study aims to examine the reliability of some tests that could be used in the service in the future. Some of
these tests are designed to identify people who have mental illness (e.g., depression). Studies have found that
people with both drug and alcohol and mental illness can have more difficulty recovering than people with
drug and alcohol problems alone. For this reason it is important to identify those people who also have mental
illness so more can be done to help this group. This study aims to find out which questionnaires work best at
identifying people who have mental illness. So several short questionnaires designed to identify whether you
have mental illness problems will be administered along with an interview against which these questionnaires
will be compared. As an additional, optional component, this interview may also be audio recorded to allow a
second trained rater to double-check the reliability of the interview conclusions. You may choose to still participate in the interview without having it audio recorded. The study also has some other short questionnaires that
examine positive, wellness-oriented mental health constructs such as satisfaction with life, community belonging and whether you feel in control of your life. This part of the study is being done because treatments that
concentrate upon positive goals and strengths have the potential to be useful in therapy.
What do I need to do?
The first thing you need to do is carefully read the rest of this ‘participant information sheet’ making sure you
understand what is required. If you do not wish to participate in this study you can simply not put your name
down on the signup sheet. There will be no negative consequences for not participating in this study. It is
entirely voluntary. If you sign up to participate, you will be contacted by Mr Kane Mortlock to arrange times
to do two sessions a couple of days apart within one month of your start date in the program. These two sessions will take approximately 2.5 hours in total. There will be a written consent form to sign before the first
session. You will be asked to complete some questionnaires and an interview with Mr Kane Mortlock. If you
would like further information you can contact Mr Kane Mortlock or Prof Frank Deane at the University of
Wollongong by calling 02 4221 4207.
Is there any risk or burden if I decide to participate?
The main burden will be related to the time it takes to complete the two interviews. There is a very small risk
that you might think some of the questions in the questionnaires or interview too personal or distressing. Many
of the questions ask you about how you have been feeling emotionally. An example item is: “Have you ever
been advised to take medication for anxiety, depression, hearing voices, or for any other emotional problem?”
However, in addition to your right not to participate at all, even if you do decide to participate, you also have
the right to refuse to answer any specific questions. If any of the questions cause you any distress the Salvation
Army staff will also be available to assist you.
It is not a component of this research to examine your involvement in any serious criminal activities. If you
choose to discuss any serious criminal activity you should avoid identifying any specific individuals who may
have committed crimes in any way. Serious criminal activity covers offences such as drug trafficking, serious
assaults, sexual assaults, child abuse or neglect, murder and manslaughter. It does not cover minor possession
of drugs. As this research is concerned with substance use the researchers will not report any illegal drug
use. If you reveal information about criminal activity that has a mandatory reporting requirement, however, (for
e.g., current criminal activity that is putting a child or children at risk of harm), the researchers will have to report it.
Are there any benefits expected?

!
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People often find that when they complete the questionnaires it helps them reflect on their progress and clarify
what it is about treatment that is helping them. Also the information from this study will hopefully contribute
to improving the treatment program for you and everyone who goes through it. You will be making a contribution to our understanding of how to best identify when people have mental health problems in addition to their
substance misuse problems. This will assist in development of better treatment programs.
How will my information be collected and used?
Your information will be collected via some written questionnaires and an interview. We would also like permission to obtain information obtained from your initial intake assessment when you first came into The Salvation Army recovery programs. Your information will be kept confidential. It will be de-identified by attaching a
special code to it so your name is not on it and you cannot be identified from it. All questionnaire material will
be stored securely at the University of Wollongong in locked filing cabinets. The information from all the participants as a whole may be used for publication in scholarly research journals, reports to the Salvation Army,
student theses, and conference presentations. You will not be personally identifiable in any of these publications. Only group information will be published. If you also agree to have your interview tape recorded, after
these tapes have been assessed by a second rater, they will be destroyed.
What if I have more questions?
You may have additional questions that you wish to ask about the research before you decide whether to participate. You can contact Mr Kane Mortlock or Prof Frank Deane at the University of Wollongong by calling 02
4221 4207. If you have any concerns or complaints regarding the way in which the research is or has been conducted, you can contact the Secretary of the University of Wollongong Human Research Ethics Committee on
Phone: (02) 4221 4457, Fax: (02) 4221 4338 email: research@uow.edu.au
!
!

!
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Appendix$I$

!
Client!Participant!Consent!Form!
!

The!Salvation!Army!Recovery!Service!Centres:!
Validation!of!Mental!Disorder!and!Mental!Health!Screening!Measures!
!

The!researchers!are:!Mr!Kane!Mortlock,!Prof!Frank!Deane!(Supervisor)!&!Dr!Trevor!Crowe!(Supervisor).!
!

I!have!been!given!information!about!the!study!‘The!Salvation!Army!Recovery!Service!Centres:!Validation!of!
Mental!Disorder!and!Mental!Health!Screening!Measures’.!I!have!discussed!the!project!with!The!Salvation!
Army!staff!and!have!been!offered!the!opportunity!to!discuss!the!research!project!with!the!chief!researcher!
(Mr!Mortlock)!who!is!conducting!this!research.!
!

I!understand!that,!if!I!consent!to!participate!in!this!project!I!will!be!asked!to:!
!

Authorise!access!to!my!intake!questionnaire!datar!
Attend!two!research!sessionsr!
o! Complete!questionnairesr!
o! Complete!an!interviewr!and!
o! Authorise!audio!recording!of!that!interview!(Optional)!

•!
•!

!

I! have! been! advised! of! the! potential! risks! and! burdens! associated! with! this! research,! which! include!
completion! of! questionnaires! that! may! contain! personal! questions! and! to! not! divulge! the! details! of! any!
serious!criminal!activity.!I!have!been!given!an!opportunity!to!contact!the!researchers!and!ask!any!questions!
I!may!have!about!the!research!and!my!participation.!!
I!understand!that!my!participation!in!this!research!is!voluntary.!I!am!free!to!refuse!to!participate!and!I!am!
free!to!withdraw!from!the!research!at!any!time.!My!refusal!to!participate!or!withdrawal!of!consent!will!not!
affect! my! relationship! with! The! Salvation! Army! or! the! University! of! Wollongong.! I! understand! that! I! can!
consent! to! the! research! without! consenting! to! the! interview! being! audio! recorded.! I! understand! that!
consenting! to! the! interview! being! audio! recorded! is! an! optional! component! and! that! I! can! consent! to! the!
research!without!consenting!to!this!optional!component!if!I!choose.!)
!

I! understand! that! the! data! collected! from! my! participation! will! be! deAidentified,! (made! so! you! cannot! be!
identified!by!it),!collated!with!other!participants’!data!and!that!I!will!not!be!identifiable!in!any!reports!of!this!
study.!I!understand!that!the!results!may!be!reported!in!journal!publications,!organisational!reports,!research!
theses,!and!conference!presentations,!and!I!consent!for!it!to!be!used!in!that!manner.!
)

If! I! have! any! enquiries! about! the! research,! I! can! contact! Mr! Mortlock! or! Prof! Deane! at! the! University! of!
Wollongong!by!calling!02!4221!4207.!If!I!have!any!concerns!or!complaints!regarding!the!way!the!research!
is!or!has!been!conducted,!I!can!contact!the!Ethics!Officer,!Human!Research!Ethics!Committee,!Office!of!
Research,! University! of! Wollongong! on! Phone:! ! (02)! 4221! 4457,! Fax:! (02)! 4221! 4338! ! ! email:! re%
search_services@uow.edu.au.!
!

By! signing! below! I! am! indicating! my! consent! to! participate! in! the! research! titled! ‘The! Salvation! Army!
Recovery! Service! Centres:! Validation! of! Mental! Disorder! and! Mental! Health! Screening! Measures’!
conducted! by! Mr! Mortlock,! Prof! Deane! and! Dr! Crowe! as! it! has! been! described! to! me! in! the! Participant!
Information!Sheet!and!discussed!with!The!Salvation!Army!staff.!!
!

I!understand!that!if!I!tick!the!checkbox!next!to,!“I!also!consent!to!the!interview!being!audio!recorded”,!I!am!
indicating!consent!to!that!optional!component!of!the!research!as!well.!!
!
!!!I!consent!to!the!interview!being!audio!recorded.!
!
Sign:!
!
!
!
!
!
!
!
!
!
!
!
Name!(please!print):_________________________________!!!!!!!!!Date:!___________!

!
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Appendix$J$
UNIVERSITY!OF!WOLLONGONG!RESEARCH!STUDY:!
MENTAL!HEALTH!SCREENING!QUESTIONAIRE!
!
Requirements:!
•! Participants!1A2!weeks!into!program!!
•! Agree!to!participate!in!study!
•! Agree!to!2!interviews!2!days!apart!
•! First!interview:!~1.5!hours!(45mins!to!2!hours!max)!
•! Second!interview:~45!minutes!(30!mins!to!1!hour!max)!
•! People!tested!on!Monday!are!reAtested!on!Wednesday!
•! People!tested!on!Tuesday!are!reAtested!on!Thursday!!
!
!
!
!
!
!
Time!
Monday!8!March!2010!
Time!
Tuesday!9!March!2010!
9.00!–!
1.!
9.00!–!
4.!
10.00!
11.00!
10.30!–!
11.30pm!

2.!

12.30!–!
2.30!

5.!

1.00!–!
2.00pm!

3.!

2.30!–!
4.30!

6.!

Wednesday!10!March!2010!
1.!

Time!
9.00!–!
11.00!

Thursday!11!March!2010!
4.!

10.30!–!
11.30pm!

2.!

12.30!–!
2.30!

5.!

1.00!–!
2.00pm!

3.!

2.30!–!
4.30!

6.!

!
!
!
!
!
!
Time!
9.00!–!
10.00!

!
!

!
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Appendix$K$
MENTAL!HEALTH!CONTINUUM!–!SHORT!FORM!(MHC!–!SF)!
!

The&following&questions&are&about&how&you&have&been&feeling&in&the&past&month.&Please&place&a&
check&mark&in&the&box&that&best&represents&how&often&you&have&felt&each&feeling.&
!

In!the!past!month,!how!often!
did!you!feel!…!&
&

1.&happy&

&
&

ONCE!
OR!
TWICE!
(1)&

NEVER!
(0)&

ABOUT!
ONCE!A!
WEEK!
(2)&

2!OR!3! ALMOST! &
TIMES!A! EVERY!
EVERY!
WEEK!
DAY!
DAY!
(3)&
(4)&
(5)&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&

&
&

2.&interested&in&life&
&
&

3.&satisfied&
&
&

4.&that&you&had&something&
important&to&contribute&to&
society&
&
&

5.&that&you&belonged&to&a&
community&(like&a&social&group,&
your&neighbourhood,&your&city)&
&
&

6.&that&our&society&is&becoming&a&
better&place&for&people&
&
&

7.&that&people&are&basically&
good&
&
&

8.&that&the&way&our&society&
works&makes&sense&to&you&
&
&

9.&that&you&liked&most&parts&of&
your&personality&
&
&

10.&good&at&managing&the&
responsibilities&of&your&daily&
life&
&
&

11.&that&you&had&warm&and&
trusting&relationships&with&
others&
&
&

12.&that&you&have&experiences&
that&challenge&you&to&grow&and&
become&a&better&person&
&
&

13.&confident&to&think&or&
express&your&own&ideas&and&
opinions&
&
&

14.&that&your&life&has&a&sense&
of&direction&or&meaning&to&it&
&

!
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SELF!REPORTING!QUESTIONNAIRE%20!
!
!
First:!Please!circle!the!“YES”!box!if!you!have!had!this!symptom!in!the!last!30!days.!
!
!
!

1.!Do!you!often!have!headaches?!

YES!

NO!

!

YES!

NO!

!

YES!

NO!

!

YES!

NO!

!

YES!

NO!

!

YES!

NO!

!

YES!

NO!

!

YES!

NO!

!

YES!

NO!

!

YES!

NO!

!

YES!

NO!

!

YES!

NO!

!

YES!

NO!

!

YES!

NO!

!

YES!

NO!

!

YES!

NO!

!

YES!

NO!

!

YES!

NO!

!

YES!

NO!

!

YES!

NO!

!

!
!

2.!Is!your!appetite!poor?!
!
!

3.!Do!you!sleep!badly?!
!
!

4.!Are!you!easily!frightened?!
!
!

5.!Do!your!hands!shake?!
!
!

6.!Do!you!feel!nervous,!tense!or!worried?!
!
!

7.!Is!your!digestion!poor?!
!

8.!Do!you!have!trouble!thinking!clearly?!
!
!

9.!Do!you!feel!unhappy?!
!
!

10.!Do!you!cry!more!than!usual?!
!
!

11.!Do!you!find!it!difficult!to!enjoy!your!daily!activities?!
!
!

12.!Do!you!find!it!difficult!to!make!decisions?!
!
!

13.!Is!your!daily!work!suffering?!
!
!

14.!Are!you!unable!to!play!a!useful!part!in!life?!
!
!

15.!Have!you!lost!interest!in!things?!
!
!

16.!Do!you!feel!like!you!are!a!worthless!person?!
!
!

17.!Has!the!thought!of!ending!your!life!been!on!your!mind?!
!
!

18.!Do!you!feel!tired!all!the!time?!
!
!

19.!Do!you!have!uncomfortable!feelings!in!your!stomach?!
!
!

20.!Are!you!easily!tired?!
!

!

!
!
Second:!Please!look!back!over!the!questions.!For!every!one!you!have!answered!“YES”,!
please!put!a!tick!in!the!final!column!if!you!had!that!problem!at!a!time!when!you!were!NOT!
using!alcohol!or!other!drugs.!
!

!
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MODIFIED!MINI!SCREEN!
!
!
!

1.!Have!you!been!consistently!depressed!or!down,!most!of!the!day,!nearly!
every!day,!for!the!past!2!weeks?!

YES!

NO!

YES!

NO!

YES!

NO!

YES!

NO!

YES!

NO!

YES!

NO!

YES!

NO!

YES!

NO!

YES!

NO!

YES!

NO!

YES!

NO!

YES!

NO!

YES!

NO!

YES!

NO!

!
!

2.!In!the!past!2!weeks,!have!you!been!less!interested!in!most!things!or!less!
able!to!enjoy!the!things!you!used!to!enjoy!most!of!the!time?!
!
!

3.!Have!you!felt!sad,!low!or!depressed!most!of!the!time!for!the!last!two!
years?!
!
!

4.!In!the!past!month,!did!you!think!that!you!would!be!better!off!dead!or!wish!
you!were!dead?!
!
!

5.!Have!you!ever!had!a!period!of!time!when!you!were!feeling!up,!hyper!or!
so!full!of!energy!or!full!of!yourself!that!you!got!into!trouble!or!that!other!
people!thought!you!were!not!your!usual!self?!(Do!not!consider!times!when!
you!were!intoxicated!on!drugs!or!alcohol).!
!
!

6.!Have!you!ever!been!so!irritable,!grouchy!or!annoyed!for!several!days,!
that!you!had!arguments,!verbal!or!physical!fights,!or!shouted!at!people!outA
side!your!family?!Have!you!or!others!noticed!that!you!have!been!more!irriA
table!or!overreacted,!compared!to!other!people,!even!when!you!thought!
you!were!right!to!act!this!way?!
!
!

7a.!Have!you!had!one!or!more!occasions!when!you!felt!intensely!anxious,!
frightened,!uncomfortable!or!uneasy!even!when!most!people!would!not!feel!
that!way?!
7b.!If!yes,!did!these!intense!feelings!get!to!be!their!worst!within!10!min?!
If!the!answer!to!both!a!and!b!is!YES,!score!the!question!YES!
If!the!answer!to!either!a!or!b!is!NO,!score!the!question!NO!
!
!

8.!Do!you!feel!anxious,!frightened,!uncomfortable!or!uneasy!in!situations!
where!help!might!not!be!available!or!escape!might!be!difficult?!
!
!

9.!Have!you!worried!excessively!or!been!anxious!about!several!things!over!
the!past!6!months?!
If!NO!to!Question!9,!answer!NO!to!Question!10!and!proceed!to!Question!
11!
!
!

10.!Are!these!worries!present!most!days?!
!
!

11.!In!the!past!month,!were!you!afraid!or!embarrassed!when!others!were!
watching!you,!or!when!you!were!the!focus!of!attention?!Were!you!afraid!of!
being!humiliated?!
!
!

12.!In!the!past!month,!have!you!been!bothered!by!thoughts,!impulses,!or!
images!that!you!couldn’t!get!rid!of!that!were!unwanted,!distasteful,!inapA
propriate,!intrusive!or!distressing?!
!
!

13.!In!the!past!month,!did!you!do!something!repeatedly!without!being!able!
to!resist!doing!it?!
!
!

14.!Have!you!ever!experienced!or!witnessed!or!had!to!deal!with!an!exA
tremely!traumatic!event!that!included!actual!or!threatened!death!or!serious!
injury!to!you!or!someone!else?!
!

!

207!

!

15.!Have!you!reAexperienced!the!awful!event!in!a!distressing!way!in!the!
past!month?!

YES!

NO!

YES!

NO!

YES!

NO!

YES!

NO!

YES!

NO!

YES!

NO!

21.!Have!you!ever!heard!things!other!people!couldn’t!hear,!such!as!voices?! YES!

NO!

!
!

16.!Have!you!ever!believed!that!people!were!spying!on!you,!or!that!someA
one!was!plotting!against!you,!or!trying!to!hurt!you?!
!
!

17.!Have!you!ever!believed!that!someone!was!reading!your!mind!or!could!
hear!your!thoughts,!or!that!you!could!actually!read!someone’s!mind!or!hear!
what!another!person!was!thinking?!
!
!

18.!Have!you!ever!believed!that!someone!or!some!force!outside!of!yourself!
put!thoughts!in!your!mind!that!were!not!your!own,!or!made!you!act!in!a!way!
that!was!not!your!usual!self?!Or,!have!you!ever!felt!that!you!were!posA
sessed?!
!
!

19.!Have!you!ever!believed!that!you!were!being!sent!special!messages!
through!the!TV,!radio,!or!newspaper?!Did!you!believe!that!someone!you!
did!not!personally!know!was!particularly!interested!in!you?!
!
!

20.!Have!your!relatives!or!friends!ever!considered!any!of!your!beliefs!
strange!or!unusual?!
!
!

!
!

22.!Have!you!ever!had!visions!when!you!were!awake!or!have!you!ever!
seen!things!other!people!couldn’t!see?!

YES!

NO!

!

!

!
!
RYFF!SCALES!OF!PSYCHOLOGICAL!WELL%BEING!54!
!
The!following!set!of!questions!deals!with!how!you!feel!about!yourself!and!your!life.!!Please!remember!that!
there!are!no!right!or!wrong!answers.!
!
!
Circle!the!number!that!best!describes!your!
Strongly!
Disagree! Disagree! Agree!
Agree!
Strongly!
present!agreement!or!disagreement!with!
Di
s
agree!
Somewhat!
Sl
i
g
htl
y
!
Somewhat!
Agree!
Slightly!
each!statement.!
1.!!Sometimes!I!change!the!way!I!
!
!
!
!
!
!
act!or!think!to!be!more!like!those!
1!
2!
3!
4!
5!
6!
around!me.!!
2.!!In!general,!I!feel!I!am!in!charge!
!
!
!
!
!
!
of!the!situation!in!which!I!live.!
1!
2!
3!
4!
5!
6!
3.!!I!am!not!interested!in!activities!
!
!
!
!
!
!
that!will!expand!my!horizons.!!
1!
2!
3!
4!
5!
6!
4.!!When!I!look!at!the!story!of!my!
!
!
!
!
!
!
life,!I!am!pleased!with!how!things!
1!
2!
3!
4!
5!
6!
have!turned!out.!!
5.!!Maintaining!close!relationships!
!
!
!
!
!
!
has!been!difficult!and!frustrating!for!
1!
2!
3!
4!
5!
6!
me.!
6.!!I!am!not!afraid!to!voice!my!opinA
!
!
!
!
!
!
ions,!even!when!they!are!in!opposiA
1!
2!
3!
4!
5!
6!
tion!to!the!opinions!of!most!people.!
7.!!The!demands!of!everyday!life!
!
!
!
!
!
!
often!get!me!down.!!
1!
2!
3!
4!
5!
6!
8.!!I!live!life!one!day!at!a!time!and!
!
!
!
!
!
!
don’t!really!think!about!the!future.!!
1!
2!
3!
4!
5!
6!

!

208!

Circle!the!number!that!best!describes!your!
present!agreement!or!disagreement!with!
each!statement.!
9.!!In!general,!I!feel!confident!and!
positive!about!myself.!
10.!!I!often!feel!lonely!because!I!
have!few!close!friends!with!whom!to!
share!my!concerns.!
11.!!My!decisions!are!not!usually!
influenced!by!what!everyone!else!is!
doing.!
12.!!I!do!not!fit!very!well!with!the!
people!and!the!community!around!
me.!
13.!!I!tend!to!focus!on!the!present,!
because!the!future!nearly!always!
brings!me!problems.!
14.!!I!feel!like!many!of!the!people!I!
know!have!gotten!more!out!of!life!
than!I!have.!
15.!!I!enjoy!personal!and!mutual!
conversations!with!family!members!
or!friends.!
16.!!I!tend!to!worry!about!what!other!
people!think!of!me.!
17.!!I!am!quite!good!at!managing!
the!many!responsibilities!of!my!daily!
life.!
18.!!I!don’t!want!to!try!new!ways!of!
doing!things!A!my!life!is!fine!the!way!
it!is.!
19.!!Being!happy!with!myself!is!
more!important!to!me!than!having!
others!approve!of!me.!
20.!!I!often!feel!overwhelmed!by!my!
responsibilities.!
21.!!I!think!it!is!important!to!have!
new!experiences!that!challenge!
how!you!think!about!yourself!and!
the!world.!
22.!!My!daily!activities!often!seem!
trivial!and!unimportant!to!me.!!!!!
23.!!I!like!most!aspects!of!my!perA
sonality.!!
24.!I!don’t!have!many!people!who!
want!to!listen!when!I!need!to!talk.!
25.!!I!tend!to!be!influenced!by!peoA
ple!with!strong!opinions.!!
26.!!When!I!think!about!it,!I!haven’t!
really!improved!much!as!a!person!
over!the!years.!!
27.!!I!don’t!have!a!good!sense!of!
what!it!is!I’m!trying!to!accomplish!in!
life.!!
28.!!I!made!some!mistakes!in!the!
past,!but!I!feel!that!all!in!all!everyA
thing!has!worked!out!for!the!best.!!
29.!!I!generally!do!a!good!job!of!
taking!care!of!my!personal!finances!
and!affairs.!

!

Strongly!
Disagree! Disagree!
Disagree! Somewhat! Slightly!

Agree!
Agree!
Slightly! Somewhat!

Strongly!
Agree!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!
!
1!
!
1!
!
1!

!
2!
!
2!
!
2!
!
2!

!
3!
!
3!
!
3!
!
3!

!
4!
!
4!
!
4!
!
4!

!
5!
!
5!
!
5!
!
5!

!
6!
!
6!
!
6!
!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!
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Circle!the!number!that!best!describes!your!
present!agreement!or!disagreement!with!
each!statement.!
30.!!I!used!to!set!goals!for!myself,!
but!that!now!seems!like!a!waste!of!
time.!
31.!!In!many!ways,!I!feel!disapA
pointed!about!my!achievements!in!
life.!
32.!!It!seems!to!me!that!most!other!
people!have!more!friends!than!I!do.!
33.!!I!enjoy!making!plans!for!the!
future!and!working!to!make!them!a!
reality.!
34.!!People!would!describe!me!as!a!
giving!person,!willing!to!share!my!
time!with!others.!
35.!!I!have!confidence!in!my!opinA
ions,!even!if!they!are!contrary!to!the!
general!consensus.!!
36.!!I!am!good!at!juggling!my!time!
so!that!I!can!fit!everything!in!that!
needs!to!be!done.!
37.!!I!have!a!sense!that!I!have!deA
veloped!a!lot!as!a!person!over!time.!
38.!!I!am!an!active!person!in!carryA
ing!out!the!plans!I!set!for!myself.!
39.!!I!have!not!experienced!many!
warm!and!trusting!relationships!with!
others.!
40.!!It’s!difficult!for!me!to!voice!my!
own!opinions!on!controversial!matA
ters.!
41.!!I!do!not!enjoy!being!in!new!sitA
uations!that!require!me!to!change!
my!old!familiar!ways!of!doing!
things.!
42.!!Some!people!wander!aimlessly!
through!life,!but!I!am!not!one!of!
them.!
43.!!My!attitude!about!myself!is!
probably!not!as!positive!as!most!
people!feel!about!themselves.!
44.!!I!often!change!my!mind!about!
decisions!if!my!friends!or!family!disA
agree.!
45.!For!me,!life!has!been!a!continuA
ous!
process!of!learning,!changing,!and!
growth.!
46.!!I!sometimes!feel!as!if!I’ve!done!
all!there!is!to!do!in!life.!
47.!!I!know!that!I!can!trust!my!
friends,!and!they!know!they!can!
trust!me.!
48.!!The!past!had!its!ups!and!
downs,!but!in!general,!I!wouldn’t!
want!to!change!it.!
49.!!I!have!difficulty!arranging!my!
life!in!a!way!that!is!satisfying!to!me.!

!

Strongly!
Disagree! Disagree!
Disagree! Somewhat! Slightly!

Agree!
Agree!
Slightly! Somewhat!

Strongly!
Agree!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!
!
1!

!
2!
!
2!

!
3!
!
3!

!
4!
!
4!

!
5!
!
5!

!
6!
!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!
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Circle!the!number!that!best!describes!your!
present!agreement!or!disagreement!with!
each!statement.!
50.!!I!gave!up!trying!to!make!big!
improvements!or!changes!in!my!life!
a!long!time!ago.!
51.!!When!I!compare!myself!to!
friends!and!acquaintances,!it!makes!
me!feel!good!about!who!I!am.!
52.!I!judge!myself!by!what!I!think!is!
important,!not!by!the!values!of!what!
others!think!is!important.!
53.!!I!have!been!able!to!build!a!
home!and!a!lifestyle!for!myself!that!
is!much!to!my!liking.!
54.!!There!is!truth!to!the!saying!that!
you!can’t!teach!an!old!dog!new!
tricks.!
!
!
!

Strongly!
Disagree! Disagree!
Disagree! Somewhat! Slightly!

Agree!
Agree!
Slightly! Somewhat!

Strongly!
Agree!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
1!

!
2!

!
3!

!
4!

!
5!

!
6!

!
!

!
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MENTAL!HEALTH!SCREENING!FORM%III!
&
Instructions:&In&this&program,&we&help&people&with&all&their&problems,&not&just&their&addictions.&This&
commitment&includes&helping&people&with&emotional&problems.&Our&staff&is&ready&to&help&you&to&
deal&with&any&emotional&problems&you&may&have,&but&we&can&do&this&only&if&we&are&aware&of&the&
problems.&Any&information&you&provide&to&us&on&this&form&will&be&kept&in&strict&confidence.&It&will&not&
be&released&to&any&outside&person&or&agency&without&your&permission.&If&you&do&not&know&how&to&
answer&these&questions,&ask&the&staff&member&giving&you&this&form&for&guidance.&Please&note,&each&
item&refers&to&your&entire&life&history,&not&just&your&current&situation,&this&is&why&each&question&beR
gins&–&“Have&you&ever&….”&
&
&

1)! Have&you&ever&talked&to&a&psychiatrist,&psychologist,&therapist,&social&worker&
YES& NO&
or&counselor&about&an&emotional&problem?&
2)! Have&you&ever&felt&you&needed&help&with&your&emotional&problems,&or&have&
you&had&people&tell&you&that&you&should&get&help&for&your&emotional&probR YES& NO&
lems?&
3)! Have& you& ever& been& advised& to& take& medication& for& anxiety,& depression,&
YES& NO&
hearing&voices,&or&for&any&other&emotional&problem?&
4)! Have&you&ever&been&seen&in&a&psychiatric&emergency&room&or&been&hospitalR
YES& NO&
ised&for&psychiatric&reasons?&
5)! Have&you&ever&heard&voices&no&one&else&could&hear&or&seen&objects&or&things&
YES& NO&
which&others&could&not&see?&
&

&

6)! a)&Have&you&ever&been&depressed&for&weeks&at&a&time,&lost&interest&or&pleasR
YES& NO&
ure& in& most& activities,& had& trouble& concentrating& and& making& decisions& or& &
&
thought&about&killing&yourself?&
YES& NO&
b)&Did&you&ever&attempt&to&kill&yourself?&
&

&

7)! Have&you&ever&had&nightmares&or&flashbacks&as&a&result&of&being&involved&in&
some& traumatic/terrible& event?& For& example,& warfare,& gang& fights,& fire,& doR YES& NO&
mestic&violence,&rape,&incest,&car&accident,&being&shot&or&stabbed?&
8)! Have& you& ever& experienced& any& strong& fears?& For& example,& of& heights,& inR
sects,& animals,& dirt,& attending& social& events,& being& in& a& crowd,& being& alone,& YES& NO&
being&in&places&where&it&may&be&hard&to&escape&or&get&help?&
9)! Have&you&ever&given&in&to&an&aggressive&urge&or&impulse,&on&more&than&one&
occasion,&that&resulted&in&serious&harm&to&others&or&led&to&the&destruction&of& YES& NO&
property?&
10)!Have& you& ever& felt& that& people& had& something& against& you,& without& them&
necessarily&saying&so,&or&that&someone&or&some&group&may&be&influencing&or& YES& NO&
trying&to&influence&your&thoughts&or&behaviour?&

!
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11)!Have& you& ever& experienced& any& emotional& problems& associated& with& your&
YES& NO&
sexual&interests,&your&sexual&activities,&or&your&choice&of&sexual&partner?&
12)!Was&there&ever&a&period&in&your&life&where&you&spent&a&lot&of&time&thinking&
and& worrying& about& gaining& weight,& becoming& fat,& or& controlling& your& eatR
ing?& For& example,& by& repeatedly& dieting& or& fasting,& engaging& in& much& exerR YES& NO&
cise& to& compensate& for& binge& eating,& taking& enemas,& or& forcing& yourself& to&
throw&up?&
13)!Have& you& ever& had& a& period& of& time& when& you& were& so& full& of& energy& and&
your& ideas& came& very& rapidly,& when& you& talked& nearly& nonRstop,& when& you&
YES& NO&
moved& quickly& from& one& activity& to& another,& when& you& needed& little& sleep,&
and&believed&you&could&do&almost&anything?&
14)!Have&you&ever&had&spells&or&attacks&when&you&suddenly&felt&anxious,&frightR
ened,& uneasy& to& the& extent& that& you& began& sweating,& your& heart& began& to&
YES& NO&
beat& rapidly,& you& were& shaking& or& trembling,& your& stomach& was& upset,& you&
felt&dizzy&or&unsteady,&as&if&you&would&faint?&
15)!Have&you&ever&had&a&persistent,&lasting&thought&or&impulse&to&do&something&
over& and& over& that& caused& you& considerable& distress& and& interfered& with&
normal&routines,&work,&or&your&social&relations?&Examples&would&include&reR
YES& NO&
peatedly&counting&things,&checking&and&rechecking&on&things&you&had&done,&
washing& and& rewashing& your& hands,& praying,& or& maintaining& a& very& rigid&
schedule&of&daily&activities&from&which&you&could&not&deviate?&
16)!Have& you& ever& lost& considerable& sums& of& money& through& gambling& or& had&
problems&at&work,&in&school,&with&your&family&and&friends&as&a&result&of&your& YES& NO&
gambling?&
17)!Have& you& ever& been& told& by& teachers,& guidance& counselors,& or& others& that&
YES& NO&
you&have&a&special&learning&problem?&
!
THE!SHORT!DEPRESSION^HAPPINESS!SCALE!(SDHS)!!
©&Stephen&Joseph&2000&&
A&number&of&statements&that&people&have&made&to&describe&how&they&feel&are&given&below.&Please&
read&each&one&and&tick&the&box&which&best&describes&how&frequently&you&felt&that&way&in&the&past&
seven&days,&including&today.&Some&statements&describe&positive&feelings&and&some&describe&negative&
feelings.&You&may&have&experienced&both&positive&and&negative&feelings&at&different&times&during&the&
past&seven&days.&
&

&
(1)&I&felt&dissatisfied&with&my&life&

&

&

Sometimes&
Often&
&
&

(2)&I&felt&happy&

&

&

&

&

(3)&I&felt&cheerless&

&

&

&

&

(4)&I&felt&pleased&with&the&way&I&am&

&

&

&

&

(5)&I&felt&that&life&was&enjoyable&
(6)&I&felt&that&life&was&meaningless&

&
&

&
&

&
&

&
&

!

Never&

Rarely&
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&

SELF!REPORTING!QUESTIONNAIRE%5!
!
First:!Please!circle!the!“YES”!box!if!you!have!had!this!symptom!in!the!last!30!days.!
!
!

1.!Do!you!feel!that!somebody!has!been!trying!to!harm!you!in!some!
way?!

YES!

NO!

!

YES!

NO!

!

YES!

NO!

!

4.!Do!you!ever!hear!voices!without!knowing!where!they!come!from!or!
YES!
which!other!people!cannot!hear?!

NO!

!

NO!

!

!
!

2.!Are!you!a!much!more!important!person!than!people!think?!
!
!

3.!Have!you!noticed!any!interference!or!anything!else!unusual!with!
your!thinking?!
!
!

!
!

5.!Have!you!ever!had!any!fits,!convulsions,!falls!to!the!ground,!with!
movements!of!the!arms!and!legs,!biting!of!the!tongue!or!loss!of!conA
sciousness?!

YES!

!

!
Second:!Please!look!back!over!the!questions.!For!every!one!you!have!answered!“YES”,!
please!put!a!tick!in!the!final!column!if!you!had!that!problem!at!a!time!when!you!were!NOT!
using!alcohol!or!other!drugs.!
!!
!
!
!
!
THE!WHO!(FIVE)!WELL^BEING!INDEX!(1998!VERSION)!!
&

Please&indicate&for&each&of&the&five&statements&which&is&closest&to&how&you&have&been&feeling&over&
the&last&two&weeks.&Notice&that&higher&numbers&means&better&wellRbeing.&
&

Example:&If&you&have&felt&cheerful&and&in&good&spirits&more&than&half&of&the&time&during&the&last&two&
weeks,&put&a&tick&in&the&box&with&a&number&3&next&to&it&for&question&1&below.&
&

Over%the%last%two%weeks:%
(1)&I&have&felt&cheerful&and&in&
good&spirits&
(2)!I!have!felt!calm!and!relaxed!
(3)!I!have!felt!active!and!vigorous!
(4)!I!woke!up!feeling!fresh!and!
rested!
(5)!My!daily!life!has!been!filled!
with!things!that!interest!me!
!

!

All&of&the&
time&

Most&of&
the&time&

More&than&
half&of&the&
time&

Less&
Some&of&
than&
the&
half&of&
time&
the&time&

At&no&
time&

5!

4!

3!

2!

1!

0!

5!

4!

3'

2'

1'

0'

5!

4!

3'

2'

1'

0'

5!

4!

3'

2'

1'

0'

5!

4!

3'

2'

1'

0'

214!

Appendix(L(
ADDICTION(SEVERITY(INDEX(PSYCHIATRIC(STATUS(DOMAIN(
(
How(many(times(have(you(been(treated(for(any((
psychological(or(emotional(problems:(
(
P1∗'''In'a'hospital'or'inpatient'setting?'
'
P2∗(('Outpatient/private'patient?'
(((((((((((•(Do'not'include'substance'abuse,'employment,''
or'family'counseling.'''
(((((((((((•(Treatment'episode'='a'series'of'continuous''
'''''''''''''visits'or'treatment'days,'not'the'number'of'visits.'
'
'

P3.'''''Do'you'receive'financial'support'for'a'psychiatric''
'''''''''''disability?''Can'be'from'government'or'employer,'etc.'

'''''''''''''' '

'

0GNo'''1GYes'

'

'

'

'

'

'

'

'

'''

'

Have(you(had(a(significant(period(of(time((that(was(not(a(direct((
result(of(alcohol/drug(use)(in(which(you(have:(
'
'

'
'

'
'

'
'

'
'

'
0MNo(((1MYes(
''''(Past(30(Days(((((Lifetime'

P4.'''''Experienced'serious'depressionG'
''''''''''sadness,'hopelessness,'loss'of'interest?'
'
'

P5.'''''Experienced'serious'anxiety/tension'
''''''''''uptight,'unreasonably'worried,''
''''''''''inability'to'feel'relaxed?'
'
'

P6.'''''Experienced'hallucinationsGsaw'things/''
''''''''''heard'voices'that'others'didn’t'see/hear?'
'''''''''''Code'other'psychotic'symptoms'here'also.'
'
'

P7.'''''Experienced'trouble'understanding,'
''''''''''concentrating,'or'remembering?'
'
(

Note:''Patient'can'be'under'the'influence'of'alcohol/drugs'for'these'questions.'
Have(you(had(a(significant(period(of(time((regardless(of(alcohol(and(drug(use)(in(which(you(
have:'' '
''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''0MNo(((1MYes((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((

'

'

'

'

'

Past(30(Days(((((Lifetime'

P8.'''''Experienced'trouble'controlling''
''''''''''violent'behavior'including'episodes'of''
''''''''''rage,'or'violence?'
(

'

P9.'''''Experienced'serious'thoughts'of'suicide?'
(

•(Patient'seriously'considered'a'plan'for''
'''taking'his/her'life.'''
'''

P10.'''Attempted'suicide?'
(

'

•(Include'actual'suicidal'gestures'or''
'''attempts.'
(('
'

P11.''Has'a'health'care'provider'recommended''
''''''''''you'take'any'medications'for''
''''''''''psychological'or'emotional'problems?'

'
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(
((((((((((•(Recommended'for'the'patient'by'a'physician'or'other'health'care''

''''''''''''provider'as'appropriate.''Record'"Yes"'if'a'medication'was''
''''''''''''recommended'even'if'the'patient'is'not'taking'it.'
'

'
'

(
P12.''How'many'days'in'the'past'30'have'you'experienced''
these'psychological'or'emotional'problems?'
•(This'refers'to'problems'noted'in'Questions'P4GP10.'
'
For(Questions(P13MP14,(ask(the(patient(to(use(the(Patient(Rating(scale(
(
(

P13.''How'troubled'or'bothered'have'you'been'by'these''
psychological'or'emotional'problems'in'the'past'30'days?'
(
'

•(Patient'should'be'rating'the'problem'days'from'Question'P12.'

P14.''How'important'to'you'now'is'treatment'for''
'''''''' ''these'psychological'or'emotional'problems?'
(
Note:(The(patient(is(rating(their(need(for(you/your(program(to(provide(or(refer(them(to(psychologiM
cal/psychiatric(services,(above(and(beyond(treatment(they(may(already(be(getting(somewhere(else.(

(
CONFIDENCE(RATING(
Is(the(above(information(significantly(distorted(by:(
P22'''Patient's'misrepresentation?'
'
''''''''''''''0GNo'1GYes'
'

P23.''Patient's'inability'to'understand?' ''''''''''''''0GNo'1GYes'
(
PSYCHIATRIC(STATUS(COMMENTS(
(Include'question'number'with'your'comments)'

_____________________________________________________(
(
Specify(Diagnoses(if(known:(_____________________________(
(
_____________________________________________________(
(
_____________________________________________________(
(
_____________________________________________________(
(
_____________________________________________________(
'
________________________________________________________________________________(
(
_____________________________________________________(
(
(
CLOSING(ITEM(
'
G12.(Special(Code(M(If(ASI(is(not(completed:(
1.'Interview'terminated'by'interviewer'
2.'Patient'refused'to'finish'interview'
3.'Patient'unable'to'respond'(language'or'intellectual'barrier,'under'
''''the'influence,'etc.')'
'
Code'“N”'if'Interview'completed.'
'
((

'
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Appendix(M(
'

STRUCTURED(CLINICAL(INTERVIEW(FOR(DSMMIVMTR(AXIS(I(DISORDERS(
'
Patient(Edition(((January(2007)(
'

S(C(I(D(M(I(/(P((
'
'
Michael'B.'First,'M.D.b'Robert'L.'Spitzer,'M.D.b'
Miriam'Gibbon,'M.S.W.b'and'Janet'B.W.'Williams,'D.S.W.'
'
'

Study:' __________________________________'
'
Subject:' __________________________________'
'
Rater:' __________________________________'
'
'
'

Study'No.:'

__''__''__''__' '

I.D.'No.:'

__''__''__''__'

P1'

'

Rater'No.:'

P2'

'

__''__''__'

'
P3'

Date'of'Interview:'

'

__''__''__''__''__''__'
Mo.'

Sources'of'information'(check'all'that'apply):' ' __'Subject'
__'Family/friends/associates'
__'Health'professional/chart/referral'note'

Edited'and'checked'by:'__________________________________'

'

Day'

P4'

Year''''

'

P5'
P6'
P7

'

Date:_______________' ' '

''
'

'
'
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